• HOME
  •  > 
  • 医学一般
  •  > 
  • 雑誌
  •  >  日本臨牀　62/増刊号3　高血圧と高血圧性臓器障害　2004年3月

日本臨牀　62/増刊号3　高血圧と高血圧性臓器障害　2004年3月

出版社： 日本臨牀社
発行日： 2004-03-28
分野： 医学一般  >  雑誌
雑誌名：
特集： 臓器障害の予防と管理
電子書籍版： 2004-03-28 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

15,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

15,400 円(税込)

購入する

目次

  • 日本臨牀　62/増刊号3 高血圧と高血圧性臓器障害 2004年3月

    ―目次―

    特集　高血圧と高血圧性臓器障害
    　　　―臓器障害の予防と管理―

    ?　疫学研究―心血管疾患の危険因子としての高血圧―
    ?　血管系障害の発症機序
    ?　高血圧性臓器障害の危険因子
    ?　高血圧性臓器障害に関する基礎研究
    ?　高血圧性臓器障害の検査とその意義
    ?　臨床―高血圧が主な原因となる合併症―
    ?　合併症・臓器障害予防の血圧管理
    ?　合併症・臓器障害時の降圧薬の選択
    ?　大規模介入試験と臓器障害進展予防
    ?　持論

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 疫学研究 - 心血管疾患の危険因子としての高血圧 -

P.13 掲載の参考文献
1) 厚生省公衆衛生局 : 昭和55年循環器疾患基礎調査報告書, 日本心臓財団, 1982.
 
2) 厚生省保健医療局編 : 第4次循環器疾患基礎調査 (平成2年) 報告, 循環器病研究振興財団, 1993.
 
3) 上島弘嗣ほか : 第31回日本循環器管理研究協議会総会記録 特別報告 1980年循環器疾患基礎調査の追跡調査 (NIPPON DATA). 日循協誌 31 : 231-237, 1997.
 
4) 上島弘嗣ほか : 特別報告7-2高齢者の循環器疾患による生活の質低下予防策に関する研究. 日循協誌 34 : 58-63, 1999.
 
5) 児玉和紀ほか : 内外の代表的なコホート研究の成果. 循環科学 41 : 532-544, 1997.
 
6) 「脳卒中などによる寝たきり・死亡の健康危険度評価システム開発事業」班 : 「脳卒中などによる寝たきり・死亡の健康危険度評価システム開発事業」「1980年循環器疾患基礎調査」追跡調査報告書, 1995.
 
7) Anonymous : The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 24 : 2413-2446, 1997.
 
8) NIPPON DATA80 Research Group : Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese : fourteen year follow up of randomly selected population from Japanese : NIPPON DATA80. J Hum Hypertens 2003. (in press)
 
P.17 掲載の参考文献
1) Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure : The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 : 2413-2446, 1997.
PubMed
2) Hiwada K, et al : Guidelines for hypertension in the elderly : 1999 revised version. Hypertens Res 22 : 231-259, 1999.
PubMed
3) Cupples LA, et al : Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Stat Med 7 : 205-222, 1988.
PubMed
4) Arima H, et al : Validity of the JNC VI recommendations on the management of hypertension in a general population of Japanese elderly : the Hisayama Study. Arch InternMed 163 : 361-366, 2003.
 
5) 清原裕 : 糖尿病と高血圧の疫学. 血圧 10 : 993-998, 2000.
Medical*Online
6) Kiyohara Y, et al : The impact of alcohol and hypertension on stroke incidence in a general Japanese population : the Hisayama Study. Stroke 26 : 368-372, 1995.
 
P.21 掲載の参考文献
1) Ohkubo T, et al : Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements : a pilot study in Ohasama. J Hypertens 15 : 357-364, 1997.
PubMed
2) Ohkubo T, et al : Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population : the Ohasama study. J Hypertens 18 : 847-854, 2000.
 
3) Ohkubo T, et al : Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion : the Ohasama Study. Hypertension 32 : 255-259, 1998.
PubMed
4) Ohkubo T, et al : Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-hour blood pressure : the Ohasama study. J Hypertens 20 : 2183-2189, 2002.
 
5) Kikuya M, et al : Prognostic signincance of blood pressure and heart rate variabilities : The Ohasama Study. Hypertension 36 : 901-906, 2000.
 
6) Ohkubo T, et al : Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement : a population-based observation in Ohasama, Japan. J Hypertens 16 : 971-975, 1998.
 
7) Tsuji I, et al : Proposal of reference values for home blood pressure measurement : prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. Am J Hypertens 10 : 409-418, 1997.
PubMed
8) Fujiwara T, et al on behalf of The HOMED-BP Study Group : Rationale and design of HOMED-BP Study : Hypertension objective treatment based on measurement by electrical devices of blood pressure study. Blood Press Monit 7 : 77-82, 2002.
 
9) Hozawa A, et al : Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home : the Ohasama study. Arch Intern Med 160 : 3301-3306, 2000.
PubMed
10) Sakuma M, et al : Reproducibility of home blood pressure measurements over a 1-year period. Am J Hypertens 10 : 798-803, 1997.
 
11) Imai Y, et al : Relationship among blood pressures obtained using different measurement methods in the general population of Ohasama, Japan. Hypertens Res 22 : 261-272, 1999.
 
12) Hozawa A, et al : Factors affecting the difference between screening and home blood pressure measurements : the Ohasama Study. J Hypertens 19 : 13-19, 2001.
Medical*Online
13) Aihara A, et al : Discrepancy between screening blood pressure and ambulatory blood pressure : a community-based study in Ohasama. Hypertens Res 21 : 127-136, 1998.
PubMed
14) Imai Y, et al : Factors that affect blood pressure variability : a community-based study in Ohasama. Am J Hypertens 10 : 1281-1289, 1997.
PubMed
15) Imai Y, et al : Factors affecting the nocturnal decrease in blood pressure : a community-based study in Ohasama. J Hypertens 15 : 827-838, 1997.
PubMed
16) Imai Y, et al : Characteristics of blood pressure measured at home in the moming and in the evening : the Ohasama study. J Hypertens 17 : 889-898, 1999.
 
17) Hozawa A, et al : Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population : The Ohasama study. Hypertens Res 25 : 57-63, 2002.
PubMed
P.24 掲載の参考文献
1) Mannami T, et al : Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city : the Suita study. Stroke 28 : 518-525, 1997.
PubMed
2) Mannami T, et al : Potential of carotid enlargement as a useful indicator affected by high blood pressure in a large general population of a Japanese city : the Suita study. Stroke 31 : 2958-2965, 2000.
 
3) Mannami T, et al : Strong and signhicant relationships between aggregation of major coronary risk factors and the acceleration of carotid atherosclerosis in the general population of a Japanese city : the Suita study. Arch Intern Med 160 : 2297-2303, 2000.
PubMed
4) Higaki J, et al : Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men : the Suita study. Circulation 101 : 2060-2065, 2000.
PubMed
5) Mannami T, et al : Low potentiality of angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism as a useful predictive marker for carotid atherogenesis in a large general population of a Japanese city : the Suita study. Stroke 32 : 1250-1256, 2001.
 
6) Ishikawa K, et al : T+31C polymorphism of angiotensinogen gene and essential hypertension. Hypertension 37 : 281-285, 2001.
PubMed
7) Katsuya T, et al : Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects : the Suita study. J Hypertens 20 : 2017-2021, 2002.
PubMed
8) Takagi S, et al : The aldehyde dehydrogenase 2 gene is a risk factor for hypertension in Japanese but does not alter the sensitivity to pressor effects of alcohol : the Suita study. Hypertens Res 24 : 365-370, 2001.
 
9) Takagi S, et al : Aldehyde dehydrogenase 2 gene is a risk factor for myocardial infarction in Japanese men. Hypertens Res 25 : 677-681, 2002.
PubMed
10) Inamoto N, et al : Association of methylenetetrahydrofolate reductase gene polymorphism with carotid atherosclerosis depending on smoking status in a Japanese general population. Stroke 34 : 1628-1633, 2003.
 
11) Iwai N, et al : Human prostacyclin synthase gene and hypertension : the Suita study. Circulation 100 : 2231-2236, 1999.
PubMed
12) Iwai N, et al : Association between SAH, an acyl-CoA synthetase gene, and hypertriglyceridemia, obesity, and hypertension. Circulation 105 : 41-47, 2002.
 
13) Iwai N, et al : Association of a sodium channel α subunit promoter variant with blood pressure. J Am Soc Nephrol 13 : 80-85, 2002.
 
14) Iwai N, et al : Association of sodium channel γ-subunit promoter variant with blood pressure. Hypertension 38 : 86-89, 2001.
 
15) Ono K, et al : A single-nucleotide polymorphism in C-type natriuretic peptide gene may be associated with hypertension. Hypertens Res 25 : 727-730, 2002.
 

II 血管系障害の発症機序

P.32 掲載の参考文献
1) Davies PF, et al : A spatial approach to transcriptional profiling : mechanotransduction and the focal origin of atherosclerosis. Trends Biotechnol 17 (9) : 347-351, 1999.
PubMed
2) Kawakami K, et al : Dynamics of integrin clustering at focal contacts of endothelial cells studied by multimode imaging microscopy. J Cell Sci 114 : 3125-3135, 2001.
PubMed
3) Dzau VJ, et al : New perspectives in hypertension research. Potentials of vascular biology. Hypertension 23 (6 Pt 2) : 1132-1140, 1994.
 
4) Buga GM, et al : Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 17 (2) : 187-193, 1991.
PubMed
5) Frangos JA, et al : Flow effects on prostacyclin production by cultured human endothelial cells. Science 227 (4693) : 1477-1479, 1985.
PubMed
6) Chun TH, et al : Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension 29 (6) : 1296-1302, 1997.
PubMed
7) Hajra L, et al : The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci USA 97 (16) : 9052-9057, 2000.
PubMed
8) De Keulenaer GW, et al : Oscillatory and steady laminar shear stress differentially affect human endothelial redox state : role of a superoxide-producing NADH oxidase. Circ Res 82 (10) : 1094-1101, 1998.
PubMed
9) Bennett MR, et al : Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 95 (5) : 2266-2274, 1995.
PubMed
10) Xu Q, et al : Acute hypertension activates mitogen-activated protein kinases in arterial wall. J Clin Invest 97 (2) : 508-514, 1996.
PubMed
11) Hu Y, et al : Activation of PDGF receptor alpha in vascular smooth muscle ceUs by mechanical stress. FASEB J 12 (12) : 1135-1142, 1998.
 
12) Xia Z, et al : Opposing effects of ERK and JNK-P38 MAP kinases on apoptosis. Science 270 (5240) : 1326-1331, 1995.
PubMed
13) Metzler B, et al : Increased expression and activation of stress-activated protein kinases/c-Jun NH (2)-terminal protein kinases in atherosclerotic lesions coincide with p53. Am J Pathol 156 (6) : 1875-1886, 2000.
PubMed
14) Mayr M, et al : Biomechanical stress-induced apoptosis in vein grafts involves p38 mitogen-activated protein kinases. FASEB J 14 (2) : 261-270, 2000.
PubMed
15) Li C, et al : Cyclic strain stress-induced mitogen-activated protein kinase (MAPK) phosphatase 1 expression in vascular smooth muscle cells is regulated by Ras/Rac-MAPK pathways. J Biol Chem 274 (36) : 25273-25280, 1999.
PubMed
P.37 掲載の参考文献
1) Gibbons GH, Dzau VJ : The emerging concept of vascular remodeling. N Engl J Med 330 : 1431-1438, 1994.
PubMed
2) Kim S, Iwao H : Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 : 11-34, 2000.
PubMed
3) Thybo NK, et al : Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 25 : 474-481, 1995.
PubMed
4) Walther T, et al : Ischemic injury in experimental stroke depends on angiotensin II. FASEB J 16 : 169-176, 2002.
PubMed
5) Saavedra JM : Emerging features of brain angiotensin receptors. Regul Pept 85 : 31-45, 1999.
PubMed
6) Blezer EL, et al : Losartan versus enalapri1 on cerebral edema and proteinuria in stroke-prone hypertensive rats. Am J Hypertens 14 : 54-61, 2001.
PubMed
7) Zhu YZ, et al : Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. Neuroreport 11 : 1191-1194, 2000.
PubMed
P.41 掲載の参考文献
1) Calver A, et al : Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension : the nitric oxide dilator mechanism appears abnormal. J Hypertens 10 : 1025-1031, 1992.
PubMed
2) Panza JA, et al : Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essendal hypertension. J Am Coll Cardiol 21 : 1145-1151, 1993.
PubMed
3) Lyons D, et al : The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension. J Hypertens 12 : 1047-1052, 1994.
 
4) Higashi Y, et al : Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects : role of endotheHum-derived nitric oxide. Circulation 100 : 1194-1202, 1999.
 
5) Lin PS, et al : Asymmetric dimethylarginine enhances superoxide production in human endothelial cells. Circulation 96 (Suppl 1) : 1-45, 1997.
 
6) Bogle RG, et al : Induction of NG monomethyl-L-arginine uptake : a mechanism for differential inhibition of NO synthases? Am J Physiol 269 : C750-756, 1995.
PubMed
7) Ushio-Fukai M, et al : p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271 : 23317-23321, 1996.
 
8) Lambeth JD, et al : Novel homologs of gp91phox. Trends Biochem Sci 25 : 459-461, 2000.
PubMed
9) Lassegue B, et al : Novel gp91Phox homologues in vascular smooth muscle cells : nox 1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88 : 888-894, 2001.
 
10) Griendling KK, et al : Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 : 1141-1148, 1994.
PubMed
11) Rajagopalan S, et al : Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation : contribution to alterations of vasomotor tone. J Clin Invest 97 : 1916-1923, 1996.
 
12) Takemoto M, et al : Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99 : 278-287, 1997.
PubMed
13) Takemoto M, et al : Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade : effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 30 : 1621-1627, 1997.
 
14) Iwatsubo H, et al : Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension 29 : 286-290, 1997.
PubMed
P.47 掲載の参考文献
1) 廣岡良隆, 下川宏明 : 高血圧と酸化ストレス. 臨床高血圧 10 : 322-329, 2003.
 
2) 井上信孝, 横山光宏 : 酸化ストレスと高血圧. 血圧 8 : 485-492, 2001.
Medical*Online
3) Touyz RM : Oxidative stress and vascular damage in hypertension. Curr Hypertens Rep 2 : 98-105, 2000.
PubMed
4) Griendling KK, FitzGerald GA : Oxidative stress and cardiovascular injury : Part I : basic mechanisms and in vivo monitoring of ROS. Circulation 108 : 1912-1916, 2003.
PubMed
5) Lassegue B, Clempus RE : Vascular NAD (P) Hoxidases : spechic features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285 : R277-R297, 2003.
 
6) 深井真寿子 : 酸化ストレスと心血管病-酸化ストレスと細胞内シグナル伝達. 分子心血管病 2 : 423-433, 2001.
 
7) Griendling KK, et al : NAD (P) Hoxidase : role in cardiovascular biology and disease. Circ Res 86 : 494-501, 2000.
 
8) Griendling KK, et al : Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20 : 2175-2183, 2000.
PubMed
9) Griendling KK, FitzGerald GA : Oxidative stress and cardiovascular injury : Part II : animal and human studies. Circulation 108 : 2034-2040, 2003.
PubMed
10) Somers MJ, et al : Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 101 : 1722-1728, 2000.
PubMed
11) Beswick RA, et al : NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38 : 1107-1111, 2001.
PubMed
12) Higashi Y, et al : Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 346 : 1954-1962, 2002.
PubMed
13) Higashi Y, et al : A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension : a multicenter study. J Am Coll Cardiol 35 : 284-291, 2000.
PubMed
14) McIntyre M, et al : Endothelial function in hypertension : the role of superoxide anion. Hypertension 34 : 539-545, 1999.
PubMed
15) Fukai T, et al : Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ Res 85 : 23-28, 1999.
PubMed

III 高血圧性臓器障害の危険因子

P.55 掲載の参考文献
1) 藤井潤 : 老人の臨床検査の正常値 1. 血圧. 日老医誌 31 : 262-269, 1994.
 
2) Benetos A, et al : A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 35 : 673-680, 2000.
 
3) Harman D : The aging process : major risk factor for disease and death. Proc Natl Acad Sci USA 88 : 5360, 1991.
PubMed
4) Comfort A : The Biology of Senescence, Churchill Livingstone, London, 1979.
 
5) Shock N : Systems integration. In : Handbook of the Biology of Aging (ed by Finch CE, Hayflick L), p640, Van Nostrand Reinhold, New York, 1977.
 
6) Sasaki R, et al : Vascular remodeling of the carotid artery in patients with untreated essential hypertension increases with age. Hypertens Res 25 : 373-379, 2002.
PubMed
7) 小澤利男 : 心臓の老化と疾患. 老化と疾患, 1 : 20-24, 1988.
 
8) 藤島正敏 : 脳血管障害の血圧管理. 日内会誌 80 : 553-558, 1991.
 
9) O'Sullivan C, et al : Hypertensive target-organ damage in the very elderly. Hypertension 42 : 130-135, 2003.
 
P.59 掲載の参考文献
1) Node K, et al : Amelioration of ischemia-and reperfusion-induced myocardial injury by 17-beta estradiol : role of nitric oxide and calcium-activated potassium channels. Circulation 96 : 1953-1963, 1997.
PubMed
2) Sugishita K, et al : Antioxidant effects of estrogen reduce [Ca2+] iduring metabolic inhibition. J Mol Cell Cardiol 35 : 331-336, 2003.
PubMed
3) Proudler AJ, et al : Hormone replacement therapy and serum angiotensin-converting enzyme activity in postmenopausal women. Lancet 346 : 89-90, 1995.59
 
5) Chen Z, et al : Estrogen receptor alpha mediates the nongenomic activation of endothelial nitricoxide synthase by estrogen. J Clin Invest 103 : 401-406, 1999.
 
6) Nozaki M : Mechanism of alteration in cardiovascular system by menopause. Acta Obstet Gynaecol Jpn 49 : 552-562, 1997.
 
7) Kawano H, et al : Menstrual cyclic variation of myocardial ischemia in premenopausal women with variant angina. Ann Intern Med 135 : 977-981, 2001.
PubMed
8) Kawano H, et al : Estradiol supplementation suppresses hyperventilation-induced attacks in postmenopausal women with variant angina. J Am Coll Cardiol 37 : 735-740, 2001.
PubMed
9) Sugishita K, et al : Gender influences [Ca2+] iduring metabolic inhibition in myocytes overexpressing the Na+ -Ca2+ exchanger. Circulation 104 : 2101-2106, 2001.
 
10) Kuroda T, et al : A single bolus administration of estrogen can exert additive cardioprotection effect on patients with mechanically reperfused AMI. Circ J 67 (Suppl I) : 298, 2003.
 
11) Hulley S, et al : Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280 : 605-613, 1998.
 
12) Grady D, et al : Cardiovascular diseases outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 288 : 49-58, 2002.
PubMed
13) Rossouw JE, et al : Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 : 321-333, 2002.
PubMed
14) Mosca L, et al : Hormone replacement therapy and cardiovascular disease. Circulation 104 : 499-503, 2001.
PubMed
P.63 掲載の参考文献
1) Fujita T, et al : Factors influencing blood pressure in salt-sensitive patients with hypertension. Am J Med 69 : 334-344, 1980.
PubMed
2) Fujita T, Bartter FC : The role of renin-angiotensin and prostaglandin systems in salt-sensitive and non-salt-sensitive hypertension in man. In : The Role of Salt in Cardiovascular Hypertension (ed by Fregly MJ, Kare MR), p 207-219, Academic Press, New York, 1982.
 
3) Kimura G, et al : Intrarenal hemodynamics in patients with essential hypertension. Circ Res 69 : 421-428, 1991.
PubMed
4) Bigazzi R, et al : Microalbuminuria in salt-sensitive patients : a marker for renal and cardiovascular risk factors. Hypertension 23 : 195-199, 1994.
PubMed
5) Chobanian AV, et al : The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
6) Guideline Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
7) Uzu T, et al : High sodium sensitivity implicates nocturnal hypertension in essential hypertension. Hypertension 28 : 139-142, 1996.
PubMed
8) Ogihara T, et al : High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats. Hypertension 40 : 83-89, 2002.
PubMed
9) Suzuki M, et al : Association of insulin resistance with salt sensitivity and nocturnal fall of blood pressure. Hypertension 35 : 864-868, 2000.
PubMed
10) Ogihara T, et al : Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40 : 872-879, 2002.
PubMed
11) Morimoto A, et al : Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 350 : 1734-1737, 1997.
PubMed
12) He J, et al : Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA 282 : 2027-2034, 1999.
PubMed
13) Kupari M, et al : Correlates of left ventricular mass in a population sample aged 36 to 37 years. Focus on lifestyle and salt intake. Circulation 89 : 1041-1050, 1994.
 
14) He FJ, MacGregor GA : Effect of modest salt reduction on blood pressure : a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 16 : 761-770, 2002.
PubMed
15) He J, et al : Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 35 : 544-549, 2000.
PubMed
P.68 掲載の参考文献
1) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
2) Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure : The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 157 : 2413-2446, 1997.
 
3) Langford HG : Dietary potassium and hypertension : epidemiologic data. Ann Intern Med 98 : 770-772, 1983.
PubMed
4) Whelton PK, et al : Effects of oral potassium on blood pressure : meta-analysis of randomized controlled clinical trials. JAMA 277 : 1624-1632, 1997.
PubMed
5) Khaw KT, Barr6tt-Connor E : Dietary potassium and stroke-associated mortality. A 12-year prospective population study. N Engl J Med 316 : 235-245, 1987.
 
6) Sugimoto T, et al : High potassium diets protect against dysfunction of endothelial cells in stroke-prone spontaneously hypertensive rats. Hypertension 11 : 579-585, 1988.
PubMed
7) Ishimitsu T, et al : High potassium diets reduce macrophage adherence to the vascular wall in stroke-prone spontaneously hypertensive rats. J Vasc Res 32 : 406-412, 1995.
 
8) Ishimitsu T, et al : High potassium diets reduce endothelial permeability in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 23 : 241-245, 1996.
PubMed
9) Ishimitsu T, et al : Protective effects of high potassium diets against oxidative stress to endothelium in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 18 : 659-673, 1996.
PubMed
10) Young DB, et al : Potassium'scardiovascular protective mechanisms. Am J Physiol 268 : R825-R837, 1995.
PubMed
11) Laragh JH, Sealy JE : K+ depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion. Hypertension 37 : 806-810, 2001.
PubMed
12) Srivastava TN, Young DB : Impairment of cardiac function by moderate potassium depletion. J Card Fail 1 : 195-200, 1995.
 
13) MacCarron DA, et al : Blood pressure and nutrient intake in the United States. Science 224 : 1392-1398, 1984.
 
14) Griffith LE, et al : The influence of dietary and nondietary calcium supplementation on blood pressure : an update metaanalysis of randomized controlled trials. Am J Hypertens 12 : 84-92, 1999.
PubMed
15) Saiichez M, et al : Oral calcium supplementation reduces intraplatelet free calcium concentration and insulin resistance in essential hypertensive patients. Hypertension 29 : 531-536, 1997.
 
16) Dazai Y, et al : Cardiovascular effect of oral calcium supplementation : echocardiographic study in patients with essential hypertension. Angiology 47 : 273-280, 1996.
PubMed
17) Hofmeyr GJ, et al : Calcium supplementation to prevent pre-eclampsia. A systematic review. S Afr Med J 93 : 224-228, 2003.
PubMed
18) Mizushima S, et al : Dietary magnesium intake and blood pressure : a qualitative overview of the observational studies. J Hum Hypertens 12 : 447-453, 1998.
PubMed
19) Sacks FM, et al : Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake. Hypertension 31 : 131-138, 1998.
PubMed
20) Kawano Y, et al : Effects of magnesium supplementation in hypertensive patients : assessment by office, home, and ambulatory blood pressures. Hypertension 32 : 260-265, 1998.
PubMed
21) Corsonello A, et al : Serum magnesium levels and cognitive impairment in hospitalized hypertensive patients. Magnes Res 14 : 273-282, 2001.
PubMed
22) Ascherio A, et al : Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation 98 : 1198-1204, 1998.
PubMed
23) Yang CY : Calcium and magnesium in drinking water and risk of death from cerebrovascular disease. Stroke 29 : 411-414, 1998.
PubMed
24) Kostis JB, et al : Prevention of heart failure by antihypertensive drug treatment in older patients with isolated systolic hypertension. JAMA 278 : 212-216, 1997.
PubMed
25) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999.
PubMed
26) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288 : 2981-2997, 2002.
PubMed
27) Svetkey LP, et al : Effects of dietary patterns on blood pressure : subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med 159 : 285-293, 1999.
PubMed
P.73 掲載の参考文献
1) Klatsky AL, et al : Alcohol consumption and blood pressure. N Engl J Med 296 : 1194-1200, 1977.
PubMed
2) Ueshima H, et al : Alcohol intake and hypertension among urban and rural Japanese populations. J Chronic Dis 37 : 585-592, 1984.
 
3) The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 157 : 2413-2446, 1997.
 
4) 若林一郎, 羽竹勝彦 : エタノールの神経系, 血管系への影響-特に高血圧の発症機序と関連して-. 日衛誌 55 : 607-617, 2001.
 
5) Vasdev S, et al : N-acetyl cysteine attenuates ethanol induced hypertension in rats. Artery 21 : 312-336, 1995.
PubMed
6) Yamada Y, et al : Genetic differences in ethanol metabolizing enzymes and blood pressure in Japanese alcohol consumers. J Hum Hypertens 16 : 479-486, 2002.
PubMed
7) Yamada Y, et al : Alcohol, high blood pressure, and serum γ-glutamyl transpeptidase level. Hypertension 18 : 819-826, 1991.
 
8) Yamada Y, et al : Serum γ-glutamyl transferase levels and blood pressure falls after alcohol moderadon. Clin Exp Hypertens 19 : 249-268, 1997.
 
P.78 掲載の参考文献
1) Green MS, et al : Blood pressure in smokers and nonsmokers : epidemiologic findings. Am Heart J 111 : 932-940, 1986.
PubMed
2) Minami J, et al : Is it time to regard cigarette smoking as a risk factor in the development of sustained hypertension? Am J Hypertens 12 : 948-949, 1999.
 
3) Cryer PE, et al : Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 295 : 573-577, 1976.
PubMed
4) Groppelli A, et al : Persistent blood pressure increase induced by heavy smoking. J Hypertens 10 : 495-499, 1992.
PubMed
5) Flegal KM, et al : The influence of smoldng cessation on the prevalence of overweight in the United States. N Engl J Med 333 : 1165-1170, 1995.
PubMed
6) Istvan JA, et al : Relation of salivary cotinine to blood pressure in middle-aged cigarette smokers. Am Heart J 137 : 928-931, 1999.
PubMed
7) Mann SJ, et al : Elevation of ambulatory systolic blood pressure in hypertensive smokers. A casecontrol study. JAMA 265 : 2226-2228, 1991.
 
8) Verdecchia P, et al : Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension. J Hypertens 13 : 1209-1215, 1995.
PubMed
9) Minami J, et al : Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. Hypertension 33 : 586-590, 1999.
PubMed
10) Vriz O, et al : Smoking is associated with higher cardiovascular risk in young women than in men : the Tecumseh Blood Pressure Study. J Hypertens 15 : 127-134, 1997.
PubMed
11) Pinto-Sietsma SJ, et al : Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 133 : 585-591, 2000.
PubMed
12) Wachtell K, et al : Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy : the LIFE study. J Hypertens 20 : 405-412, 2002.
PubMed
13) Klag MJ, et al : Blood pressure and end-stage renal disease in men. N Engl J Med 334 : 13-18, 1996.
 
14) Orth SR : Smoking and the kidney. J Am Soc Nephrol 13 : 1663-1672, 2002.
PubMed
P.86 掲載の参考文献
1) Blair SN, et al : Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA 252 (4) : 487-490, 1984.
PubMed
2) Tanaka H, et al : Prevalence rate of hypertension in relation to physical fitness. In : Sports, Medicine and Health (ed by Hermans GPH), p 1059, Elsevier Science, Amsterdam, 1990.
 
3) Kukkonen K, et al : Physical training of middle-aged men with borderline hypertension. Ann Clin Res 14 (Suppl 34) : 139-145, 1982.
 
4) Kiyonaga A, et al : Blood pressure and hormonal responses to aerobic exercise. Hypertension 7 (1) : 125-131, 1985.
PubMed
5) Duncan JJ, et al : The effects of aerobic exercise on plasma catecholamines and blood pressure in patients with mild essential hypertension. JAMA 254 (18) : 2609-2613, 1985.
PubMed
6) Urata H, et al : Antihypertensive and volume-depleting effects of mild exercise on essential hypertension. Hypertension 9 (3) : 245-252, 1987.
PubMed
7) Tanabe Y, et al : Changes in serum concentrations of taurine and other amino acids in clinical antihypertensive exercise therapy. Clin Exp Hypertens A 11 (1) : 149-165, 1989.
PubMed
8) Arakawa K, et al : Activation of renal dopamine system by physical exercise. Hypertens Res 18 (Suppl 1) : S73-77, 1995.
 
9) Tashiro E, et al : Crossover comparison between the depressor effects of low and high work-rate exercise in mild hypertension. Clin Exp Pharmacol Physiol 20 (11) : 689-696, 1993.
PubMed
10) Arakawa K : Antihypertensive mechanism of exercise. J Hypertens 11 (3) : 223-229, 1993.
PubMed
11) Kinoshita A, et al : What types of hypertensives respond better to mild exercise therapy? J Hypertens Suppl 6 (4) : S631-633, 1988.
PubMed
12) Rost R : Physical exercise and antihypertensive drugs. Nephron 47 (Suppl 1) : 27-29, 1987.
 
13) Motoyama M, et al : Blood pressure lowering effect of low intensity aerobic training in elderly hypertensive patients. Med Sci Sports Exerc 30 (6) : 818-823, 1998.
PubMed
14) Sasaki J, et al : Mild exercise therapy increases serum high density lipoprotein 2 cholesterol levels in patients with essential hypertension. Am J Med Sci 297 (4) : 220-223, 1989.
PubMed
15) Bursztyn M, et al : Disparate effects of exercise training on glucose tolerance and insulin levels and on ambulatory blood pressure in hypertensive patients. J Hypertens 11 (10) : 1121-1125, 1993.
PubMed
16) Jennings G, et al : Effects of exercise and other nonpharmacological measures on blood pressure and cardiac hypertrophy. J Cardiovasc Pharmacol 17 (Suppl 2) : S70-74, 1991.
PubMed
P.90 掲載の参考文献
1) Examination Committee of Criteria for 'Obesity Diseases' in Japan ; Japan Society for the Study of Obesity : New Criteria for 'Obesity Disease' in Japan. Circ J 66 : 987-992, 2002.
 
2) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289 (19) : 2560-2572, 2003.
 
3) Guideline Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
4) Nakamura T, et al, The group of the Research for the Association between Host Origin and Atherosclerotic Diseases under the Preventive Measure for Work-related Diseases of the Japan Labor Ministry : Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees : A case-control study. Jpn Circ J 65 : 11-17, 2001.
 
5) Kuczmarski RJ, et al : Varying body mass index cutoff points to describe overweight prevalence among U. S. adults ; HANES III (1988 to 1994). Obes Res 5 : 542-548, 1997.
 
6) Wilett WC, et al : Weight, weight change, and coronary heart disease in woman. Risk within the 'normal' weight range. JAMA 273 : 461-465, 1995.
 
7) 厚生労働省健康局 : 第5次循環器疾患基礎調査報告 (平成12年), 平成14年3月.
 
8) Yamamoto A, et al : Risk factors for coronary heart disease in the Japanese-Comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population. J Atheroscler Thromb 9 : 191-199, 2002.
PubMed
9) Okuno A, et al : Troglitazone increases the number of small adiposis without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101 : 1354-1361, 1998.
 
10) Weidmann P : Recent pathogenic aspects in essential hypertension and hypertension associated with diabetes mellitus. Min Wochenschr 58 : 1071-1089, 1980.
 
11) MacGregar GA, et al : Double-blind randomized crossover trial of moderate sodium restriction in essential hypertension. Lancet i : 351-355, 1982.
 
12) DeFronzo RA : The effect of insulin on renal sodium metabolism. Diabetologia 21 : 165-171, 1981.
PubMed
13) Cordes U, et al : Plasma catecholamines in long term diabetes. Horm Metab Res Suppl 9 : 90-93, 1980.
PubMed
14) Rowe JR, et al : Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 30 : 219-225, 1981.
 
15) Mutzel MS, et al : Mechanisms of insulin action on sympathetic nerve activity. Clin Exp Hypertens 17 (1&2) : 39-50, 1995.
 
16) Zhang Y, et al : Positional cloning of the mouse obese gene and its human homologue. Nature 372 : 425-432, 1994.
PubMed
17) Campfield LA, et al : Strategies and potential molecular targets for obesity treatment. Science 280 : 1383-1387, 1998.
PubMed
18) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン2000年版, 日本高血圧学会, 2000.
 
19) The Trial of Hypertension Prevention Collaborative Research Group : Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trial of Hypertension. Arch Intern Med 157 : 657-667, 1997.
 
20) He J, et al : Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 35 : 544-549, 2000.
PubMed
21) Whelton PK, et al : Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of non pharmacologic interventions in the elderly (TONE). JAMA 279 : 839-846, 1998.
 
22) Sacks FM, et al : Effects on blood pressure of reduced dietary sodium and the Dietary Approach to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344 : 3-10, 2001.
 
23) Vollmere WM, et al : Effects of diet and sodium intake on blood pressure : Subgroup analysis of the DASH-sodium trial. Ann Intern Med 135 : 1019-1028, 2001.
 
24) Arakawa K : Antihypertensive mechanism of exercise. J Hypertens 11 : 223-229, 1993.
PubMed
25) Kiyonaga A, et al : Blood pressure and hormonal responses to aerobic exercise. Hypertension 7 : 125-131, 1985.
PubMed
26) 大蔵倫博, 田中喜代次 : 内臓脂肪と運動療法. 肥満研究 6 (2) : 125-129, 2000.
Medical*Online
P.96 掲載の参考文献
1) Hilbert P, et al : Chromosomal mapping of two genetic loci associated with blood pressure regulation in hereditary hypertensive rats. Nature 353 : 521-529, 1991.
PubMed
2) Ogihara T, et al : Genetic analysis of essential hypertension in Japanese populations. Ann NY Acad Sci 902 : 8-16, 2001.
 
3) Deschepper CF : In search of cardiovascular candidate genes : interactions between phenotypes and genotypes. Hypertension 39 : 332-336, 2002.
PubMed
4) Lifton RP, et al : A chimaeric l l beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355 : 262-265, 1992.
 
5) Stewart PM, et al : Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the l l beta-hydroxysteroid dehydrogenase type 2 gene. Lancet 347 : 88-91, 1996.
 
6) Lifton RP, et al : Molecular mechanisms of human hypertension. Cell 104 : 545-556, 2001.
PubMed
7) Hansson JH, et al : Hypertension caused by a truncated epithelial sodium channel gamma subunit : genetic heterogeneity of Liddle syndrome. Nat Genet 11 : 76-82, 1995.
PubMed
8) Geller DS, et al : Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 19 : 279-281, 1998.
 
9) Wilson FH, et al : Human hypertension caused by mutations in WNK kinases. Science 293 : 1107-1112, 2001.
PubMed
10) Inoue I, et al : Nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99 : 1786-1797, 1997.
PubMed
11) Takami S, et al : Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study. Am J Hypertens 13 : 121-127, 2000.
PubMed
12) Yilmaz H, et al : Is epsilon4 allele of apolipoprotein E associated with more severe end-organ damage in essential hypertension? Cell Biochem Funct 19 : 191-195, 2001.
 
13) Lajemi M, et al : Endothelin gene variants and aortic and cardiac structure in never-treated hypertensives. Am J Hypertens 14 : 755-760, 2001.
PubMed
14) Ravera M, et al : 5, 10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. Am J Hypertens 14 : 371-376, 2001.
PubMed
P.103 掲載の参考文献
1) Jeunemaitre X, et al : Molecular basis of human hypertension : role of angiotensinogen. Cell 71 (1) : 1992.
PubMed
2) Sethi AA, et al : Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease : a meta-analysis. Arterioscler Thromb Vasc Biol 23 (7) : 1269-1275, 2003.
PubMed
3) Lalouel JM : From genetics to mechanism of disease liability. Adv Genet 42 : 517-533, 2001.
PubMed
4) Inoue I, et al : A mutation of angiotensinogen in a patient with preeclampsia leads to altered kinetics of the renin-angiotensin system. J Biol Chem 270 (19) : 11430-11436, 1995.
 
5) Inoue L et al : A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99 (7) : 1786-1797, 1997.
 
6) Nakajima T, et al : Molecular cloning and functional analysis of a factor that binds to the proximal promoter of human angiotensinogen. J Hum Genet 47 (1) : 7-13, 2002.
 
7) Ishigami T, et al : Angiotensinogen gene polymorphism near transcription start site and blood pressure : role of a T-to-C transition at intron 1. Hypertension 34 (3) : 430-434, 1999.
 
8) Zhao YY, et al : Role of C/A polymorphism at-20 on the expression of human angiotensinogen gene. Hypertension 33 (1) : 108-115, 1999.
 
9) Hunt SC, et al : Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension : trials of hypertension prevention, phase II. Hypertension 32 (3) : 393-401, 1998.
PubMed
10) Hilgers KF, et al : Angiotensinogen gene core promoter variants and non-modulating hypertension. Hypertension 38 (6) : 1250-1254, 2001.
PubMed
11) Jeunemaitre X, et al : Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet 60 (6) : 1448-1460, 1997.
PubMed
12) Nakajima T, et al : Nucleotide diversity and haplotype structure of the human angiotensinogen gene in two populations. Am J Hum Genet 70 (1) : 108-123, 2002.
PubMed
13) Navar LG, et al : Tubular fluid concentrations and kidney contents of angiotensins I and II in anesthetized rats. J Am Soc Nephrol 5 (4) : 1153-1158, 1994.
PubMed
14) Lantelme P, et al : Effects of dietary sodium and genetic background on angiotensinogen and renin in mouse. Hypertension 39 (5) : 1007-1014, 2002.
PubMed
P.107 掲載の参考文献
1) 檜垣實男 : アンジオテンシン変換酵素遺伝子. 分子高血圧 (萩原俊男ほか編), p18-19, 先端医学社, 2002.
 
2) Morgan T, et al : Overestimation of genetic risks owing to small sample sizes in cardiovascular studies. Clin Genet 64 : 7-17, 2003.
PubMed
3) Hibi K, et al : Angiotensin-converting enzyme gene polymorphism adds risk for the severity of coronary atherosclerosis in smokers. Hypertension 30 : 574-579, 1997.
PubMed
4) Olivieri O, et al : Different impact of deletion polymorphism of gene on the risk of renal and coronary artery disease. J Hypertens 20 : 37-43, 2002.
PubMed
5) Sayed-Tabatabaei FA, et al : Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness : a meta-analysis. Stroke 34 : 1634-1639, 2003.
PubMed
6) Higaki J, et al : Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men : the Suita Study. Circulation 101 : 2060-2065, 2000.
PubMed
7) Murphey LJ, et al : Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 102 : 829-832, 2000.
 
8) Zhang B, et al : The I allele of the angiotensin-converting enzyme gene is associated with an increased percentage of slow-twitch type I fibers in human skeletal muscle. Clin Genet 63 : 139-144, 2003.
PubMed
9) Hernandez N, et al : Muscle fiber composition and capillarization in relation to metabolic alterations in hypertensive men. J Med 32 : 67-82, 2001.
 
10) Gallagher PE, et al : Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension 33 : 323-328, 1999.
PubMed
11) Yoram Y, Chana Y : Hypothesis ACE2 modulates blood pressure in the mammalian organism. Hypertension 41 : 871-873, 2003.
 
12) Scwartz GL, et al : Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 62 : 1718-1723, 2002.
 
13) Zhang B, et al : Association of angiotensin-converting enzyme gene polymorphism With the depressor response to mild exercise therapy in patients with mild to moderate essential hypertension. Clin Genet 62 : 328-333, 2002.
PubMed
14) 川端雅彦, 高畠利一 : ACE阻害薬と腎保護作用. ACE阻害薬のすべて, 第3版 (日和田邦男ほか編), p78-86, 先端医学社, 1999.
 
P.111 掲載の参考文献
1) Gardner K, Bennett V : A new erythrocyte membrane-associated protein with calmodulin binding activity. Identification and purification. J Biol Chem 261 (3) : 1339-1348, 1986.
 
2) Manunta P, et al : Genetic determinants and renal mechanisms in essential hypertension. J Hum Hypertens 10 : 649-656, 1996.
PubMed
3) Bianchi G, et al : Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 91 : 3999-4003, 1994.
PubMed
4) Cusi D, et al : Polymorphism of α-adducin and salt sensitivity in patients with essential hypertension. Lancet 349 : 1353-1357, 1997.
 
5) Manunta P, et al : Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. Hypertension 33 : 694-697, 1999.
PubMed
6) Iwai N, et al : Polymorphism of α-adducin and hypertension. Lancet 350 : 369, 1997.
 
7) Tamaki S, et al : Polymorphism of α-adducin in Japanese patients with essential hypertension. Hypertens Res 21 : 29-32, 1998.
 
8) Sugimoto K, et al : Alpha-adducin Gly460Trp polymorphism is associated with low renin hypertension in younger subjects in the Ohasama study. J Hypertens 20 : 1730-1735, 2002.
 
9) Kato N, et al : Lack of association between the α-adducin locus and essential hypertension in the Japanese population. Hypertension 31 : 730-733, 1998.
 
10) Ishikawa K, et al : No association between alpha-adducin 460 polymorphism and essential hypertension in a Japanese population. Am J Hypertens 11 (4 Pt 1) : 502-506, 1998.
 
11) Wang WY, et al : The Gly460Trp variant of alpha-adducin is not associated with hypertension in white Anglo-Australians. Am J Hypertens 12 (6) : 632-636, 1999.
 
12) Kamitani A, et al : Human alpha-adducin gene, blood pressure, and sodium metabolism. Hypertension 32 (1) : 138-143, 1998.
PubMed
13) Castellano M, et al : Alpha-adducin gene polymorphism and cardiovascular phenotypes in a general population. J Hypertens 15 (12 Pt 2) : 1707-1710, 1997.
 
14) Sciarrone MT, et al : ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 41 : 398-403, 2003.
PubMed
15) Morrison AC, et al : ADDI 460W allele associated with cardiovascular disease in hypertensive individuals. Hypertension 39 : 1053-1057, 2002.
 
P.115 掲載の参考文献
1) Kuro-o M, et al : Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 : 45-51, 1997.
PubMed
2) Shirald-Iida T, et al : Improvement of multiple pathophysiological phenotypes of klotho (kl/kl) mice by adenovirus-mediated expression of the klotho gene. J Gene Med 2 : 233-242, 2000.
 
3) Matsumura Y, et al : Identification of the human klotho gene and its tWo transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun 242 : 626-630, 1998.
PubMed
4) Shiraki-Iida T, et al : Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett 424 : 6-10, 1998.
PubMed
5) Saito Y, et al : Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 248 : 324-329, 1998.
PubMed
6) Nakamura T, et al : Production of nitric oxide, but not prostacyclin, is reduced in klotho mice. Jpn J Pharmacol 89 : 149-156, 2002.
 
7) Nagai T, et al : Cognition impairment in the genetic model of aging klotho gene mutant mice : a role of oxidative stress. FASEB J 17 : 50-52, 2003.
PubMed
8) Aizawa H, et al : Downregulation of the Klotho gene in the kidney under sustained circulatory stress in rats. Biochem Biophys Res Commun 249 : 865-871, 1998.
PubMed
9) Yamagishi T, et al : Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. Hypertens Res 24 : 705-709, 2001.
PubMed
10) Saito Y, et al : In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun 276 : 767-772, 2000.
PubMed
11) Mitani H, et al : In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 39 : 838-843, 2002.
PubMed
P.120 掲載の参考文献
1) Szpirer C, et al : Chromosomal assignment of human and rat hypertension candidate genes : type 1 angiotensin II receptor genes and the SA gene. J Hypertens 11 : 919-925, 1993.
 
2) Clauser E, et al : Angiotensin II receptors : protein and gene structures, expression and potential pathological involvements. Eur J Endocrinol 134 : 403-411, 1996.
PubMed
3) Deng AY, Rapp JP : Evaluation of the angiotensin II receptor AT1B gene as a candidate gene for blood pressure. J Hypertens 12 : 1001-1006, 1994.
PubMed
4) Ito M, et al : Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92 : 3521-3525, 1995.
PubMed
5) Chen X, et al : Targeting deletion of angiotensin type 1B receptor gene in the mouse. Am J Physiol 272 : F299-304, 1997.
PubMed
6) Oliverio MI, et al : Reduced growth, abnomal kidney stnlcture, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc Natl Acad Sci USA 95 : 15496-15501, 1998.
 
7) Kantachuvesiri S, et al : Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats. Kidney Int 56 : 414-420, 1999.
PubMed
8) Hoffmann S, et al : Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy. J Mol Med 79 : 601-608, 2001.
PubMed
9) Leclerc PC, et al : A polyaromatic caveolin-binding-like motif in the cytoplasmic tail of the type 1 receptor for angiotensin II plays an important role in receptor trafficking and signaling. Endocrinology 143 : 4702-4710, 2002.
PubMed
10) Bonnardeaux A, et al : Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24 : 63-69, 1994.
PubMed
11) Benetos A, et al : Influence of angiotensin II type 1 receptor polymorphism on aortic stiffness in never-treated hypertensive patients. Hypertension 26 : 44-47, 1995.
PubMed
12) Takami S, et al : Angiotensin II type 1 receptor gene polymorphism is associated with increase of left ventricular mass but not with hypertension. Am J Hypertens 11 : 316-321, 1998.
 
13) Takami S, et al : Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study. Am J Hypertens 13 : 121-127, 2000.
PubMed
14) Kikuya M, et al : A/C1166 gene polymorphism of the angiotensin II type 1 receptor (AT1) and ambulatory blood pressure : the Ohasama Study. Hypertens Res 26 : 141-145, 2003.
PubMed
15) Ono K, et al : Lack of association between angiotensin II type 1 receptor gene polymorphism and hypertension in Japanese. Hypertens Res 26 : 131-134, 2003.
PubMed
16) Zhang X, et al : Evaluation of three polymorphisms in the promoter region of the angiotensin II type I receptor gene. J Hypertens 18 : 267-272, 2000.
 
17) Tiret L, et al : Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 344 : 910-913, 1994.
PubMed
18) Henskens LH, et al : Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in ahealthy normotensive primary care population : first results of the Hippocates study. J Hypertens 21 : 81-86, 2003.
 
19) Hindorff LA, et al : Angiotensin II type 1 receptor polymorphisms in the cardiovascular health study : relation to blood pressure, ethnicity, and cardiovascular events. Am J Hypertens 15 : 1050-1056, 2002.
PubMed
20) Coll E, et al : Association between the A1166C polymorphism of the angiotensin II receptor type 1 and progression of chronic renal insufficiency. J Nephrol 16 : 357-364, 2003.
PubMed
21) Buraczynska M, et al : Angiotensin II type 1 receptor gene polymorphism in end-stage renal disease. Nephron 92 : 51-55, 2002.
PubMed
22) Wallukat G, et al : Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 103 : 945-952, 1999.
PubMed
23) Katsuya T, et al : Effects of antihypertensive drugs and gene variants in the renin-angiotensin system. Hypertens Res 24 : 463-467, 2001.
PubMed
24) Takahashi N, et al : Minireview : computer simulations of blood pressure regulation by the renin-angiotensin system. Endocrinology 144 : 2184-2190, 2003.
PubMed
25) AbdAlla S, et al : AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407 : 94-98, 2000.
PubMed
P.125 掲載の参考文献
1) Mitchell BD, et al : A paired sibling analysis of the β3-adrenergic receptor and obesity in Mexican Arnericans. J Clin Invest 101 : 584-587, 1998.
 
2) Walston J, et al : Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β3-adrenergic-receptor gene. N Engl J Med 333 : 343-347, 1995.
 
3) Widen E, et al : Association of a polymorphism in the β3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 333 : 348-351, 1995.
 
4) Clement K, et al : Genetic variation in the, β3-adenergic receptor and capacity to gain weight in patients with morbid obesity. N Engl J Med 333 : 352-354, 1995.
 
5) Yoshida T, et al : Mutation of β3-adrenergic-receptor gene and response to treatment of obesity. Lancet 346 : 1433-1434, 1995.
 
6) Yoshioka K, et al : Association ofTrp64Arg mutation of the β3-adrenergic receptor gene with NIDDM, current and maximal body mass index. Diabetologia 39 : 1410, 1996.
 
7) Sakane N, et al : β3-adrenergic-receptor polymorphism : agenetic marker for obesity and insulin resistance syndrome. Diabetologia 40 : 200-204, 1997.
 
8) 吉田俊秀 : 一塩基多型遺伝子と肥満. 臨床検査 47 : 310-312, 2003.
 
9) Pietri-Rouxel F, et al : The biochemical effect of the naturally occurring Trp64→Arg mutation on humanβ3-adrenoceptor activity. Eur J Biochem 247 : 1174-1179, 1997.
 
10) Kimura K, et al : Mutated human β3-adrenergic receptor (Trp64Arg) lowers the response to β3-adrenergic agonist in transfected 3T3-L1 preadipocytes. Horm Metab Res 32 : 91, 2000.
 
11) Umekawa T, et al : Trp64Arg mutation of β3-adrenoceptor gene deteriorates lipolysis induced by β3-adrenoceptor agonist in human omental adipocytes. Diabetes 48 : 117, 1999.
 
12) Egan BM : Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep 5 : 247-254, 2003.
PubMed
13) Trochu JN, et al : β3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol 128 : 69-76, 1999.
 
14) Donckier JE, et al : Cardiovascular effects of β3-adrenoceptor stimulation in perinephritic hypertension. Eur J Clin Invest 31 : 681-689, 2001.
 
15) 吉田俊秀 : 遺伝子診断に基づいた高血圧・糖尿病合併肥満症のテーラーメイド食事療法. 日本臨牀 61 : 1093-1098, 2003.
Medical*Online
P.129 掲載の参考文献
1) Hamm HE : The many faces of G protein signaling. J Biol Chem 273 : 669-672, 1998.
PubMed
2) Siffert W, et al : Associadon of a human G-protein beta3 subunit variant with hypertension. Nat Genet 18 : 45-48, 1998.
 
3) Rosskopf D, et al : Gprotein beta 3 gene : structure, promoter, and additional polymorphisms. Hypertension 36 : 33-41, 2000.
 
4) Zeltner R, et al : G-protein beta (3) subunit gene (GNB3) 825T allele is associated with enhanced renal perfusion in early hypertension. Hypertension 37 : 882-886, 2001.
PubMed
5) Bluthner M, et al : Increased frequency of G-protein beta 3-subunit 825 T allele in dialyzed patients with type 2 diabetes. Kidney Int 55 : 1247-1250, 1999.
PubMed
6) Siffert W, et al : Worldwide ethnic distribudon of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 10 : 1921-1930, 1999.
 
7) Ishikawa K, et al : Human G-protein beta 3 subunit variant is associated with serum potassium and total cholesterol levels but not with blood pressure. Am J Hypertens 13 : 140-145, 2000.
 
8) Kato N, et al : Gprotein beta3 subunit vanant and essential hypertension in Japanese. Hypertension 32 : 935-938, 1998.
 
9) Ohshiro Y, et al : Analysis of 825C/T polymorphism of G protein beta3 subunit in obese/diabetic Japanese. Biochem Biophys Res Commun 286 : 678-680, 2001.
 
10) Poch E, et al : G-protein beta (3) subunit gene variant and left ventricular hypertrophy in essential hypertension. Hypertension 35 (1 Pt 2) : 214-218, 2000.
 
11) Wascher TC, et al : Associations of a human G protein beta3 subunit dimorphism with insulin resistance and carotid atherosclerosis. Stroke 34 : 605-609, 2003.
 
12) Turner ST, et al : C825T polymorphism of the G protein beta (3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 37 : 739-743, 2001.
 
13) von Beckerath N, et al : Gprotein beta 3 subunit 825T allele caniage and risk of coronary artery disease. Atherosclerosis 167 : 135-139, 2003.
 
14) Morrison AC, et al : G-protein beta3 subunit and alpha-adducin polymorphisms and risk of subclinical and clinical stroke. Stroke 32 : 822-829, 2001.
PubMed
15) Fernaiidez-Real JM, et al : Gprotein beta3 gene variant, vascular function, and insulin sensitivity in type 2 diabetes. Hypertension 41 : 124-129, 2003.
 
16) Abe M, et al : Association of GNAS1 gene variant with hypertension depending on smoking status. Hypertension 40 : 261-265, 2002.
PubMed

IV 高血圧性臓器障害に関する基礎研究

P.137 掲載の参考文献
1) Kjeldsen SE, et al : Arterial plasma norepinephrine correlates to blood pressure in middle-aged men with sustained essential hypertension. Am Heart J 118 : 775-781, 1989.
PubMed
2) Ross AE, et al : Gender specific sympathetic and hemorrheological responses to mental stress in healthy young subjects. Scand Cardiovasc J 35 : 307-312, 2001.
PubMed
3) Rostrup M, et al : Cardiovascular reactivity, coronary risk factors, and sympathetic activity in young men. Hypertension 22 : 891-899, 1993.
PubMed
4) Korner PI, et al : Autonomic and non-autonomic circulatory components in essential hypertension in man. Circulation 48 : 107, 1973.
PubMed
5) Alvarez GE, et al : Sympathetic neural activation in visceral obesity. Circulation 106 : 2533-2536, 2002.
PubMed
6) Moan A, et al : Insulin sensitivity, sympathetic activity, and cardiovascular reactivity in young men. Am J Hypertens 8 : 268-275, 1995.
PubMed
7) Nishimura M, et al : The effects of insulin and insulin-like materials in the brain on central cardiovascular regulation : with special reference to the central effects of sodium chloride. J Hypertens 9 : 509-517, 1991.
 
8) Fossum E, et al : Relationship between insulin sensitivity and maximal forearm blood flow in young men. Hypertension 32 : 838-843, 1998.
PubMed
9) Kjeldsen SE, et al : World Health Organization ; International Society of Hypertension. 1999 WHO/ISH hypertension guidelines-highlights and esh update. J Hypertens 19 : 2285-2288, 2001.
 
P.143 掲載の参考文献
1) Miyazaki M, Takai S : Involvement of angiotensin II in development of atherogenesis. Nippon Rinsho 60 : 1904-1910, 2002.
PubMed
2) Varagic J, Frohlich ED : Local cardiac renin-angiotensin system : hypertension and cardiac failure. J Mol Cell Cardiol 34 : 1435-1442, 2002.
PubMed
3) Weber KT, Brilla CG : Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 : 1849-1865, 1991.
PubMed
4) Lonn E, et al ; SECURE Investigators : Effects of ramipril and vitamin E on atherosclerosis : the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitanmin E (SECURE). Circulation 103 : 919-925, 2001.
 
5) Heart Outcomes Prevention Evaluation Study Investigators : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus : results of the HOPE study and MICRO-HOPE substudy. Lancet 355 : 253-259, 2000.
PubMed
6) Cohn JN, et al : A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 : 303-310, 1991.
PubMed
7) The CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
 
8) The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 : 293-302, 1991.
PubMed
9) Pitt B, et al : Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure : randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 : 1582-1587, 2000.
PubMed
10) Cohn JN, Tognoni G ; Valsartan Heart Failure Trial Investigators : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
 
11) Dahlof B, et al : Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5 : 95-110, 1992.
PubMed
12) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study lnvestigators. N Engl J Med 341 : 709-717, 1999.
PubMed
13) Pitt B, et al ; Eplerenone Post-Acute Myocardial lnfarction Heart Failure Ethcacy and SurVival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
 
14) Powell JS, et al ; Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245 : 186-188, 1989.
PubMed
15) Peters S, et al : Valsartan for prevention of restenosis after stenting of type B2/C lesions : the VAL-PREST trial. J Invasive Cardiol 13 : 93-97, 2001.
 
16) Brenner BM, et al ; RENAAL Study Investigators : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861-869, 2001.
 
P.146 掲載の参考文献
1) Stier CT, et al : Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10 : 97-107, 2002.
PubMed
2) Weber KT, Brilla CG : Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 : 1849-1865, 1991.
PubMed
3) Rocha R, et al : Aldosterone : A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141 : 3871-3878, 2001.
 
4) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
5) Zennad F, et al : Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure : Insights from the randomized aldactone evaluation study (RALES). Circulation 102 : 2700-2706, 2000.
 
6) Bonvalet Jp, et al : Aldosterone : intracellular receptors in human heart. Eur Heart J 16 (Suppl) : 92-97, 1995.
PubMed
7) Zennaro M-C, et al : Human mineralocorticoid receptor genomic structure and identification of expressed isoforms. J Biol Chem 270 : 21016-21020, 1996.
 
8) Zennaro M-C, et al : Characterization of human mineralocorticoid receptor gene 5' regulatory region : evidence for differential hormonal regulation of two alternative promoters via non classical mechanism. Mol Endocrinol 12 (12) : 1549-1560, 1996.
 
9) Le Menuet D, et al : Alteration of cardiac and renal function in transgenic mice overexpressing human mineralocorticoid receptor J Biol Chem 276 : 38911-38920, 2001.
PubMed
10) Beggah AT, et al : Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc Natl Acad Sci USA 99 (10) : 7160-7165, 2002.
PubMed
11) Hatakeyama H, et al : 11β-hydroxysteroid dehydrogenase in cultured human vascular cells. Hypertension 33 : 1179-1184, 1999.
 
12) Koppel H, et al : Nongenomic effects of aldosterone on human renal cells. J Clin Endocrinol Metab 88 : 1297-1302, 2003.
 
13) Pitt B, et al ; Eplerenone Post-Acute Myocardial Infarction Heart Failure Ethcacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (14) : 1309-1321, 2003.
 
P.151 掲載の参考文献
1) Ihara M, et al : High cardiac angiotensin-II-forming activity in infarcted and non-infarcted human myocardium. Cardiology 94 : 247-253, 2000.
PubMed
2) Ihara M, et al : Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 33 : 1399-1405, 1999.
PubMed
3) Uehara Y, et al : Increased chymase activity in internal thoracic artery of patients with hypercholesterolemia. Hypertension 35 : 55-60, 2000.
PubMed
4) Toth T, et al : Mast cells in rapidly progressive glomerulonephritis. J Am Soc Nephrol 10 : 1498-1505, 1999.
PubMed
5) Takai S, et al : Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci 69 : 1725-1732, 2001.
PubMed
6) Takai S, et al : An orally active chymase inhibitor, BCEAB, suppresses heart chymase activity in the hamster. Jpn J pharmacol 86 : 124-126, 2001.
PubMed
7) Jin D, et al : Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci 71 : 437-446, 2002.
PubMed
8) Uehara Y, et al : Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res 55 : 870-876, 2002.
PubMed
9) Inoue Y, et al : Antihypertensive and antihypertrophic effects of chymase inhibitor in human chymase transgenic mice. Circ J 66 : 802, 2002.
 
10) Hoshino F, et al : Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol 41 : S11-18, 2003.
PubMed
P.155 掲載の参考文献
1) Catterall WA : Structure and regtilation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 16 : 521-555, 2000.
PubMed
2) Fleckenstein A : History of calcium antagonists. Circ Res 52 : 3-16, 1983.
 
3) Ino M, et al : Functional disorders of the sympathetic nervous system in mice lacking the α1B subunit (Cav2.2) of N-type calcium channels. Proc Natl Acad Sci USA 98 : 5323-5328, 2001.
 
4) Mori Y, et al : Ca2+ channel α1B subunit knockout mouse reveals a predominant role of N-type channels in the sympathetic regulation of the circulatory system. Trends Cardiovasc Med 12 : 270-275, 2002.
 
5) Murakami M, et al : Conserved smooth muscle contractility and blood pressure increase in response to high salt diet in mice lacking the β3 subunit of the voltage-dependent calcium channel. J Cardiovasc Pharmacol 36 : S69-73, 2000.
 
6) Murakami M, et al : Pain perception in mice lacking β3 subunit of voltage-activated calcium channels. J Biol Chem 277 : 40342-40351, 2002.
 
7) Speisenberger C, et al : Functional embryonic cardiomyocytes after disruption of the L-type alpha1C (Cav1.2) calcium channel gene in the mouse. J Biol Chem 275 : 39193-39199, 2000.
 
8) Chen L, et al : Stargazin regulates synaptic targeting of AMPA receptor by two distinct mechanisms. Nature 408 : 936-943, 2000.
PubMed
9) Hibino H, et al : Direct interaction with a nuclear protein and regulation of gene silencing by a variant of the Ca2+ -channel β4 subunit. Proc Natl Acad Sci USA 100 : 307-312, 2003.
 
P.159 掲載の参考文献
1) Gauthier C, et al : The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102 : 1377-1384, 1998.
PubMed
2) 小林俊一ほか : αアドレナリン受容体遺伝子. 日本臨牀 58 (増刊 : 高血圧 (上)) : 540-545, 2000.
 
3) 溝部俊樹 : アドレナリン受容体とノックアウトマウスー1) βアドレナリン受容体ノックアウトマウス. 麻酔 49 : 1349-1357, 2000.
 
4) Albrecht FE, et al : Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. J Clin Invest 97 : 2283-2288, 1996.
PubMed
5) Asico LD, et al : Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest 102 : 493-498, 1998.
PubMed
6) Takata Y, Kato H : Adrenoceptors in SHR : alterations in binding characteristics and intracellular signal transduction pathways. Life Sci 58 : 91-106, 1996.
PubMed
7) Sanchez A, Pettinger WA : Dietary sodium regulation of blood pressure and renal α1- and α2-receptors in WKY and SH rats. Life Sci 29 : 2795-2802, 1981.
 
8) Propping P, Friedl W : Genetic control of adrenergic receptors on human platelet. Hum Genet 64 : 105-109, 1983.
PubMed
9) Goldstein DS : Plasma catecholamines and essential hypertension. An analytical review. Hypertension 5 : 86-99, 1983.
PubMed
10) Philipp T, et al : Sympathetic nervous system and blood-pressure control in essential hypertension. Lancet ii : 959-963, 1978.
PubMed
11) Kato N, et al : Association analysis of beta (2)-adrenergic receptor polymorphisms with hypertension in Japanese. Hypertension 37 : 286-292, 2001.
PubMed
12) O'Shaughnessy KM, et al : The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 99 : 233-238, 2000.
PubMed
P.163 掲載の参考文献
1) Goldstein M, et al : Characterization and tissue localization of catecholamine synthesizing enzymes. Pharmacol Rev 24 : 293-308, 1972.
PubMed
2) Zinlichman R, et al : Derivation of urinary dopamine from plasma dopa. Clin Sci 75 : 515-520, 1988.
 
3) Jose PA, et al : The renal dopamine receptors. J Am Soc Nephrol 2 : 1265-1278, 1992.
PubMed
4) Lokhandwala MF, Chen CJ : Peripheral dopamine receptors. In : Dopamine Receptors and Transporters (ed by Niznik HB), p 89-102, Marcel Dekker, New York, 1994.
 
5) Felder CC, et al : Dopamine receptor subtypes in renal brush border and basolateral membrane. Kidney Int 36 : 183-193, 1989.
PubMed
6) Shusterman NH, et al : Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 95 : 161-168, 1993.
PubMed
7) Murphy MB, et al : Fenoldopam-A selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 345 : 1548-1557, 2001.
PubMed
8) Tumlin JA, et al : Fenoldopam, a dopamine agonist, for hypertensive emergency : amulticenter randomized trial. Fenoldopam study group. Acad Emerg Med 7 : 653-662, 2000.
 
9) Brooks DP, et al : Prevention and complete reversal of cyclosporin A-induced renal vasoconstriction and nephrotoxicity in the rat by fenoldopam. J Pharmacol Exp Ther 254 : 375-379, 1990.
PubMed
10) Nichols AJ, et al : The effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog. J Pharmacol Exp Ther 260 : 269-274, 1992.
PubMed
11) Yasunari K, et al : Dopamine as novel antioxidative agent for rat vascular smooth muscle cells through dopamine D1-like receptors. Circulation 101 : 2302-2308, 2000.
PubMed
12) Weinberger MH, et al : Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 37 : 429-432, 2001.
PubMed
13) Morimoto A, et al : Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 350 : 1734-1737, 1997.
PubMed
14) Sanada H, et al : Dopamine-1 receptor defect in renal proximal tubular cells in essential hypertension. Hypertension 33 : 1036-1042, 1999.
 
15) Felder RA, et al : G protein-coupled receptor kmase 4 gene variants in human essential hypertension. Proc Natl Acad Sci USA 99 : 3872-3877, 2002.
 
P.167 掲載の参考文献
1) Yanagisawa M, et al : A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 : 411-415, 1988.
PubMed
2) Inoue A, et al : The human endothelin family : three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86 : 2863-2867, 1989.
PubMed
3) Kurihara Y, et al : Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368 : 703-710, 1994.
PubMed
4) Kurihara Y, et al : Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest 96 : 293-300, 1995.
PubMed
5) Shimada K, et al : Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 269 : 18275-18278, 1994.
PubMed
6) Xu D, et al : ECE-1 : A membrane-bound metalloprotease that catalyses the proteolytic activation of big endothelin-1. Cell 78 : 473-485, 1994.
 
7) Emoto N, et al : Endothelin-converting enzyme-2 is a membrane-bound phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 270 : 15262-15268, 1995.
PubMed
8) Arai H, et al : Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348 : 730-732, 1990.
PubMed
9) Sakurai T, et al : Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348 : 732-735, 1990.
PubMed
10) Panza JA : High-normal blood pressure-more "high" than "normal". N Engl J Med 345 : 1337-1340, 2001.
PubMed
11) Krum H, et al : The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 338 : 784-790, 1998.
PubMed
12) Channick RN, et al : Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension : a randomised placebo-controlled study. Lancet 358 : 1119-1123, 2001.
PubMed
13) Sitbon O, et al : Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension : a 1-year follow-up study. Chest 124 : 247-254, 2003.
PubMed
P.173 掲載の参考文献
1) Dmitrieva RI, et al : Cardiotonic steroids : potential endogenous sodium pump ligands with diverse function. Exp Biol Med 227 : 561-569, 2002.
PubMed
2) Goto A, Yamada K : Ouabain-like factor. Curr Opin Nephrol Hypertens 7 (2) : 189-196, 1998.
PubMed
3) Periyasamy SM, et al : Effects of uremic serum on isolated cardiac myocyte calcium cycling and contractile function. Kidney Int 60 : 2367-2376, 2001.
PubMed
4) Aizman O, et al : Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc Natl Acad Sci USA 98 : 13420-13424, 2001.
PubMed
5) Xie Z, Askari A : Na (+) /K (+) -ATPase as a signal transducer. Eur J Biochem 269 : 2434-2439, 2002.
PubMed
6) Echevarria-Lima J, et al : Ca2+ mobilization induced by ouabain in thymocytes involves intracellular and extracellular Ca2+ pools. Hypertension 41 : 1386-1392, 2003.
PubMed
7) Aviv A : Salt consumption, reactive oxygen species and cardiovascular ageing : a hypothetical link. J Hypertens 20 : 555-559, 2002.
 
8) Goto A, Yamada K : Putative roles of ouabain-like compound in hypertension : revisited. Hypertens Res 23 : S7-S13, 2000.
PubMed
9) Fedorova OV, et al : Endogenous Na, K pump ligands are differentially regulated during acute NaCl loading of Dahl rats. Circulation 102 : 3009-3014, 2000.
 
10) Fedorova OV, et al : Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats. Hypertension 37 : 462-466, 2001.
PubMed
11) Fridman AI, et al : Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. J Hypertens 20 : 1189-1194, 2002.
PubMed
12) Fedorova OV, et al : Endogenous ligand of alpha (1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation 105 : 1122-1127, 2002.
PubMed
13) Manunta P, et al : Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 38 : 198-203, 2001.
PubMed
14) Hamlyn JM, et al : 11-hydroxylation in the biosynthesis of endogenous ouabain : multiple implications. Ann NY Acad Sci 986 : 685-693, 2003.
PubMed
15) El-Masri MA, et al : Human adrenal cells in culture produce both ouabain-like and dihydroouabain-like factors. Clin Chem 48 : 1720-1730, 2002.
PubMed
P.178 掲載の参考文献
1) 末松誠 : Gas biology : ガス分子による生体制御の生物学. 生化学 74 : 1317-1328, 2002.
 
2) Shibahara S, et al : Cloning and expression of cDNA for rat heme oxygenase. Proc Natl Acad Sci USA 82 : 7865-7869, 1985.
PubMed
3) Maines MD, et al : The inhibition of testicular heme oxygenase activity by cadmium. A novel cellular response. J Biol Chem 257 : 14116-14121, 1982.
PubMed
4) Sacerdoti D, et al : Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 243 : 388-390, 1989.
PubMed
5) Sabaawy HE, et al : Human heme oxygenase-1 gene transfer lowers blood pressure and promotes growth in spontaneously hypertensive rats. Hypertension 38 : 210-215, 2001.
PubMed
6) Suematsu M, et al : Carbon monoxide as an endogenous modulator of hepatic vascular perfUsion. Biochem Biophys Res Commun 205 : 1333-1337, 1994.
PubMed
7) Suematsu M, et al : Carbon monoxide : an endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest 96 : 2431-2437, 1995.
 
8) Goda N, et al : Distribution of heme oxygenase isoforms in rat liver. Topographic basis for carbon monoxide-mediated microvascular relaxation. J Clin Invest 101 : 604-612, 1998.
PubMed
9) Suematsu M, Ishimura Y : The heme oxygenase-carbon monoxide system : aregulator of hepatobiliary function. Hepatology 31 : 3-6, 2000.
PubMed
10) Minamino T, et al : Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA 98 : 8798-8803, 2001.
PubMed
11) Kyokane T, et al : Carbon monoxide from heme catabolism protects against hepatobiliary dysfunction in endotoxin-treated rat liver. Gastroenterology 120 : 1227-1240, 2001.
PubMed
12) Kharitonov VG, et al : Basis of guanylate cyclase activation by carbon mono) dde. Proc Natl Acad Sci USA 92 : 2568-2571, 1995.
 
13) Stone JR, Marletta MA : Soluble guanylate cyclase from bovine lung : activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry 33 : 5636-5640, 1994.
PubMed
14) Makino N, et al : Altered expression of heme oxygenase-1 in the livers of patients with portal hypertensive diseases. Hepatology 33 : 32-42, 2001.
PubMed
15) Shinoda Y, et al : Carbon monoxide as a regulator of bile canalicular contractility in cultured rat hepatocytes. Hepatology 28 : 286-295, 1998.
PubMed
P.188 掲載の参考文献
1) Reaven GM : Role of insulin resistance in human disease. Diabetes 37 : 1595-1607, 1988.
PubMed
2) Kaplan NM : The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149 : 1514-1520, 1989.
PubMed
3) DeFronzo RA, Ferrannini E : Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 : 173-194, 1991.
PubMed
4) Nakamura T, et al : Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107 : 239-246, 1994.
 
5) Nolan JJ, et al : Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331 : 1188-1193, 1994.
PubMed
6) Jurgen ML, et al : An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270 : 12953-12956, 1995.
 
7) Tanaka T, et al : Down regulation of peroxisome proliferator-activated receptor γ expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia 42 : 702-710, 1999.
 
8) Bany MF, et al : 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determinadon factor PPARγ. Cell 83 : 803-812, 1995.
 
9) Devchand PR, et al : The PPAR α-leukotriene B4 pathway to inflammation control. Nature 384 : 39-43, 1996.
 
10) Tontonoz P, et al : Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79 : 1147-1156, 1994.
 
11) Barroso I, et al : Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 : 880-883, 1999.
 
12) Ristow M, et al : Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 339 : 953-959, 1998.
 
13) Beamer BA, et al : Association of the Pro 12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes 47 : 1806-1808, 1998.
 
14) Deeb SS, et al : A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20 : 284-287, 1998.
 
15) Kubota N, et al : PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insuhn resistance. Mol Cell 4 : 597-609, 1999.
 
16) Ferrannini E, et al : Insulin resistance in essential hypertension. N Engl J Med 317 : 350-357, 1987.
PubMed
17) Flack JM, Sowers JR : Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med 91 : 11S-21S, 1991.
PubMed
18) Kaufman LN, et al : Pioglitazone attenuates diet-induced hypertension in rats. Metabolism 44 : 1105-1109, 1995.
PubMed
19) Yoshioka S, et al : Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42 : 75-80, 1993.
PubMed
20) Kemnitz JW, et al : Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 43 : 204-211, 1994.
PubMed
21) Song J, et al : Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Cae+currents and not endothelial nitric oxide production. Diabetes 46 : 659-664, 1997.
 
22) Fukunaga Y, et al : Endothelial actions of thiazolidines, peroxisome proliferator-activated receptor γ agonists, on cell growth and secretion of vasoactive substances. Atherosclerosis 158 : 113-117, 2001.
 
23) Diep QN, et al : Structure, endothelial function, cell growth, and inflammation in blood vessels of angio tensin II-infused rats : role of peroxisome proliferator-activated receptor-γ. Circulation 105 : 2296-2302, 2002.
 
24) Asakawa M, et al : Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105 : 1240-1246, 2002.
 
25) Ricote M, et al : Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95 : 7614-7619, 1998.
 
26) Itoh H, et al : Muldple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91 : 2268-2274, 1993.
PubMed
27) Itoh H, et al : Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 86 : 1690-1697, 1990.
 
28) Itoh H, et al : Hypertension and insulin resistance : role of peroxisome proliferator-activated receptor γ. Clin Exp Pharmacol Physiol 26 : 558-560, 1999.
 
29) Satoh H, et al : Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells : a new possible role of PPARγ on vascular endothelial function. Biochem Biophys Res Commun 254 : 757-763, 1999.
 
30) Delerive P, et al : Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85 : 394-402, 1999.
 
31) Dubey RK, et al : Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 265 : R726-732, 1993.
PubMed
32) Law RE, et al : Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98 : 1897-1905, 1996.
PubMed
33) Minamikawa J, et al : Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83 : 1818-1820, 1998.
PubMed
34) Tontonoz P, et al : PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 : 241-252, 1998.
 
35) Moore KJ, et al : The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat Med 7 : 41-47, 2001.
 
36) Chawla A, et al : PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7 : 48-52, 2001.
 
37) Chinetti G, et al : PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 : 53-58, 2001.
 
38) Pasceri V, et al : Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101 : 235-238, 2000.
 
39) Inoue M, et al : Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions : possible pathophysiological significance of VEGF in progression of atherosclerosis. Circuladon 98 : 2108-2116, 1998.
PubMed
40) Inoue M, et al : Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-γ. Arterioscler Thromb Vasc Biol 21 : 560-566, 2001.
 
P.194 掲載の参考文献
1) 上羽洋人, 川上正舒 : サイトカイン・成長因子と動脈硬化. 医学のあゆみ 193 : 308-318, 2000.
Medical*Online
2) Sawamura T, et al : A novel endothelial receptor for oxidized low density lipoprotein. Nature 386 : 73-77, 1997.
 
3) Adachi H, et al : Expression cloning of a novel scavenger receptor from human endothelial cells. J Biol Chem 272 : 31217-31220, 1997.
PubMed
4) Kume N, et al : Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 83 : 322-327, 1998.
PubMed
5) Hotamisligil GS, et al : Adipose expression of tumor necrosis factor-α : direct role in obesity-linked insulin resistance. Science 259 : 87-91, 1993.
 
6) Saghizadeh M, et al : The expression of TNFα by human muscle. Relationship to insulin resistance. J Clin Invest 97 : 1111-1116, 1996.
 
7) Togashi N, et al : The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats. J Hypertens 18 : 1605-1610, 2000.
 
8) Togashi N, et al : Effect of TNF-α-converting enzyme inhibitor on insulin resistance in fructosefed rats. Hypertension 39 : 578-580, 2002.
 
P.201 掲載の参考文献
1) Jiang W, et al : Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 29 : 209-248, 1999.
PubMed
2) Morishita R, et al : Hepatocyte growth factor as cardiovascular hormone : role of HGF in the pathogenesis of cardiovascular disease. Endocr J 49 : 273-284, 2002.
PubMed
3) Matsumoto K, Nakamura T : Hepatocyte growth factor : renotropic role and potential therapeutics for renal diseases. Kidney Int 59 : 2023-2038, 2001.
PubMed
4) Funakoshi H, Nakamura T : Hepatocyte growth factor : from diagnosis to clinical applications. Clin Chim Acta 327 : 1-23, 2003.
PubMed
5) Nakamura Y, et al : Hepatocyte growth factor is a novel member of the endothelium-specific growth factors : additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 14 : 1067-1072, 1996.
 
6) Yo Y, et al : Actions of hepatocyte growth factor as a local modulator in the kidney : potential role in pathogenesis of renal disease. Kidney Int 53 : 50-58, 1998.
PubMed
7) Nakagami H, et al : Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 37 : 581-586, 2001.
PubMed
8) Ueki T, et al : Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5 : 226-230, 1999.
PubMed
9) Taniyama Y, et al : Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 102 : 246-252, 2000.
PubMed
10) Nakamura Y, et al : Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun 215 : 483-488, 1995.
PubMed
11) Nakano N, et al : Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats. Hypertension 30 : 1448-1454, 1997.
PubMed
12) Nakano N, et al : Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-beta in blood vessels : potential role of HGF in cardiovascular disease. Hypertension 32 : 444-451, 1998.
PubMed
13) Matsumoto K, et al : Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Hypertension 34 : 279-284, 1999.
PubMed
14) Nakamura Y, et al : A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 28 : 409-413, 1996.
 
15) Yasuda S, et al : Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure. Hypertension 33 : 1374-1378, 1999.
PubMed
P.205 掲載の参考文献
1) Hall A : Rho GTPases and the actin cytoskeleton. Science 279 : 509-514, 1998.
PubMed
2) Kaibuchi K, et al : Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 68 : 459-486, 1999.
PubMed
3) Hirata K, et al : Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. J Biol Chem 267 : 8719-8722, 1992.
PubMed
4) Kitazawa T, et al : Gprotein-mediated inhibition of myosin light-chain phosphatase in vascular smooth muscle. Proc Natl Acad Sci USA 88 : 9307-9310, 1991.
 
5) Noda M, et al : Involvement of rho in GTP gamma S-induced enhancement of phosphorylation of 20 kDa myosin light chain in vascular smooth muscle cells : inhibition of phosphatase activity. FEBS Lett 367 : 246-250, 1995.
PubMed
6) Kimura K, et al : Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273 : 245-248, 1996.
PubMed
7) Amano M, et al : Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271 : 20246-20249, 1996.
PubMed
8) Uehata M, et al : Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389 : 990-994, 1997.
PubMed
9) Asano T, et al : Mechanism of action of a novel antivasospasm drug, HA1077. J Phamlacol Exp Ther 241 : 1033-1040, 1987.
PubMed
10) Shimokawa H, et al : Rho-kinase-mediated pathway induces enhanced myosin light chain phosphrylations in a swine model of coronary artery spasm. Cardiovasc Res 43 : 1029-1039, 1999.
 
11) Mukai Y, et al : Involvement of Rho-kinase in hypertensive vascular disease : a novel therapeutic target in hypertension. FASEB J 15 : 1062-1064, 2001.
PubMed
12) Eto Y, et al : Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J physiol Heart Circ Physiol 278 : H1744-1750, 2000.
PubMed
13) Miyata K, et al : Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 20 : 2351-2358, 2000.
PubMed
14) Shimokawa H, et al : Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 51 : 169-177, 2001.
 
15) Kandabashi T, et al : Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 22 : 243-248, 2002.
PubMed
P.210 掲載の参考文献
1) Agata J, et al : Association of insulin resistance and hyperinsulinemia with disturbed lipid metabolism in patients with essential hypertension. Hypertens Res 21 : 57-62, 1998.
PubMed
2) Pyorala M, et al : Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality : the 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care 23 : 1097-1102, 2000.
PubMed
3) Fontbonne A, et al : Coronary heart disease mortality risk : Plasma insulin level is a more sensitive marker than hypertension or abnormal glucose tolerance in overweight males. The Paris Prospective Study. Int J Obes 12 : 557-565, 1988.
PubMed
4) 高木覚ほか : 動脈硬化性疾患発症・進展とインスリン抵抗性/高インスリン血症-端野・壮瞥町研究より-. 第24回日本高血圧学会総会・抄録集, p62, 2001.
 
5) Tsuchihashi K, et al : Role of hyperinsulinemia in atherosclerotic coronary arterial disease : Studies of semi-quantitative coronary angiography. Intern Med 38 : 691-697, 1999.
PubMed
6) Welin L, et al : Hyperinsulinemia is not a major coronary risk factor in elderly men. The study of men born in 1913. Diabetologia 35 : 766-770, 1992.
 
7) Ferrara CM, Goldberg AP : Limited value of the homeostasis model assessment to predict insulin resistance in older men with impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 24 : 245-249, 2001.
 
8) Tominaga M, et al : Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 22 : 920-924, 1999.
 
9) Oimatsu H, et al : A practical index for evaluation of insulin resistance. J Japan Diab Soc 43 : 205-213, 2000.
 
10) Baron AD : The coupling of glucose metabolism and perfUsion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Diabetes 45 : S105-S109, 1996.
PubMed
11) King CL, Wakasaki H : Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular disease in diabetes. Diabetes Care 22 (Suppl 3) : C31-C37, 1999.
 
12) Hyakukoku M, et al : Tissue-specific impairment of insulin signaling in vasculature and skeletal muscle of fructose-fed rats. Hypertens Res 26 : 169-176, 2003.
PubMed
13) Yamaguchi Y, et al : The effect of tumor necrosis factor-α on tissue specificity and selectivity to insulin signaling. Hypertens Res 26 : 389-396, 2003.
 
P.214 掲載の参考文献
1) 森田啓行, 永井良三 : ホモシステイン代謝における遺伝子多型. 循環器専門医 10 : 101-106, 2002.
 
2) Morita H, et al : Polymorphism of the methionine synthase gene : association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. Arterioscler Thromb Vasc Biol 19 : 298-302, 1999.
 
3) Morita H, et al : Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury. Circulation 103 : 133-139, 2001.
PubMed
4) van Guldener C, Stehouwer CD : Hyperhomocysteinemia, vascular pathology, and endothelial dys function. Semin Thromb Hemost 26 : 281-289, 2000.
 
5) Bortolotto LA, et al : Plasma homocysteine, aortic stitlhess, and renal function in hypertensive patients. Hypertension 34 : 837-842, 1999.
PubMed
6) Hoogeveen EK, et al : Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation 101 : 1506-1511, 2000.
PubMed
7) Nygard O, et al : Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274 : 1526-1533, 1995.
PubMed
8) Osganian SK, et al : Distribution of and factors associated with serum homocysteine levels in children : Child and Adolescent Trial for Cardiovascular Health. JAMA 281 : 1189-1196, 1999.
PubMed
9) van Dijk RA, et al : Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness : a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 21 : 2072-2079, 2001.
PubMed
P.220 掲載の参考文献
1) Zhang Y, et al : Positional cloning of the mouse obese gene and its human homologue. Nature 372 : 425-432, 1994.
PubMed
2) Maffei M, et al : Leptin levels in human and rodent : measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1 : 1155-1161, 1995.
PubMed
3) Considine RV, et al : Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334 : 292-295, 1996.
PubMed
4) Tartaglia LA, et al : Identification and expression cloning of leptin receptor, OB-R Cell 83 : 1263-1271, 1995.
PubMed
5) Agata J, et al : High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 10 : 1171-1174, 1997.
PubMed
6) Shek EW, et al : Chronic leptin infusion increases arterial pressure. Hypertension 31 : 409-414, 1998.
PubMed
7) Casto RM, et al : Effects of central leptin administration on blood pressure in normotensive rats. Neurosci Lett 246 : 29-32, 1998.
PubMed
8) Ogawa Y, et al : Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 48 : 1822-1829, 1999.
PubMed
9) Masuzaki H, et al : Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation : usefulness of leptin for the treatment of obesity-associated diabetes. Diabetes 48 : 1615-1622, 1999.
PubMed
10) Aizawa-Abe M, et al : Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 105 : 1243-1252, 2000.
PubMed
P.227 掲載の参考文献
1) Funahashi T, et al : Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38 (2) : 202-206, 1999.
PubMed
2) Arita Y, et al : Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 : 79-83, 1999.
PubMed
3) Okamoto Y, et al : An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32 (2) : 47-50, 2000.
PubMed
4) Hotta K, et al : Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (6) : 1595-1599, 2000.
PubMed
5) Hotta K, et al : Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50 (5) : 1126-1133, 2001.
PubMed
6) Maeda N, et al : PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (9) : 2094-2099, 2001.
PubMed
7) Zoccali C, et al : Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13 : 134-141, 2002.
PubMed
8) Mallamaci F, et al : Adiponectin in essential hypertension. J Nephrol 15 : 507-511, 2002.
PubMed
9) Ouchi N, et al : Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 102 (11) : 1296-1301, 2000.
 
10) Arita Y, et al : Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105 (24) : 2893-2898, 2002.
PubMed
11) Ouchi N, et al : Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (8) : 1057-1063, 2001.
 
12) Kondo H, et al : Association of adiponectin mutation with type 2 diabetes. Diabetes 51 (7) : 2325-2328, 2002.
PubMed
13) Maeda N, et al : Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 (7) : 731-737, 2002.
PubMed
14) Matsuda M, et al : Role of adiponectin in preventing vascular stenosis-Missing link of adipo-vascular axis-. J Biol Chem 277 (40) : 37487-37491, 2002.
 
15) Okamoto Y, et al : Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (22) : 2767-2770, 2002.
PubMed
P.232 掲載の参考文献
1) Omata K, et al : Localization of active and inactive kallikrein (kininogenase activity) in the microdissected rabbit nephron. Kidney Int 22 : 602, 1982.
PubMed
2) Margolius HR : Kallikreins and kinins. Hypertension 26 : 221, 1995.
 
3) Monbouli JV, Vanhoutte PM : Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 35 : 679, 1995.
 
4) 平山良孝, 茅切浩 : ブラジキニン受容体拮抗薬の開発現況と今後の展開. 日薬理誌 (Folia Pharmacol Jpn) 119 : 45, 2002.
 
5) Majima M, Katori M : Approaches to the development of novel antihypertensive drugs : crucial role of the renal kallikrein-kinin system. Trends Pharmacol Sci 16 : 239, 1995.
 
6) Madeddu P, et al : Kallikrein-kinin system and blood pressure sensitivity to salt. Hypertension 29 (Part 2) : 471, 1997.
 
7) Alfie ME, et al : Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension 29 (Part 2) : 483, 1997.
 
8) Wang D, et al : Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 29 (Part 2) : 488, 1997.
 
9) Schmaier AH : The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol 285 : R1, 2003.
PubMed
P.237 掲載の参考文献
1) Narumiya S, et al : Prostanoid receptors : structures, properties and functions. Physiol Rev 79 : 1193-1226, 1999.
PubMed
2) Ushikubi F, et al : Molecular biology of prostanoid receptors : an overview. J Lipid Mediat Cell Signal 12 : 343-359, 1995.
PubMed
3) Watanabe H, et al : Effect of salt loading on blood pressure in mice lacking prostanoid receptor gene. J Am Soc Nephrol 9 : 318A, 1998.
 
4) Kennedy CRJ, et al : Salt-sensitive hypertension and reduced fenility in mice lacking the prostaglandin EP2 receptor. Nat Med 5 : 217-220, 1999.
 
5) Welch WJ, et al : Potentiation of tubuloglomerular feedback in the rat by thromboxane mimetic ; Role of macula densa. J Clin Invest 89 : 1857-1865, 1992.
PubMed
6) Welch WJ, et al : Salt loading enhances rat renal TXA2/PGH2 receptor expression and TGF response to U-46,619. Am J Physiol 273 : F976-F983, 1997.
 
7) Schnermann J, et al : Normal tubuloglomerular feedback in thromboxane receptor knockout mice. J Am Soc Nephrol 9 : 347A, 1998.
 
8) Ito S, et al : Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa. Kidney Int 35 : 1138-1144, 1989.
PubMed
9) Cheng HF, et al : Prostaglandins that increase renin production in response to ACE inhibition are not derived from cyclooxygenase-1. Am J Physiol 283 : R638-646, 2002.
PubMed
10) Bunting S, et al : The prostacyclin-thromboxane A2 balance : pathophysiological and therapeutic implications. Br Med Bull 39 : 271-276, 1983.
PubMed
11) Murata T, et al : Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 : 648-682, 1997.
 
12) Kramer HJ, et al : Effect of thromboxane A2 receptor blockade on oliguric ischemic acute renal failure in conscious rats. J Am Soc Nephrol 4 : 50-57, 1993.
 
13) Mandal AK, Miller J : Protection against ischemic acute renal failure by prostaglandin infusion. Prostaglandins Leukot Med 8 : 361-373, 1982.
PubMed
14) Eiro M, et al : Lack of prostanoid receptor involvement in ischemic acute renal failure in mice. Clin Exp Nephrol 6 : 85-90, 2002.
 
P.242 掲載の参考文献
1) Kitamura K, et al : Adrenomedullin : a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192 : 553-560, 1993.
PubMed
2) Kitamura K, et al : Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun 194 : 720-725, 1993.
PubMed
3) Shimosawa T, et al : Proadrenomedullin NH (2)-terminal 20 peptide, a new product of the adrenomedullin gene, inhibits norepinephrine overflow from nerve endings. J Clin Invest 96 (3) : 1672-1676, 1995.
PubMed
4) Mclatchie LM, et al : RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 : 333, 1998.
PubMed
5) Khan AI, et al : Hypotensive effect of chronically infused adrenomedullin in conscious Wistar-Kyoto and spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 24 : 139-142, 1997.
PubMed
6) Rademaker MT, et al : Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. Circulation 96 (6) : 1983-1990, 1997.
 
7) Tsuruda T, et al : Adrenomedullin : a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension 31 : 505-510, 1998.
 
8) Shindo T, et al : Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature. Circulation 101 : 2309-2316, 2000.
PubMed
9) Shindo T, et al : Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 104 : 1964-1971, 2001.
PubMed
10) Shimosawa T, et al : Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation 105 : 106-111, 2002.
PubMed
11) Ishimitsu T, et al : Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 94 (5) : 2158-2161, 1994.
PubMed
12) Kita T, et al : Short-term modulation of the renin-angiotensin system does not alter plasma adrenomedullin concentration in humans. J Hypertens 16 (12 Pt 2) : 2057-2062, 1998.
PubMed
13) Nishikimi T, et al : Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. J Hypertens 19 (4) : 765-773, 2001.
 
14) Mori Y, et al : Long-term adrenomedullin infusion improves survival in malignant hypertensive rats. Hypertension 40 (1) : 107-113, 2002.
PubMed
15) Chao J, et al : Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. Peptides 22 (11) : 1731-1737, 2001.
PubMed
P.246 掲載の参考文献
1) Paiva H, et al : Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 40 : 1241-1247, 2002.
PubMed
2) Kielstein JT, et al : Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 107 : 1891-1895, 2003.
PubMed
3) Cooke JP : Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20 : 2032-2037, 2000.
PubMed
4) Li L, et al : Endothelin-1 increases vascular superoxide via endothelin (A)-NADPH oxidase pathway in low-renin hypertension. Circulation 107 : 1053-1058, 2003.
PubMed
5) Landmesser U, et al : Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111 : 1201-1209, 2003.
PubMed
6) Taddei S, et al : Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 97 : 2222-2229, 1998.
PubMed
7) Rossi GP, et al : The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol 41 : 938-945, 2003.
 
8) Perticone F, et al : Prognostic signhicance of endothelial dysfunction in hypertensive patients. Circulation 104 : 191-196, 2001.
PubMed
9) Ceravolo R, et al : Pulse pressure and endothelial dysfunction in never-treated hypertensive patients. J Am Coll Cardiol 41 : 1753-1758, 2003.
PubMed
10) Guidelines Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
11) Verma S, et al : A self-fulfilling prophecy : C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106 : 913-919, 2002.
PubMed
12) Hill JM, et al : Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 : 593-600, 2003.
PubMed
13) 平田恭信 : 一酸化窒素と臓器保護. 内科 90 : 305-308, 2002.
 
14) Ghiadoni L, et al : Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 41 : 1281-1286, 2003.
PubMed
15) Klingbeil AU, et al : Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 16 : 123-128, 2003.
PubMed

V 高血圧性臓器障害の検査とその意義

P.252 掲載の参考文献
1) Franklin SS, et al : Measuring hypertensive cardiovascular risk ; The vascular overload concept. Am Heart J 128 : 793-803, 1994.
PubMed
2) Mitchell GF, et al : Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation 96 (12) : 4254-4260, 1997.
PubMed
3) Verdecchia P, et al : Ambulatory pulse pressure : a potent predictor of total cardiovascular risk in hypertension. Hypertension 32 (6) : 983-988, 1998.
PubMed
4) Yaginuma T, et al : Interaction of left ventricular contraction and aortic input impedance in experimental and clinical studies. Jpn Circ J 49 (2) : 206-214, 1985.
PubMed
5) 高沢謙二 : 左心室収縮期後方成分の臨床的検討. 東京医科大学雑誌 45 : 256-270, 1987.
 
6) Takazawa K, et al : Underestimation of vasodilator effects of nitroglycerin by upper limb blood pressure. Hypertension 26 : 520-523, 1995.
PubMed
7) Takazawa K, et al : Assessment of vasoactive agents and vascular aging by the second derivative of photoplethysmogram waveform. Hypertension 32 : 365-370, 1998.
PubMed
8) O'Rourke MF : Introduction. In : Arterial Function in Health and Disease, p 3-10, Churchill Livingstone, Edinburgh, 1982.
 
9) Nicols W, O'Rourke MF : McDonald's Blood Flow in Arteries. Theoretical, experimental and clinical principles, 4th ed, Arnold, London, 1998.
 
10) Wilkinson IB, et al : Pressure amplhication explains why pulse pressure is unrelated to risk in young subjects. Hypertension 38 (6) : 1461-1466, 2001.
PubMed
11) Blacher J, et al : Pulse pressure not mean pressure detemlines cardiovascular risk in older hypertensive patients. Arch Intern Med 160 (8) : 1085-1089, 2000.
 
12) Benetos A, et al : Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness : clinical applications. Am J Hypertens 15 (12) : 1101-1108, 2002.
PubMed
13) Ferrara LA, et al : Clinic and ambulatory pulse pressure segregate a cluster of cardiovascular risk factors. J Hum Hypertens 16 (10) : 719-724, 2002.
PubMed
14) Asmar R, et al : Pulse pressure : an important tool in cardiovascular pharmacology and therapeutics. Drugs 63 (10) : 927-932, 2003.
PubMed
15) Mitchell GF, et al : Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension. The role of proximal aortic diameter and the aortic pressure-flow relationship. Circulation 108 (13) : 1592-1598, 2003.
PubMed
P.258 掲載の参考文献
1) 宗像正徳 : 循環器疾患における動脈硬化. 消化器疾患と動脈硬化 (中澤三郎編), p37-49, 杏林書院, 2002.
 
2) Li Q, et al : Stretch-induced collagen synthesis in cultured smooth muscle cells from rabbit aortic media and possible involvement of angiotensin II and transforming growth factor-beta. J Vasc Res 35 : 93-103, 1998.
PubMed
3) Laurent S, et al : Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37 : 1236-1241, 2001.
PubMed
4) Blacher J, et al : Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99 : 2434-2439, 1999.
PubMed
5) Munakata M, et al : Utility of automated brachial ankle pulse wave velocity measurements in hypertensive patients. Am J Hypertens 16 : 653-657, 2003.
PubMed
6) Tomiyama H, et al : Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement-a survey of 12517 subjects. Atherosclerosis 166 (2) : 303-309, 2003.
PubMed
7) Ohnishi H, et al : Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose. Diabetes Care 26 : 437-440, 2003.
PubMed
8) Yamashina A, et al : Validity, reproducibility, and clinical significance of noninvasive brachialankle pulse wave velocity measurement. Hypertens Res 25 : 359-364, 2002.
 
9) Suzuki E, et al : Increased arterial wall stiffness limits flow volume in the lower extremities in type 2 diabetic patients. Diabetes Care 24 : 2107-2114, 2001.
PubMed
10) Syeda B, et al : Arterial compliance : a diagnostic marker for atherosclerotic plaque burden? Am J Hypertens 16 : 356-362, 2003.
 
11) Grey E, et al : Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am J Hypertens 16 (4) : 265-269, 2003.
 
12) 宗像正徳 : 高齢者のarterial stiffnessを考慮した高血圧治療. Arterial Stiffhess 4 : 35-40, 2003.
 
13) Munakata M, et al : Angiotensin II receptor blocker valsartan reduced arterial stiffness with favorable cardiac autonomic change in patients with essential hypertension. (submitted)
 
14) 宗像正徳 : 高血圧性臓器障害を適切に予防する降圧治療の確立にむけた多施設共同研究 (Japanese Trial On Prognostic implication of PWV : J-TOPP研究). 公益信託日本動脈硬化予防研究基金平成14年度研究報告, プロシーディング, p119-120, 2003.
 
P.262 掲載の参考文献
1) Kelly RP, et al : Non-invasive determination of age-related changes in the human arterial pulse. Circulation 80 : 1652-1659, 1989.
 
2) Yaginuma T, et al : Interaction of left ventricular contraction and aortic input impedance in experimental and clinical studies. Jpn Circ J 49 (2) : 206-214, 1985.
PubMed
3) Nicols W, O'Rourke MF : McDonald's Blood Flow in Arteries. Theoretical, experimental and clinical principles, 4th ed, Arnold, London, 1998.
 
4) Westerhof N, et al : Forward and backward waves in the arterial system. Cardiovasc Res 6 : 648-656, 1972.
PubMed
5) Iketani T, et al : The influence of the peripheral reflection wave on left vennicular hypertrophy in patients with essential hypertension. Hypertens Res 23 (5) : 451-458, 2000.
PubMed
6) 高沢謙二 : 左心室収縮期後方成分の臨床的検討. 東京医科大学雑誌 45 : 256-270, 1987.
 
7) Nurnberger J, et al : Augmentation index is associated with cardiovascular risk. J Hypertens 20 (12) : 2407-2414, 2002.
PubMed
8) Murgo JP, et al : Aortic input impedance in normal man. Circulation 62 : 105-116, 1980.
PubMed
9) Takazawa K, et al : Underestimation of vasodilator effects of nitroglycerin by upper limb blood pressure. Hypertension 26 : 520-523, 1995.
PubMed
10) Chen CH, et al : Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation 95 : 1827-1837, 1997.
PubMed
11) Takazawa K, et al : Assessment of vasoactive agents and vascular aging by the second derivative of photoplethysmogram waveform. Hypertension 32 : 365-370, 1998.
PubMed
12) Wilkinson IB, et al : The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 525 (Pt 1) : 263-270, 2000.
PubMed
13) Smulyan H, et al : Influence of body height on pulsatile arterial hemodynamic data. J Am Coll Cardiol 31 (5) : 1103-1109, 1998.
 
P.267 掲載の参考文献
1) 日本脳神経超音波学会頸動脈エコー検査ガイドライン作成委員会, 動脈硬化性疾患のスクリーニング法に関する研究班 : 頸動脈エコーによる動脈硬化性病変のガイドライン (案). Neurosonology 15 : 20-33, 2002.
 
2) Takiuchi S, et al : Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries. Circulation 102 : 766-770, 2000.
PubMed
3) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
4) Simon A, et al : Intima-media thickness : a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 20 : 159-169, 2002.
PubMed
5) Pitt B, et al : Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 102 : 1503-1510, 2000.
PubMed
6) Lonn E, et al : Effects of ramipril and vitamin E on atherosclerosis : the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103 : 919-925, 2001.
Medical*Online
7) Borhani NO, et al : Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 276 : 785-791, 1996.
PubMed
8) Zanchetti A, et al : The Verapamil in Hypertension and Atherosclerosis Study (VHAS) : results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 16 : 1667-1676, 1998.
 
9) Simon A, et al : Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 103 : 2949-2954, 2001.
PubMed
10) Zanchetti A, et al : Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis : principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106 : 2422-2427, 2002.
 
P.271 掲載の参考文献
1) Handa N, et al : Ultrasonic evaluation of early carotid atherosclerosis. Stroke 21 : 1567-1572, 1990.
PubMed
2) Crouse JR, et al : Evaluation of a scoring system for extracranial carotid atherosclerosis extent with B-mode ultrasound. Stroke 17 : 270-275, 1986.
PubMed
3) 半田伸夫ほか : 動脈硬化性頸動脈病変と虚血性脳血管障害 高解像超音波断層法を用いた検討. 日老医誌 29 : 742-747, 1992.
 
4) 北川一夫ほか : 動脈硬化性頸動脈病変の内科的治療戦略. 脈管学 42 : 797-802, 2002.
 
5) 榛沢和彦 : 頸動脈エコー検査の有用性について 実際と現況. 新潟県立中央病院医誌 5 : 11-26, 1998.
 
6) Ebrahim S, et al : Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women : the British Regional Heart Study. Stroke 30 : 841-850, 1999.
PubMed
7) Handa N, et al : Ischemic stroke events and carotid atherosclerosis. Results of the Osaka Follow-up Study for Ultrasonographic Assessment of Carotid Atherosclerosis (the OSACA Study). Stroke 26 : 1781-1786, 1995.
PubMed
8) Tanaka H, et al : Progression of carotid atherosclerosis in Japanese patients with coronary artery disease. Stroke 23 : 946-951, 1992.
PubMed
9) Hougaku H, et al : Asymptomatic carotid lesions and silent cerebral infarction. Stroke 25 : 566-570, 1994.
PubMed
P.281 掲載の参考文献
1) Safar ME, et al : Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107 : 2864-2869, 2003.
PubMed
2) O'Rourke M : Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. Hypertension 15 : 339-347, 1990.
 
3) Kingwell BA, et al : Large artery stiffness predicts ischemic threshold in patients with coronary artery disease. J Am Coll Cardiol 40 : 773-779, 2002.
PubMed
4) Blacher J, et al : Carotid arterial stiffhess as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 32 : 570-574, 1998.
PubMed
5) Kass DA, et al : Improved arterial compliance by novel advanced glycation end-product crosslink breaker. Circulation 104 : 1464-1470, 2001.
PubMed
6) Mitchell GF, et al : Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension. Circulation 105 : 2955-2961, 2002.
PubMed
7) Mozersky DJ, et al : Transcutaneous measurement of elastic properties of human femoral artery. Circulation 46 : 948-956, 1972.
PubMed
8) Hayashi K, et al : Stiffiness and elastic behavior of human intracranial and extracranial arteries. J Biomech 13 : 175-184, 1980.
 
9) Kawasaki T, et al : Non-invasive assessment of the age related changes in stiffhess of major branches of the human arteries. Cardiovasc Res 21 : 678-687, 1987.
PubMed
10) Barenbrock M, et al : Reduced distensibility of the common carotid artery in patients treated with ergotamine. Hypertension 28 : 115-119, 1996.
PubMed
11) Hirai T, et al : Stiffness of systemic arteries in patients with myocardial infarction. Noninvasive method to predict severity of coronary atherosclerosis. Circulation 80 : 78-86, 1988.
 
12) Hokanson DE, et al : A phase-10cked echo tracking system for recording arterial diameter change in vivo. J Appl Physiol 32 : 728-733, 1972.
 
13) 原田烈光 : エコートラッキング法による動脈硬化指標の計測. 超音波検査技術 28 : 334-340, 2003.
Medical*Online
14) Giannattasio C, et al : Radial, carotid and aortic distensibility in congestive heart failure : effects of high-dose angiotensin-converting enzyme inhibitor or low dose association with angiotensin type I receptor blockade. J Am Coll Cardiol 39 : 1275-1282, 2002.
PubMed
15) Benetos A, et al : Arterial alteration with aging and high blood pressure. A noninvasive study of carotid and femoral arteries. Arterioscler Thromb 13 : 90-97, 1993.
 
P.286 掲載の参考文献
1) O'Leary DH, et al : Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke 23 : 1752-1760, 1992.
 
2) Salonen JT, Salonen R : Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 11 : 1245-1259, 1991.
PubMed
3) Handa N, et al : Ultrasonic evaluation of early carotid arteriosclerosis. Stroke 21 : 1567-1572, 1990.
PubMed
4) Barzilai B, et al : Quantitative ultrasonic characterization of the nature of atherosclerotic plaques in human aorta. Circ Res 60 : 459-463, 1987.
PubMed
5) Shepard RK, et al : Quantification of atherosclerotic plaque composition in cholesterol-fed rabbits with 50-MHz acoustic microscopy. Arterioscler Thromb 12 : 1227-1234, 1992.
PubMed
6) Wickline SA, et al : Quantitative ultrasonic characterization of lesion composition and remodeling in atherosclerotic rabbit aorta. Arterioscler Thromb 13 : 1543-1550, 1993.
PubMed
7) Takiuchi S, et al : Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries. Circulation 102 : 766-770, 2000.
PubMed
8) Urbani MP, et al : In vivo radiofrequency-based ultrasonic tissue characterization of the atherosclerotic plaque. Stroke 24 : 1507-1512, 1993.
PubMed
9) Kawasaki M, et al : Noninvasive quantitative tissue characterization and two-dimensional colorcoded map of human atherosclerotic lesions using ultrasound integrated backscatter. J Am Coll Cardiol 38 : 486-492, 2001.
 
P.291 掲載の参考文献
1) Bell MR, et al : Validation of minimally invasive measurement of myocardial perfUsion using electron beam computed tomography and application in human volunteers. Heart 81 : 628-635, 1999.
PubMed
2) Mintz GS, et al : Atherosclerosis in angiographically "norma1" coronary artery reference segments ; an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 25 : 1479-1485, 1995.
 
3) Fuster V : The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326 : 242-250, 1992.
PubMed
4) Agatston A, et al : Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15 : 827-832, 1990.
PubMed
5) Simons DB, et al : Noninvasive definition of anatomic coronary artery disease by ultrafast computed tomographic scannig : a quantitative pathologic comparison study. J Am Coll Cardiol 20 : 1118-1126, 1992.
 
6) Sangiorgi G, et al : Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plauque burden in humans ; Ahistologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 31 : 126-133, 1998.
 
7) Rumberger JA, et al : Electron beam computed tomographic coronary calcium scanning : a review and guidelines for use in asymptomatic persons [published erratum appears in Mayo Clin Proc 74 (5) : 538, 1999]. Mayo Clin Proc 74 : 243-252, 1999.
 
8) Haberl R, et al : Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease : results of 1, 764 patients. J Am Coll Cardiol 37 : 451-457, 2001.
PubMed
9) Hosoi M, et al : Impact of diabetes on coronary stenosis and coronary artery calcification detected by electron-beam computed tomography in symptomatic patients. Diabetes Care 25 : 696-701, 2002.
PubMed
10) Kondos GT, et al : Electron-beam tomography coronary artery calcium and cardiac events : a 37-month follow-up of 5635 initially asymptomatic low-to intemediate-risk adults. Circulation 107 : 2571-2576, 2003.
 
11) Arad Y, et al : Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 36 : 1253-1260, 2000.
PubMed
12) Greenland P, Gaziano JM : Clinical practice. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing. N Engl J Med 349 : 465-473, 2003.
PubMed
13) Callister T, et al : Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 339 : 1972-1978, 1998.
PubMed
14) Motro M, Shemesh J : Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 37 : 1410-1413, 2001.
PubMed
P.295 掲載の参考文献
1) Liuzzo G, et al : The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331 : 417-424, 1994.
PubMed
2) Ridker PM, et al : Infiammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 : 973-979, 1997.
 
3) Ridker PM, et al : C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 : 836-843, 2000.
 
4) Pradhan AD, et al : C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 : 327-334, 2001.
PubMed
5) Chul SK, et al : High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 16 : 429-433, 2003.
 
6) Forouhi NG, et al : Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord 25 : 1327-1331, 2001.
PubMed
7) Ballou SP, et al : Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 4 : 361-368, 1992.
 
8) Pasceri V, et al : Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 : 2165-2168, 2000.
PubMed
9) Pasceri V, et al : Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerotic drugs. Circulation 103 : 2531-2534, 2001.
 
10) Zwaka TP, et al : C-reactive protein-mediated low density lipoprotein uptake by macrophages : implications for atherosclerosis. Circulation 103 : 1194-1197, 2001.
PubMed
11) Fichtlscherer S, et al : Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102 : 1000-1006, 2000.
PubMed
12) Cleland SJ, et al : Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci 98 : 531-535, 2000.
PubMed
13) Esposito K, et al : Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women : a randomized trial. JAMA 289 : 1799-1804, 2003.
PubMed
14) Ouchi N, et al : Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107 : 671-674, 2003.
PubMed
15) Ouchi N, et al : Novel modulator for endothelial adhesion molecules : adipocyte-derived plasma protein, adiponectin. Circulation 100 : 2473-2476, 1999.
PubMed
P.299 掲載の参考文献
1) Tomita S, et al : Relationship between electrocardiographic voltage and geometric pattems of left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 21 : 259-266, 1998.
 
2) Tomita S, et al : Different effects of temocapril and cadralazine on electrocardiographic voltages and left ventricular mass in patients with essential hypertension. Jpn Heart J 40 : 55-63, 1999.
PubMed
3) Levy D, et al : Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90 : 1786-1793, 1994.
PubMed
4) Dahlof B, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomised trial against atenolo1. Lancet 359 : 995-1003, 2002.
PubMed
5) Okin PM, et al : Relation of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients : The LIFE study. J Am Coll Cardiol 38 : 514-520, 2001.
 
6) 八木朝子ほか : 心エコー図によるST-T変化を加味した心電図左室肥大の検討. 臨床病理 45 : 757-762, 1997.
Medical*Online
7) Kawamura T, et al : Newly developed ST-T abnormalities on the electrocardiogram and chronologic changes in cardiovascular risk factors. Am J Cardiol 77 : 823-827, 1996.
 
8) Takagi T, Okada R : An electrocardiographic-pathologic correlative study on left axis deviation in hypertensive heart. Am Heart J 100 : 838-846, 1980.
 
9) 高木達治 : 剖検高血圧心の形態 (肥厚, 拡張) と心電図の対比. 日内会誌 68 : 389-396, 1979.
 
10) Fragola PV, et al : Use of the signal-averaged QRS duration for diagnosing left ventricular hypertrophy in hypertensive patients. Int J Cardiol 44 : 261-270, 1994.
PubMed
11) Siscovick DS, et al : Clinically silent electrocardiographic abnormalities and risk of primary cardiac arrest among hypertensive patients. Circulation 94 : 1329-1333, 1996.
PubMed
12) Takahashi T, et al : Angiotensin-converting enzyme-gene polymorphism is associated with collagen Isynthesis and QT dispersion in essential hypertension. J Hypertens 21 : 985-991, 2003.
 
13) Galinier M, et al : Prognostic value of ventricular arrhythmias in systemic hypertension. J Hypertens 15 : 1779-1783, 1997.
PubMed
14) 井上博, 富田新 : 高血圧とQT dispersion. 日本臨牀 58 (増刊 : 高血圧 (上)) : 732-735, 2000.
 
15) Kishida H, et al : Negative U-wave as a predictor of antihypertensive treatment effect on regression of echocardiographic hypertrophy in hypertensive patients. Jpn Heart J 40 : 31-44, 1999.
PubMed
16) Twidale N, et al : Echocardiographic study of U wave inversion in the electrocardiograms of hypertensive patients. J Electrocardiol 22 : 365-371, 1989.
PubMed
17) McLenachan JM, et al : Ventricular arrhythmia in patients with hypertensive left ventricular hypertrophy. N Engl J Med 317 : 787-792, 1989.
 
18) Levy D, et al : Echocardiographically determined left ventricular structural and functional correlates of complex or frequent ventricular arrhythmias on one-hour ambulatory electrocardiographic monitoring. Am J Cardiol 59 : 836-840, 1987.
PubMed
19) Ijiri H, et al : Cardiac arrhythmias and left ventricular hypertrophy in dipper and nondipper patients with essendal hypertension. Jpn Circ J 64 : 499-504, 2000.
PubMed
20) Bayes-Genis A, et al : Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. Am J Cardiol 76 : 54D-59D, 1995.
PubMed
21) Tomita F, et al : Prevalence and clinical characteristics of patients with atrial fibrillation : analysis of 20,000 cases in Japan. Jpn Circ J 64 : 653-658, 2000.
PubMed
22) The Stroke Prevention in Atrial Fibrillation Investigators : Predictors of thromboembolism in atrial fibrillation : II. Echocardiographic features of patients at risk. Ann Intern Med 116 : 6-12, 1992.
PubMed
P.305 掲載の参考文献
1) Cuspidi C, et al : Role of echocardiography and carodd ultrasonography in stratifying risk in padents with essential hypertension : Assessment of Prognostic Risk Observation Survey. J Hypertens 20 : 1307-1314, 2002.
 
2) Zehender M, et al : Ventricular tachyarrhythmias, myocardial ischemia, and sudden cardiac death in padents with hypertensive heart disease. Clin Cardiol 18 : 377-383, 1995.
 
3) Ghali JK, et al : The prognostic role of left ventdcular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 117 : 831-836, 1992.
 
4) Reichek N, et al : Left ventricular hypertrophy : relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 63 : 1391-1398, 1981.
PubMed
5) Savage DD, et al : Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation 59 : 623-632, 1979.
PubMed
6) Devereux RB, et al : Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 4 : 1222, 1984.
PubMed
7) 田中伸明 : 拡張不全の診断と評価をどうするか. 心エコー・ドップラ法を用いて. Heart View 1520-1528, 2001.
 
8) Takatsuji H, et al : A new approach for evaluation of left ventricular diastolic function : Spatial and tempora1 analysis of left ventricular filling flow propagation by color-M-mode Doppler echocardiography. J Am Coll Cardiol 27 : 365-371, 1996.
PubMed
9) Tei C, et al : New index of combined systolic and diastolic myocardial performance : A simple and reproducible measure of cardiac function : A study in normals and dilated cardiomyopathy. J Cardiol 26 : 357-366, 1995.
PubMed
P.309 掲載の参考文献
1) Levy D, et al : Prognostic implication of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 : 1561-1566, 1990.
 
2) Dahlof B, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomised trial against atenolol. Lancet 359 : 995-1003, 2002.
PubMed
3) Devereux RB, et al : Echocardiographic assessment of left ventricular hypertrophy : comparison to necropsy findings. Am J Cardiol 57 : 450-458, 1986.
PubMed
4) Ganau A, et al : Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19 : 1550-1558, 1992.
 
5) Wachtell K, et al : Change in systolic left ventricular performance after 3 years of antihypertensive treatment. Circulation 106 : 227-232, 2002.
PubMed
6) Gopal AS, et al : Freehand three-dimensional echocardiography for measurement of left ventricular mass : In vivo anatomic validation using explanted human hearts. J Am Coll Cardiol 30 : 802-810, 1997.
PubMed
7) Grothues F, et al : Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90 : 29-34, 2002.
 
8) Park SH, et al : Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography : correlation with autopsy and M-mode echocardiography. J Am Soc Echocardiogr 9 : 119-128, 1996.
 
9) Kaji S, et al : Rapid evaluation of left ventricular volume and mass without breath-holding using real-time interactive cardiac magnetic resonance imaging system. J Am Coll Cardiol 38 : 527-533, 2001.
PubMed
P.314 掲載の参考文献
1) Matsuo H : Discovery of a natriuretic peptide family and their clinical application. Can J Physiol Pharmacol 79 : 736-740, 2001.
PubMed
2) Flynn TG, et al : The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun 117 : 859-865, 1983.
PubMed
3) Kangawa K, Matsuo H : Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun l18 : 131-139, 1984.
 
4) Sudoh T, et al : Anew natriuretic peptide in porcine brain. Nature 332 : 78-81, 1988.
 
5) Sudoh T, et al : C-type natriuretic peptide (CNP) : anew member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 168 : 863-870, 1990.
 
6) Nakao K, et al : The natriuretic peptide family. Curr Opin Nephrol Hypertens 5 : 4-11, 1996.
PubMed
7) Yasujima M, et al : Atrial natriuretic factor inhibits the hypertension induced by chronic infusion of norepinephrine in conscious rats. Circ Res 57 : 470-474, 1985.
PubMed
8) 向山政志ほか : ナトリウム利尿ペプチドファミリー. 日本臨牀 58 (増刊 : 高血圧 (上)) : 466-471, 2000.
 
9) Kimura T, et al : Effects of acute water load, hypertonic saline infusion, and furosemide administration on atrial natriuretic peptide and vasopressin release in humans. J Clin Endocrinol Metab 62 : 1003-1010, 1986.
PubMed
10) Takemura G, et al : Expression and distribution of atrial natriuretic peptide in human hypertrophic ventricle of hypertensive hearts and hearts with hypertrophic cardiomyopathy. Circulation 83 : 181-190, 1991.
PubMed
11) Mukoyama M, et al : Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 : 1402-1412, 1991.
PubMed
12) Maisel AS, et al : Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 : 161-167, 2002.
PubMed
13) Nagaya N, et al : Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 135 : 21-28, 1998.
PubMed
14) Kojima S, et al : Plasma concentrations of immunoreactive-atrial natriuretic polypeptide in patients on hemodialysis. Nephron 46 : 45-48, 1987.
PubMed
15) de Lemos JA, et al : B-type natriuretic peptide in cardiovascular disease. Lancet 362 : 316-322, 2003.
PubMed
P.319 掲載の参考文献
1) Levey AS : Measurement of renal function in chronic renal disease. Kidney Int 38 (1) : 167-184, 1990.
PubMed
2) Shemesh O, et al : Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28 (5) : 830-838, 1985.
PubMed
3) Heymsfield SB, et al : Measurement of muscle mass in humans : validity of the 24-hour urinary creatinine method. Am J Clin Nutr 37 (3) : 478-494, 1983.
 
4) James GD, et al : Alongitudmal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences. Am J Hypertens 1 (2) : 124-131, 1988.
 
5) Goldwasser P, et al : Race and creatinine excretion in chronic renal insufficiency. Am J Kidney Dis 30 (1) : 16-22, 1997.
PubMed
6) King AJ, Levey AS : Dietary protein and renal function. J Am Soc Nephrol 3 (11) : 1723-1737, 1993.
PubMed
7) Reams GP : Renal effects of antihypertensive drugs. In : Pharmacology and Management of Hypertension (ed by Bennett WM, et al), p 29, Churchill Livingstone, New York, 1994.
 
8) Cockcroft DW, Gault MH : Prediction of creatinine clearance from serum creatinine. Nephron 16 (1) : 31-41, 1976.
PubMed
9) Levey AS, et al : A more accurate method to estimate glomerular filtration rate from serum creatinine : a new prediction equation. Modkication of Diet in Renal Disease Study Group. Ann Intern Med 130 (6) : 461-470, 1999.
 
10) Toto RD, et al : Evaluation of serum creatinine for estimating glomerular mtration rate in African Americans with hypertensive nephrosclerosis : results from the African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study. J Am Soc Nephrol 8 (2) : 279-287, 1997.
 
11) Perrone RD, et al : Utility of radioisotopic filtration markers in chronic renal insufficiency : simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modhication of Diet in Renal Disease Study. Am J Kidney Dis 16 (3) : 224-235, 1990.
PubMed
12) Rodby RA, et al : Renal scanning 99mTc diethylene-triamine pentaacetic acid glomerular filtration rate (GFR) determination compared with iothalamate clearance GFR in diabetics. The Collaborative Study Group for The study of Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy. Am J Kidney Dis 20 (6) : 569-573, 1992.
 
13) Jurado R, Mattix H : The decreased serum urea nitrogen-creatinine ratio. Arch Intern Med 158 (22) : 2509-2511, 1998.
PubMed
P.324 掲載の参考文献
1) 緒方奈保子ほか : [身体診察法と異常所見の診方] 眼底検査. 日内会誌 89 : 2477-2486, 2000.
 
2) 中木敦子ほか : 眼底血管変化と動脈硬化危険因子との関連 (事後指導のありかたへの一考察). 健康医学 16 : 231-234, 2001.
Medical*Online
3) 林秀介ほか : 人間ドックにおける散瞳下眼底検査の有用性について. 近畿中央病院医学雑誌 21 : 71-74, 2001.
 
4) 国田義則ほか : 脳ドックにおける眼底検査所見とMRI所見の対比. 岐阜県立下呂温泉病院温泉医学研究所年報 26 : 82-87, 1999.
 
5) 鈴木悦子ほか : 眼底検査は全身の動脈硬化性変化の把握に有意義か. 臨床眼科 53 : 1023-1026, 1999.
 
6) Pache M, et al : Do angiographic data support a detailed classification of hypertensive fundus changes? J Hum Hypertens 16 : 405-410, 2002.
PubMed
7) 安東克之ほか : 高齢者の心血管合併症と血圧値との関係. 日循協誌 32 : 109-114, 1997.
 
8) Duncan BB, et al : Hypertensive retinopathy and incident coronary heart disease in high risk men. Br J Ophthalmol 86 : 1002-1006, 2002.
PubMed

VI 臨床 - 高血圧が主な原因となる合併症 -

P.332 掲載の参考文献
1) Perera GA : Hypertensive vascular disease ; description and natural history. J Chronic Dis 1 : 33-42, 1955.
 
2) Kannel WB : Blood pressure as a cardiovascular risk factor : prevention and treatment. JAMA 275 : 1571-1576, 1996.
PubMed
3) 柊山幸志郎 : Hypertension and cardiovascular diseases in Japanese elderly. 日老医誌 35 : 335-339, 1996.
 
4) 厚生統計協会 : 国民衛生の動向. 厚生の指標 49 (臨時増刊) : 52, 2002.
 
5) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン2000年版, p8, 日本高血圧学会, 2000.
 
6) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288 : 2099-2110, 2002.
 
7) Staessen JA, et al : Cardiovascular prevention and blood pressure reduction : aquantitative overview updated until 1 March 2003. J Hypertens 21 : 1055-1076, 2003.
 
8) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
9) Chobanian AV : 1989 Corcoran lecture : adaptive and maladaptive responses of the arterial wall to hypertension. Hypertension 15 : 666-674, 1990.
PubMed
10) 矢崎義雄 : 高血圧と心肥大. 腎と透析 39 (臨時増刊号) : 468-472, 1995.
 
11) Pedrinelli R, et al : Urinary albumin excretion and atherosclerosis in essential hypertension. Clin Sci 92 : 45-50, 1997.
PubMed
P.336 掲載の参考文献
1) MacMahon S, et al : Blood pressure, stroke, and coronary heart disease. Lancet 335 : 765-774, 1990.
PubMed
2) 上田一雄 : 久山町住民にみられた虚血性心疾患, とその危険因子の時代的動向. 日循協誌 26 : 155-160, 1992.
 
3) 脳卒中などによる寝たきり・死亡の健康危険度評価システム開発事業-1980年循環器疾患基礎調査追跡調査報告書, 日本循環管理研究協議会, 1995.
 
4) Kato J, et al : Risk factors and predictors of coronary arterial lesion in Japanese hypertensive patients. Hypertens Res 24 : 3-11, 2001.
PubMed
5) Glagov S, et al : Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316 : 1371-1375, 1987.
PubMed
6) Suwaidi JA, et al : Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 : 948-954, 2000.
PubMed
7) Schachinger V, et al : Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 : 1899-1906, 2000.
PubMed
8) Koren MJ, et al : Relation of left ventricular mass and geometry to mobility and mortality in uncomplicated essential hypertension. Ann Intern Med 114 : 345-352, 1991.
 
9) Cruickshank JM, et al : Benefits and potential harm of lowering high blood pressure. Lancet i (8533) : 581-584, 1987.
PubMed
10) Lennart H, et al : Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 351 : 1755-1762, 1998.
 
11) Hasebe N, et al : Reverse J-curve relation between diastolic blood pressure and severity of coronary artery lesion in hypertensive patients with angina pectoris. Hypertens Res 25 : 381-387, 2002.
 
12) Somes GW, et al : The role of diastolic blood pressure when treated isolated systolic hypertension. Arch Intern Med 159 (17) : 2004-2009, 1999.
PubMed
13) Franklin SS, et al : Is pulse pressure useful in predicting risk for coronary heart disease? Circulation 100 : 354-360, 1999.
PubMed
14) Sesso HD, et al : Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men. Hypertension 36 : 801-807, 2000.
PubMed
P.341 掲載の参考文献
1) Libby P : Molecular bases of the acute coronary syndromes. Circulation 91 : 2844-2850, 1995.
PubMed
2) 泰江弘文 : 急性冠症候群 基礎から臨床まで ; 冠動脈疾患の病態解明と急性冠症候群. 最新医学 54 : 1165-1171, 1999.
 
3) Badimon JJ, et al : Coronary atherosclerosis. A multifactorial disease. Circulation 87 (Suppl) : II3-16, 1993.
PubMed
4) Ryan TJ, et al : ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 28 : 1328-1428, 1996.
 
5) Ross AM, et al : A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction. J Am Coll Cardiol 34 : 1954-1962, 1999.
PubMed
6) Hjalmarson A : Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 80 : 35J-39J, 1997.
PubMed
7) GISSI-3 : Effects of lisinopril and transdermal glycery1 trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell' infarto Miocardico. Lancet 343 : 1115-1122, 1994.
 
8) ISIS-2 (Second International Study of Infarct Survival) Collaborative Group : Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction : ISIS-2. Lancet ii : 349-360, 1988.
PubMed
9) Antiplatelet Trialists' Collaboration : Collaborative overview of randomised trials of antiplatelet therapy-I : Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 : 81-106, 1994.
PubMed
10) Hansson L, et al : Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 : 1755-1762, 1998.
PubMed
11) UK Prospective Diabetes Study Group : Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 39. BMJ 317 : 713-720, 1998.
Medical*Online
12) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
13) Guidelines Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
14) Berl T, et al : Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of paUents with type 2 diabetes and overt nephropathy. Ann Intern Med 138 : 542-549, 2003.
 
15) Hasebe N, et al : Reverse J-curve relation between diastolic blood pressure and severity of coronary artery lesion in hypertensive patients with angina pectoris. Hypertens Res 25 : 381-387, 2002.
 
P.345 掲載の参考文献
1) Dahlof B, et al : Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE) : a randomized trial against atenolol. Lancet 359 : 995-1003, 2002.
PubMed
2) Kleldsen SE, et al : Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA 288 : 1491-1498, 2002.
 
3) Wachtell K, et al : Changes in diastolic left ventricular filling after one year of antihypertensive treatment. Circulation 105 : 1071-1076, 2002.
PubMed
4) Devereux RB, et al : Progressive hypertrophy regression with sustained pressure reduction in hypertension : the losartan intervention for endpoint reduction study. J Hypertens 20 : 1445-1450, 2002.
PubMed
5) Wing LMH, et al : A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 : 583-592, 2003.
 
6) Liebson PR, et al : Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 91 : 698-706, 1995.
PubMed
7) Simpson PC, et al : Adrenergic hormones and control of cardiac myocyte growth. Mol Cell Biochem 104 : 35-43, 1991.
PubMed
8) Lenfant C, et al : Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure : Resetting the hypertension sails. Circulation 107 : 2993-2994, 2003.
 
P.356 掲載の参考文献
1) Klag MJ, et al : Blood pressure and end-stage renal disease in men. N Engl J Med 334 : 13-18, 1996.
 
2) Tozawa M, et al : Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 41 : 1341-1345, 2003.
PubMed
3) George A, Perera GA : Hypertensive vascular disease ; Description and natural history. J Chronic Dis 1 : 33-42, 1955.
 
4) Madhavan S, et al : Renal function during antihypertensive treatment. Lancet 345 : 749-751, 1995.
PubMed
5) 阿部圭志 : 高血圧の病態と治療. 日内会誌 86 : 1545-1555, 1997.
 
6) Luke RG : Hypertensive nephrosclerosis : pathogenesis and prevalence. Essential hypertension is an important cause of end-stage renal disease. Nephrol Dial Transplant 14 : 2271-2278, 1999.
PubMed
7) Vikse BE, et al : Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrol Dial Transplant 18 : 517-523, 2003.
PubMed
8) Voyaki SM, et al : Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 19 : 511-519, 2001.
 
9) Agodoa LY, et al : Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA 285 : 2719-2728, 2001.
PubMed
10) Wright JT Jr, et al : Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial. JAMA 288 : 2421-2431, 2002.
PubMed
11) 富永忠広ほか : 降圧薬継続治療下の本態性高血圧の予後. Ther Res 17 : 163-181, 1996.
 
12) Shulman NB, et al : Prognostic value of serum creatinine and effect of treatment of hypertension on renal function : Results from the hypertension detection and follow-up program. Hypertension 13 : 180-193, 1989.
 
13) Ruilope LM, et al : Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 12 : 218-225, 2001.
PubMed
14) Mann JFE, et al : Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril : the HOPE Randomized Trial. Ann Intern Med 134 : 629-636, 2001.
 
15) Brown MJ, et al : Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study : Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356 : 366-372, 2000.
PubMed
P.361 掲載の参考文献
1) Luke RG, Reif MC : Hypertension. In : Textbook of Nephrology, 4th ed (ed by Massry SG, Glassock RJ), p 1305-1313, Lippincott Williams & Wilkins, Philadelphia, 2001.
 
2) わが国の慢性透析療法の現況 2000年, 日本透析医学会, 2001.
 
3) United States Renal Data System. USRDS 2001 Annual Data Report. U. S. Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2001.
 
4) Kimura G, et al : Intrarenal hemodynamics in patients with essential hypertension. Circ Res 69 : 421-428, 1991.
PubMed
5) Brenner BM, et al : Dietary protein intake and the progressive nature of kidney disease : the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307 : 652-659, 1982.
PubMed
6) Keller G, et al : Nephron number in patients with primary hypertension. N Engl J Med 348 : 101-108, 2003.
PubMed
7) 木村玄次郎 : 腎疾患における. 至適血圧値. 血圧 5 : 1047-1053, 1998.
 
8) Klag MJ, et al : Blood pressure and end-stage renal disease in men. N Engl J Med 334 : 13-18, 1996.
 
9) Maschio G, et al for The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group : Effect of the angiotension-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334 : 939-945, 1996.
 
10) Walker WG, et al : Renal function change in hypertensive members of the Multiple r isk Factor Intervention Trial : Racial and treatment effects. JAMA 268 : 3085-3091, 1992.
 
11) Kimura G, Brenner BM : The renal basis for salt sensitivity in hypertension. In : Hypertension : Pathophysiology, Diagnosis and Management, 2nd ed (ed by Laragh JH, Brenner BM), p 1569-1588, Raven Press, New York, 1995.
 
12) Agodoa LY, et al : Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis : a randomized controlled trial. JAMA 285 : 2719-2728, 2001.
PubMed
13) Wright JT Jr, et al for the ASK study group : Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288 : 2421, 2002.
 
14) Fukuda M, et al : Antihypertensive drugs and renal protection. JAMA 289 : 1102-1103, 2003.
PubMed
P.368 掲載の参考文献
1) 小町喜男ほか : 脳出血の疫学. Chnical neuroscience 14 : 1326-1328, 1994.
 
2) 島健, 山中千恵 : 高血圧性脳内出血. Clinical neuroscience 19 : 1003-1007, 2001.
 
3) 小島英明, 丸島愛樹 : 高血圧性脳内出血 : 出血源としての動脈解離の可能性. 分子脳血管病 2 : 30-35, 2003.
Medical*Online
4) Lammie GA : Hypertensive cerebral small vessel disease and stroke. Brain Patho1 12 : 358-370, 2002.
 
5) 川又達郎, 片山容一 : 脳出血と頭蓋内圧. 循環科学 18 : 1010-1013, 1998.
 
6) 嶋津基彦, 池田幸穂 : 脳出血の鑑別診断と治療. 救急医学 26 : 1033-1040, 2002.
 
7) 安井信之, 鈴木明文 : 高血圧性脳出血の外科的治療. 脳卒中 20 : 539-544, 1998.
Medical*Online
8) 中井易二 : 高血圧性脳出血に対する定位的血腫溶解排除術に関する研究. 和歌山医学 50 : 33-42, 1999.
 
P.372 掲載の参考文献
1) Sacco RA : Frequency and determinants of stroke. In : Cerebrovascular Disorders (ed by Fisher M), p1. 1-1. 16, Wolfe, Boston, 1994.
 
2) 木村和美ほか : 脳卒中の疫学動向. 脳梗塞急性期医療の全国実態調査. 臨床医 29 : 19-22, 2003.
 
3) 湧川佳幸ほか : 概日リズムと脳血管障害. 循環器科 46 : 390-394, 1999.
 
4) Special report from the National Institute of Neurological Disorders and Stroke. Classh6cation of cerebrovascular diseases III. Stroke 21 : 637-676, 1990.
PubMed
5) Yasaka M, et al : Distribution of atherosclerosis and risk factors in atherothrombotic occlusion. Stroke 24 : 206-211, 1993.
PubMed
6) Atrial Fibrillation Investigators : Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 : 1449-1457, 1994.
 
7) Yasaka M, et al : Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 40 : 1183-1188, 2001.
PubMed
8) Minematsu K, et al : 'Spectacular shrinking deficit' : rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology 42 : 157-162, 1992.
 
P.376 掲載の参考文献
1) 澤田徹ほか : 無症候性脳血管障害の診断基準に関する研究. 脳卒中 19 : 489-493, 1998.
 
2) 奥寺年男ほか : 脳の血管周囲腔. II. 血管周囲腔-映像上から-. 脳神経 52 : 671-690, 2000.
 
3) Vermeer SE, et al : Silent brain infarcts and white matter lesions increase stroke risk in the general population : the Rotterdam Scan Study. Stroke 34 : 1126-1129, 2003.
PubMed
4) 延原幸嗣, 西丸雄也 : 無症候性脳梗. 塞の長期予後. 脳卒中 18 : 302-309, 1996.
 
5) Vermeer SE, et al : Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348 : 1215-1222, 2003.
PubMed
6) 小林祥泰ほか : 無症候性脳梗塞と高血圧. 脳卒中 20 : 545-549, 1998.
Medical*Online
7) 小林祥泰 : 無症候性脳梗塞の臨床的意義. 神経研究の進歩 45 : 450-460, 2001.
 
8) Tuszynski MH, et al : Risk factors and clinical manifestations of pathologically verified lacunar infarctions. Stroke 20 : 990-999, 1989.
PubMed
9) Longstreth WT Jr, et al : Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people : the Cardiovascular Health Study. Arch Neurol 55 : 1217-1225, 1998.
PubMed
10) Longstreth WT Jr, et al : Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly : the Cardiovascular Health Study. Stroke 33 : 2376-2382, 2002.
PubMed
11) Kobayashi S, et al : Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 28 : 1932-1939, 1997.
PubMed
12) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
13) PROGRESS Collaborative Group : Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 : 1033-1041, 2001.
PubMed
P.379 掲載の参考文献
1) Masdeu JC, et al : Brain white-matter changes in the elderly prone to falling. Arch Neurol 46 : 1292-1296, 1989.
PubMed
2) Whitman GT, et al : A prospective study of cerebral white matter abnormalities in older people with gait dysfunction. Neurology 57 : 990-994, 2001.
PubMed
3) Skoog I, et al : 15-year longitudinal study of blood pressure and dementia. Lancet 347 : 1141-1145, 1996.
PubMed
4) Kilander L, et al : Hypertension is related to cognitive impairment : a 20-year follow-up of 999 men. Hypertension 31 : 780-786, 1998.
PubMed
5) Forette F, et al : The prevention of dementia with antihypertensive treatment : new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162 : 2046-2052, 2002.
PubMed
6) Tedesco MA, et al : Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 12 : 1130-1134, 1999.
PubMed
7) PROGRESS Collaborative Group : Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 : 1033-1041, 2001.
PubMed
8) Bosch J, et al : Use of ramipril in preventing stroke : double blind randomised trial, BMJ 324 : 699-702, 2002.
PubMed
9) Guo Z, et al : Low blood pressure and dementia in elderly people : the Kungsholmen project. BMJ 312 : 805-808, 1996.
PubMed
10) Guo Z, et al : Low blood pressure and early death of elderly people with dementia. Lancet 352 : 1035-1036, 1998.
PubMed
P.385 掲載の参考文献
1) 久良木徳仁ほか : 最近経験したAngiospastic Retinopathyの5例. 眼紀 34 : 2267-2274, 1983.
 
2) 吉本弘志, 松山秀一 : 実験的高血圧ラットにおける末期重症網脈絡膜症の研究. 日眼会誌 91 : 756-770, 1987.
 
3) 吉本弘志 : 高血圧性眼底病変の病理. あたらしい眼科 5 : 11-20, 1988.
 
4) 吉本弘志 : 眼微小循環と眼科臨床. 眼紀 51 : 435-445, 2000.
 

VII 合併症・臓器障害予防の血圧管理

P.392 掲載の参考文献
1) 谷崎弓裕ほか : 久山町の地域住民におけるJNCVIの血圧分類とタイプ別脳梗塞発症率の関係-血圧レベルの時代的変化を考慮に入れた検討-. 第21回日本高血圧学会総会プログラム抄録集, p22, 1998.
 
2) Muratani H, et al : Current status of antihypertensive therapy for elderly patients in Japan. Hypertens Res 19 : 281-290, 1996.
 
3) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
4) Vasan RS, et al : Residual life-time risk for developing hypertension in middle-aged women and men : The Framingham Heart Study. JAMA 287 : 1003-1010, 2002.
 
5) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
6) Cushman WC, et al : Success and predictors of blood pressure control in diverse North American settings : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 4 : 393-404, 2002.
PubMed
7) Neal B, et al : Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs. Lancet 356 : 1955-1964, 2000.
PubMed
8) National High Blood Pressure Education Program : The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157 : 2413-2446, 1997.
 
9) The Capricorn Investigators : Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : The CAPRICORN randomized trial. Lancet 357 : 1385-1390, 2001.
 
10) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
11) Hunt SA, et al : ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult : Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice GuideUnes (Committee to revise the 1995 Guidelmes for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38 : 2101-2113, 2001.
 
12) Brenner BM, et al : Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861-869, 2001.
PubMed
13) Wright JT Jr, et al : Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial. JAMA 288 (19) : 2421-2431, 2002.
 
14) The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nephrologia) : Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 : 1857-1863, 1997.
 
15) Hyman CJ, Pavlik VN : Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 345 : 479-486, 2001.
 
16) PROGRESS Collaborative Group : Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 : 1033-1041, 2001.
PubMed
P.398 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2000年改訂版, 2000.
 
2) 荻原俊男ほか : 老年者高血圧治療ガイドライン-2002年改訂版. 日老医誌 39 : 322-351, 2002.
 
3) Kario K, et al : Morning surge in blood pressure as a predictor of silent and clinical cardiovascular disease in the elderly hypertensives. Circulation 107 : 1404-1406, 2003.
 
4) Lithell H, et al : The Study on Cognition and Prognosis in the Elderly (SCOPE) : principal results of a randomized double intervention trial. J Hypertens 21 : 875-886, 2003.
 
5) Ogiahra T : A practitioner's trial on the efficacy of antihypertensive treatment in the elderly (The PATE-Hypertension Study) in Japan. Am J Hypertens 13 : 461-467, 2000.
 
6) Arima H, et al : Validity of JNC VI recommendations for the management of hypertension in a general population of Japanese elderly : The Hisayama Study. Arch Intern Med 163 : 361-366, 2003.
 
7) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC Report. JAMA 289 : 2560-2572, 2003.
PubMed
8) Wing LM, et al : A comparison of outcomes with angiotensin-convening-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 : 583-592, 2003.
 
9) Somes GW, et al : The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 159 : 2004-2009, 1999.
PubMed
10) Perry HM, et al : Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA 284 : 465-471, 2000.
PubMed
11) Black HR, et al : One-year study of felodipine or placebo for stage l isolated systolic hypertension. Hypertension 38 : 1118-1123, 2001.
PubMed
12) Kjeldsen SE, et al : Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA 288 : 1491-1498, 2002.
PubMed
P.402 掲載の参考文献
1) Bernstein D : Systemic hypertension. In : Textbook of Pediatrics, 17th ed (ed by Behrman RE, et al), p 1592-1598, WB Saunders, Philadelphia, 2003.
 
2) 内山聖 : 小児高血圧. 医学のあゆみ 202 : 636-640, 2002.
Medical*Online
3) 高血圧治療ガイドライン2000年版 (日本高血圧学会高血圧治療ガイドライン作成委員会編), 日本高血圧学会, 2000.
 
4) 長沼賢寛ほか : 肥満または高血圧児における家庭血圧測定の有用性に関する研究-24時間血圧との比較-. 小児保健研究 57 : 85-89, 1998.
 
5) Dillon MJ : Clinical aspects of hypertension. In : Pediatric Nephrology, 2nd ed (ed by Holliday MA), p743-757, Williams & Wilkins, Baltimore, 1987.
 
6) 内山聖ほか : 小児肥満の高血圧発症機序に関する検討. 肥満研究 8 : 259-263, 2002.
 
7) Uchiyama M, Satokata I : Genetic factors in essential hypertension, with a special focus on children. Acta Med Biol 42 : 137-144, 1994.
 
8) 内山聖 : 高血圧. 小児科学, 第2版 (白木和夫, 前川喜平監), p1275-1279, 医学書院, 2002.
 
9) Uchiyama M, et al : Is childhood hypertension a predictor of adult hypertension? Lancet i : 1247, 1984.
PubMed
P.407 掲載の参考文献
1) Pickering T, et al : How common is white coat hypertension? JAMA 259 : 225-228, 1988.
PubMed
2) Ohkubo T, et al : Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements : a pilot study in Ohasama. J Hypertens 15 : 357-364, 1997.
PubMed
3) Clement D L, et al : Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 348 : 2407-2415, 2003.
PubMed
4) Ohkubo T, et al : Relation between nocturnal decline in blood pressure and mortality : the Ohasama study. Am J Hypertens 10 : 1201-1207, 1997.
PubMed
5) Ohkubo T, et al : Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure : the Ohasama study. J Hypertens 20 : 2183-2189, 2002.
PubMed
6) Kario K, et al : Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. Circulation 107 : 1401-1406, 2003.
PubMed
7) Kikuya M, et al : Prognostic significance of blood pressure and heart rate variabilities : the Ohasama study. Hypertension 36 : 901-906, 2000.
PubMed
8) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
9) Guidelines committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
10) Ohkubo T, et al : Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement : apopulation-based observation in Ohasama, Japan. J Hypertens 16 : 971-975, 1998.
 
11) Zarnke KB, et al : A randomized study comparing a patient-directed hypertension management strategy with usual office based care. Am J Hypertens 10 : 58-68, 1997.
PubMed
P.413 掲載の参考文献
1) Clement DL, et al : Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 348 (24) : 2407-2415, 2003.
PubMed
2) Neutel JM, et al : The circadian pattem of blood pressure : cardiovascular risk and therapeutic opportunities. Curr Opin Nephrol Hypertens 6 : 250-256, 1997.
 
3) Staessen JA, et al : Noctumal blood pressure fall on ambulatory blood pressure monitoring in a large international database. The 'Ad-Hoc' Working Group. Hypertension 29 : 30-39, 1997.
 
4) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289 : 2560-2572, 2003.
PubMed
5) Kobrin I, et al : Diurnal variation of blood pressure in elderly patients with essential hypertension. J Am Geriatr Soc 32 : 896-899, 1984.
PubMed
6) O'Brien E, et al : Dippers and non-dippers. Lancet ii : 397, 1988.
 
7) Kario K, et al : Relationships between nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensives : advanced silent cerebrovascular damage in extreme dippers. Hypertension 27 : 130-135, 1996.
 
8) White WB, et al : Nocturnal blood pressure : epidemiology, determinants, and effects of antihypertensive therapy. Blood Press Monit 3 : 43-51, 1998.
PubMed
9) White WB, et al : Ambulatory blood pressure monitoring : dippers compared with non-dippers. Blood Press Monit 5 (Suppl 1) : S17-S23, 2000.
 
10) Pickering TG : The clinical significance of diurnal blood pressure variations. Dipper and nondippers. Circulation 81 : 700-702, 1990.
 
11) Mansoor GA, et al : The relationship of electronically monitored physical activity to blood pressure, heart rate, and the circadian blood pressure profile. Am J Hypertens 13 : 262-267, 2000.
PubMed
12) Uzu T, et al : High sodium sensitivity implicates nocturnal hypertension in essential hypertension. Hypertension 28 : 139-142, 1996.
PubMed
13) Kuwajima I, et al : Diminished nocturnal decline in blood pressure in elderly hypertensive patients with left ventricular hypertrophy. Am Heart J 123 (5) : 1307-1311, 1992.
PubMed
14) Verdecchia P, et al : Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 81 : 528-536, 1990.
PubMed
15) Rizzoni D, et al : Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring. Am J Hypertens 5 : 180-186, 1992.
PubMed
16) Fagard R, et al : The relationships between left ventricular mass and daytime and night-time blood pressures : a meta-analysis of comparative studies. J Hypertens 13 : 823-829, 1995.
PubMed
17) Hoshide S, et al : Association between nondipping of nocturnal blood pressure decrease and cardiovascular target damage in strictly selected community-dwelling normotensives. Am J Hypertens 16 : 434-438, 2003.
 
18) Bianchi S, et al : Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 7 (1) : 23-29, 1994.
PubMed
19) Timio M, et al : "Non-dipper" hypertensive patients and progressive renal insufficiency : a 3-year longitudinal study. Clin Nephrol 43 : 382-387, 1995.
PubMed
20) Shimada K, et al : Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 10 : 875-878, 1992.
PubMed
21) Yamamoto Y, et al : Adverse effect of nighttime blood pressure on the outcome of lacunar infarct patients. Stroke 29 : 570-576, 1998.
PubMed
22) Kario K, et al : Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 38 : 852-857, 2001.
PubMed
23) Verdecchia P, et al : Altered circadian blood pressure profile and prognosis. Blood Press Monit 2 : 347-352, 1997.
PubMed
24) Staessen JA, et al : Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in old patients with systolic hypertension. JAMA 282 : 539-546, 1999.
 
25) Ohkubo T, et al : Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens 10 (11) : 1201-1207, 1997.
PubMed
26) Ohkubo T, et al : Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure : the Ohasama study. J Hypertens 20 : 2183-2189, 2002.
PubMed
27) Uzu T, et al : Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 96 : 1859-1862, 1997.
PubMed
28) Uzu T, et al : Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 100 : 1635-1638, 1999.
PubMed
29) Kario K, et al : Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure. Am J Hypertens 10 (3) : 261-268, 1997.
PubMed
30) White WB, et al : Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers). COER Verapamil Study Group. Am J Cardiol 80 (4) : 469-474, 1997.
 
31) Palatini P, et al : Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther 52 : 378-383, 1992.
PubMed
32) Wu H, et al : Clinical trial of arotinolol in the treatment of hypertension : dippers vs. non-dippers. Hypertens Res 24 (5) : 605-610, 2001.
PubMed
33) Kario K, et al : Change of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of α-adrenergic blocker, doxazosin. Result from the HALT study. Hypertension 35 : 787-794, 2000.
 
P.421 掲載の参考文献
1) Muller JE, et al : Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79 : 733-743, 1989.
PubMed
2) White WB : Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 6 : 63-72, 2001.
PubMed
3) Kuwajima I, et al : Cardiac implications of the morning surge in blood pressure in elderly hypertensive patients : relation to arising time. Am J Hypertens 8 : 29-33, 1995.
PubMed
4) Kario K, et al : Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives : a prospective study. Circulation 107 : 1401-1406, 2003.
PubMed
5) 苅尾七臣 : 早朝高血圧の臨床的意義と機序. 今月の治療 特集 : 早朝高血圧-重要性とその管理-, p57-63, 総合医学社, 2003.
 
6) Reppert SM, Weaver DR : Coordination of circadian timing in mammals. Nature 418 : 935-941, 2002.
PubMed
7) Maemura K, et al : CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem 275 : 36847-36851, 2000.
PubMed
8) Nonaka H, et al : Angiotensin II induces circadian gene expression of clock genes in cultured vascular smooth muscle cells. Circulation 104 : 1746-1748, 2001.
PubMed
9) Naito Y, et al : Augmented diurnal variations of the cardiac renin-angiotensin system in hypertensive rats. Hypertension 40 : 827-833, 2002.
PubMed
10) Kario K, et al : Increased coronary heart disease mortality after the Hanshin-Awaji earthquake among the older community on Awaji Island. J Am Geriatr Soc 45 : 610-613, 1997.
 
11) Kario K, et al : Stroke prognosis and abnormal noctumal blood pressure falls in older hypertensives. Hypertension 38 : 852-857, 2001.
 
12) Kario K, et al : Abnormal nocturnal blood pressure falls in elderly hypertension : clinical significance and determinants. J Cardiovasc Pharmacol 41 (Suppl 1) : S61-S66, 2003.
 
13) Ohkubo T, et al : Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure : the Ohasama study. J Hypertens 20 : 2183-2189, 2002.
PubMed
14) Chonan K, et al : Insufficient duration of action of antihypertensive drugs mediates high blood pressure in the moming in hypertensive population : the Ohasama study. Clin Exp Hypertens 24 : 261-275, 2002.
 
15) Kario K, et al : U-curve relationship between orthostatic blood pressure change and silent cerebrovascular disease in elderly hypertensives : orthostatic hypertension as a new cardiovascular risk factor. J Am Coll Cardiol 40 : 133-141, 2002.
PubMed
16) Tochikubo O, et al : Circadian variation of hemodynamics and baroreflex functions in patients with essential hypertension. Hypertens Res 20 : 157-166, 1997.
PubMed
17) Marfella R, et al : Morning blood pressure peak, QT intervals, and sympathetic activity in hypertensive patients. Hypertension 41 : 237-243, 2003.
PubMed
18) Kario K, et al : Clinical implication of morning blood pressure surge in hypertension. J Cardiovasc Pharmacol 2004. (in press)
 
19) Ikeda Y, et al : The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 87 : 1234-1240, 1991.
PubMed
20) Kario K, et al : Hyperinsulinemia and hemostatic abnormalities are associated with silent cerebral lacunar infarcts in elderly hypertensive subjects. J Am Coll Cardiol 37 : 871-877, 2001.
PubMed
21) Kario K, et al on behalf of the Jichi Morning Hypertension Research (J-MORE) Pilot Study. Circulation 108 : 72e-73, 2003.
 
P.428 掲載の参考文献
1) 松岡秀洋, 今泉勉 : 白衣高血圧. 別冊医学のあゆみ 202 : 621-625, 2002.
 
2) Staessen JA, et al ; Participants of the 2001 Consensus Conference on Ambulatory Blood Pressure Monitoring : Task Force II : blood pressure measurement and cardiovascular outcome. Blood Press Monit 6 (6) : 355-370, 2001.
PubMed
3) Moser M : Wllite-coat hypertension-to treat or not to treat : a clinical dilemma. Arch Intern Med 161 (22) : 2655-2656, 2001.
 
4) Pickering TG : White coat hypertension : time for action. Circulation 98 : 1834-1836, 1998.
PubMed
5) Mancia G, Zanchetti A : White-coat hypertension : misnomers, misconceptions and misunderstandings. What should we do next? J Hypertens 14 (9) : 1049-1052, 1996.
PubMed
6) Palatini P, et al : White-coat hypertension : a selection bias? Harvest Study Investigators. Hypertension and Ambulatory Recording Venetia Study. J Hypertens 16 (7) : 977-984, 1998.
 
7) Myers MG, et al : Prevalence of white coat effect in treated hypertensive patients in the community. Am J Hypertens 8 (6) : 591-597, 1995.
PubMed
8) 1999 World Health Organization-lnternational Society of Hypertension Guidelines for the Management of Hypertension : Guidelines Subcommittee. J Hypertens 17 : 151-183, 1999.
 
9) Verdecchia P, et al : White coat hypertension and white coat effect. Similarities and differences. Am J Hypertens 8 : 790-798, 1995.
PubMed
10) Lantelme P, et al : White coat effect and reactivity to stress : cardiovascular and autonomic nervous system responses. Hypertension 31 : 1021-1029, 1998.
PubMed
11) Nakao M, et al : Mental arithmetic is a useful diagnostic evaluation in white coat hypertension. Am J Hypertens 11 : 41-45, 1998.
PubMed
12) Parati G, et al : Difference between clinic and daytime blood pressure is not a measure of the white coat effect. Hypertension 31 : 1185-1189, 1998.
 
13) Smith PA, et al : Sympathetic neural mechanisms in white-coat hypertension. J Am Coll Cardiol 40 (1) : 126-132, 2002.
PubMed
14) Staessen JA, et al : Short report : ambulatory blood pressure in normotensive compared with hypertensive subjects. The Ad-Hoc Working Group. J Hypertens 11 : 1289-1297, 1993.
 
15) Verdecchia P, et al : Independent predictors of isolated clinic ('white-coat') hypertension. J Hypertens 19 : 1015-1020, 2001.
 
16) Fotherby MD, Potter JF : Variation of within visit blood pressure readings at a single visit in the elderly and their relationship to ambulatory measurements. J Hum Hypertens 8 : 107-111, 1994.
 
17) 梅井秀和ほか : 高血圧とマルチプルリスクファクター症候群. The Lipid 10 : 50-57, 2002.
 
18) Julius S, et al : "White coat" versus "sustained" borderline hypertension in Tecumseh, Michigan. Hypertension 16 : 617-623, 1990.
PubMed
19) Cavallini MC, et al : Is white coat hypertension associated with arterial disease or left ventricular hypertrophy? Hypertension 26 : 413-419, 1995.
PubMed
20) Pierdomenico SD, et al : Target organ status and serum lipids in patients with white coat hypertension. Hypertension 26 : 801-807, 1995.
PubMed
21) Chang NC, et al : Left ventricular filling profiles in young white-coat hypertensive patients without hypertrophy. Hypertension 30 : 746-752, 1997.
 
22) Muldoon MF, et al : White-coat hypertension and carotid artery atherosclerosis : a matching study. Arch Intern Med 160 : 1507-1512, 2000.
PubMed
23) Bjorklund K, et al : Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period : a population-based study of elderly men. Circulation 106 (1) : 63-68, 2002.
 
24) Matsuoka H : Endothelial dysfunction associated with oxidative stress in human. Diabetes Res Clin Pract 54 (Suppl 2) : S65-S72, 2001.
 
25) Pierdomenico SD, et al : Low-density lipoprotein oxidation and vitamins E and C in sustained and white-coat hypertension. Hypertension 31 : 621-626, 1998.
 
26) 松岡秀洋, 今泉勉 : 降圧治療による心肥大・心筋梗塞の予防. Mebio 16 (9) : 17-26, 1999.
 
27) Glen SK, et al : White-coat hypertension as a cause of cardiovascular dysfunction. Lancet 348 : 654-657, 1996.
PubMed
28) Soma J, et al : Left ventricular systolic and diastolic function assessed with two-dimensional and doppler echocardiography in "white coat" hypertension. J Am Coll Cardiol 28 : 190-196, 1996.
PubMed
29) Muscholl MW, et al : Changes in left ventricular structure and function in patients with white coat hypertension : cross sectional survey. BMJ 317 : 565-570, 1998.
PubMed
30) Palatini P, et al : Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension : results from the HARVEST study. Hypertension 31 : 57-63, 1998.
 
31) Sega R, et al : Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension : Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 104 : 1385-1392, 2001.
PubMed
32) Kuwajima I, et al : Is white coat hypertension innocent? Structure and function of the heart in the elderly. Hypertension 22 : 826-831, 1993.
PubMed
33) Cuspidi C, et al : Cardiac and carotid struculre in patients with established hypertension and whitecoat hypertension. J Hypertens 13 : 1707-1711, 1995.
 
34) Matsuoka H : Novel coronary risk factors and endothelial dysfunction. In : Proceedings for the 5th World Congress of Echocardiography and Vascular Ultrasound (ed by Bae JH, Nanda NC), p 221-226, Monduzzi Editore, Bologna, 2002.
 
35) Gomez-Cerezo J, et al : Noninvasive study of endothelial function in white coat hypertension. Hypertension 40 (3) : 304-309, 2002.
PubMed
36) Pierdomenico SD, et al : Endothelial function in sustained and white coat hypertension. Am J Hypertens 15 (11) : 946-952, 2002.
PubMed
37) Shimada K, et al : Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. Hypertension 16 : 692-699, 1990.
PubMed
38) Kario K, et al : Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 27 : 130-135, 1996.
PubMed
39) Kario K, et al : Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol 38 : 238-245, 2001.
PubMed
40) Hoegholm A, et al : Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension 24 : 101-105, 1994.
PubMed
41) Verdecchia P, et al : Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 24 (6) : 793-801, 1994.
PubMed
42) Khattar RS, et al : Cardiovascular outcome in white-coat versus sustained mild hypertension : a 10-year follow-up study. Circulation 98 : 1892-1897, 1998.
PubMed
43) Pickering TG, et al : Masked hypertension. Hypertension 40 (6) : 795-796, 2002.
PubMed
44) Mancia G : Reversed white-coat hypertension : definition, mechanisms and prognostic implications. J Hypertens 20 (4) : 579-581, 2002.
PubMed
45) Liu JE, et al : Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med 131 (8) : 564-572, 1999.
PubMed
46) Wing LM, et al ; ANBP2 Management Committee and Investigators. Second Australian National Blood Pressure Study : 'Reverse white-coat hypertension' in older hypertensives. J Hypertens 20 (4) : 639-644, 2002.
PubMed
47) Bjorklund K, et al : Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation 107 (9) : 1297-1302, 2003.
PubMed
48) White WB : Ambulatory blood-pressure monitoring in clinical practice. N Engl J Med 348 (24) : 2377-2378, 2003.
PubMed
49) Guidelines Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (6) : 1011-1053, 2003.
 
50) 松岡秀洋, 今泉勉 : 動脈硬化と高血圧-予防・発見・治療の指針. 21世紀への医学-動脈硬化診療の新展開 (横山光宏監), p98-106, メジカルセンス, 2000.
 
51) 松岡秀洋, 今泉勉 : 高血圧の非薬物療法. 循環器疾患最新の治療 2000-2001 (篠山重威, 矢崎義雄編), p406-409, 南江堂, 2000.
 
52) Pickering TG, et al : Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension. Results of the HALT Study. Hypertension and Lipid Trial Study Group. Am J Hypertens 7 : 848-852, 1994.
 
53) Myers MG, Reeves RA : White coat phenomenon in patients receiving antihypertensive therapy. Am J Hypertens 4 : 844-849, 1991.
PubMed
54) Hond ED, et al ; THOP investigators : Self-measured versus ambulatory blood pressure in the diagnosis of hypertension. J Hypertens 21 (4) : 717-722, 2003.
 
55) Imai Y, et al : Predictive values of automated blood pressure measurement : what can we learn from the Japanese population-the Ohasama study. Blood Press Monit 6 (6) : 335-339, 2001.
PubMed
56) Clement DL, et al ; Othce versus Ambulatory Pressure Study lnvestigators : Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 348 (24) : 2407-2415, 2003.
PubMed
57) Imai Y : Prognostic significance of ambulatory blood pressure. Blood Press Monit 4 (5) : 249-256, 1999.
PubMed
58) Pickering T : Future developments in ambulatory blood pressure monitoring and self-blood pressure monitoring in clinical practice. Blood Press Monit 7 (1) : 21-25, 2002.
PubMed
P.434 掲載の参考文献
1) Kaplan NM : Hypertension with pregnancy and the pill. In : Clinical Hypertension, 7th ed, p 323-344, Williams & Wilkins, Baltimore, 1998.
 
2) 角野博之, 市川秀一 : 女性における高血圧管理 : 妊娠, 出産, 閉経. Medical Practice 19 : 1507-1513, 2002.
Medical*Online
3) 高血圧治療ガイドライン2000年版 (日本高血圧学会高血圧治療ガイドライン作成委員会編), 日本高血圧学会, 2000.
 
4) National High Blood Pressure Education Program : Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol 183 : S1-S22, 2000.
 
5) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : The JNC 7 Report. JAMA 289 : 2560-2572, 2003.
PubMed
6) Cunningham FG, Lindheimer MD : Hypertension in pregnancy. N Engl J Med 326 : 927-932, 1992.
PubMed
P.439 掲載の参考文献
1) 鴫谷亮一, 土屋幸彦 : 本態性高血圧および悪性高血圧の診断. 高血圧のすべて (上田英雄編), p127-138, 南江堂, 1973.
 
2) Kaplan MN : Hypertensive crises. In : Clinical Hypertension, 8th ed, p 339-356, Williams & Wilkins, Baltimore, 2003.
 
3) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 特殊条件下高血圧の治療. 高血圧治療ガイドライン 2000年版, p39-44, 日本高血圧学会, 2000.
 
4) Blumenfeld JD, Laragh JH : Management of hypertensive crises : The scientific basis for treatment decisions. Am J Hypertens 14 : 1154-1167, 2001.
PubMed
5) 山門実 : 緊急降圧を要する高血圧. 循環器 NOW 5高血圧, p226-230, 南江堂, 1994.
 
6) The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157 : 2413-2446, 1997.
PubMed
7) Furberg CD, et al : Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92 : 1326-1331, 1995.
PubMed
8) Psaty BM, et al : The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274 : 620-625, 1995.
PubMed
9) 1997 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 17 : 151-183, 1999.
PubMed
10) Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension. J Hypertens 15 : 105-115, 1997.
 
P.447 掲載の参考文献
1) Page IH : Essential Hypertension, p 1-29, Springer-Verlag, New York, 1960.
 
2) 檜垣實男, 萩原俊男 : 血圧・循環調節システム. 日本臨牀 58 (増刊 : 高血圧 (上)) : 13-18, 1999.
 
3) Guyton AC, Hall JE : Human Physiology and Mechanism of Disease, 6th ed, WB Saunders, Philadelphia, 1997.
 
4) 萩原俊男, 大塚篤弘 : 高血圧症, 低血圧症-二次性低血圧. 最新内科学大系, 第35巻 (井村裕夫ほか編), p393-403, 中山書店, 1991.
 
5) 平野誠一郎ほか : 本態性低血圧症の循環動態と神経・体液性因子の調節障害. 北里医学会雑誌 17 : 432, 1987.
 
6) 国民栄養の現状 (平成11年国民栄養調査結果), 第一出版, 2000.
 
7) 筒井末春 : 低血圧症-初診から治療管理まで, 医学図書出版, 1979.
 
8) 筒井末春ほか : 低血圧の心身療法. 低血圧者のマネージメント (心身医療研究会編), p9-16, 医薬ジャーナル社, 1997.
 
9) 姫野友美 : 本態性低血圧に関する断面調査と愁訴調査, および循環動態. 民族衛生 60 : 299-314, 1994.
 
P.450 掲載の参考文献
1) Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157 : 2413-2449, 1997.
PubMed
2) Hansson L, et al : Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351 : 1755-1762, 1998.
PubMed
3) UK Prospective Diabetes Study (UKPDS) Group : Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. BMJ 317 : 703-713, 1998.
PubMed
4) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン2000年版, 日本高血圧学会, 2000.
 
5) American Diabetes Association : Treatment of hypertension in adults with diabetes. Diabetes Care 25 : S71-S89, 2002.
 
6) Chobanian AV, et al : The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : The JNC 7. JAMA 289 : 2560-2572, 2003.
PubMed
7) Guideline Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
8) 日本糖尿病学会「EBMに基づく糖尿病診療ガイドライン委員会」 : 科学的根拠に基づく糖尿病診療ガイドライン, 南江堂. (印刷中)
 
9) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288 : 2981-2997, 2002.
PubMed
P.458 掲載の参考文献
1) Nakai S, et al : An overview of dialysis treatment in Japan (as of Dec. 31, 1999). J Jpn Soc Dial Ther 34 : 1121-1147, 2001.
 
2) Klag MJ, et al : Blood pressure and end-stage renal disease in men. N Engl J Med 334 : 13-18, 1996.
 
3) The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 157 : 2413-2446, 1997.
 
4) 1999 World Health Organization-lnternational Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17 : 151-183, 1999.
 
5) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (The JNC 7 Report). JAMA 289 : 2560-2572, 2003.
 
6) Perdini MT, et al : The effect of dietary protein restriction on the progression of diabetic and nondia-betic renal disease : A meta-analysis. Ann Intern Med 124 : 627-632, 1996.
 
7) Klahr S, et al : The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330 : 877-884, 1994.
PubMed
8) Locattelli F, et al : Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Lancet 337 : 1299-1304, 1991.
 
9) Neal B, et al : Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs : Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trials'Collaboration. Lancet 356 : 1955-1964, 2000.
PubMed
10) Black HR, et al : Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA 289 : 2073-2082, 2003.
 
11) Dahlof B, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : A randomised trial against atenolol. Lancet 359 : 995-1003, 2002.
PubMed
12) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 : 2981-2997, 2002.
PubMed
13) The Heart Outcomes Prevention Evaluation Study Investigators : Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 : 1033-1041, 2001.
 
14) PROGRESS Collaborative Group : Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 : 1033-1041, 2001.
PubMed
15) Wing LMH, et al : A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 : 583-592, 2003.
PubMed
16) Psaty BM, et al : Health outcomes associated with antihypertensive therapies used as first-line agents. A systemic review and meta-analysis. JAMA 277 : 739-745, 1997.
 
17) 萩本剛一ほか : 透析患者の高血圧治療. 腎と透析 (増刊) : 400-405, 1995.
 
18) Parving HH, et al : Renal protection in diabetes : an emerging role for calcium antagonists. J Hypertens 14 : S21-S25, 1996.
 
19) Bakris GL, et al : Effects on ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54 : 1283-1289, 1998.
PubMed
20) Lewis EJ, et al : The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329 : 1456-1462, 1993.
PubMed
21) Brenner BM, et al : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861-869, 2001.
PubMed
22) The GISEN Group : Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 : 1857-1863, 1997.
PubMed
23) Bakris GL, Weir MR : Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine : Is this a cause for concern? Arch Intern Med 160 : 685-693, 2000.
 
24) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study lnvestigators. N Engl J Med 341 : 709-711, 1999.
 
25) Tomita J, et al : Role of systolic blood pressure in determining prognosis of hemodialyzed patients. Am J Kidney Dis 25 : 405-412, 1995.
PubMed
P.463 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2000年版, 日本高血圧学会, 2000.
 
2) International Society of Hypertension Writing Group : International Society of Hypertension (ISH) : Statement on the management of blood pressure in acute stroke. J Hypertens 21 : 665-672, 2003.
 
3) Adams HP, et al : Guidelines for the management of patients with acute stroke. A statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Stroke 25 : 1901-1914, 1994.
PubMed
4) Schrader J, et al : The ACCESS Study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34 : 1699-1703, 2003.
PubMed
5) Chobanian AV, et al : The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289 : 2560-2572, 2003.
PubMed
6) PROGRESS Collaborative Group : Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358 : 1033-1041, 2001.
PubMed
7) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 : 2981-2997, 2002.
PubMed
P.469 掲載の参考文献
1) MacMahon S, et al : Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure : prospective observational studies corrected for the regression dilution bias. Lancet 335 : 765-774, 1990.
PubMed
2) Neaton JD, Wentworth D : Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 152 : 56-64, 1992.
 
3) Ganz P, Ganz W : Coronary blood flow and myocardial ischemia. In : Heart Disease : A Textbook of Cardiovascular Medicine, 6th ed (ed by Braunwald E, et al), p 1087-1113, WB Saunders, Philadelphia, 2001.
 
4) Farnett L, et al : The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 265 : 489-495, 1991.
 
5) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン2000年度版, 日本高血圧学会, 2000.
 
6) Hansson L, et al : Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 : 1755-1762, 1998.
 
7) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
8) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
9) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 : 2981-2997, 2002.
PubMed
10) The CAPRICORN Investigators : Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial. Lancet 357 : 1385-1390, 2001.
 
11) Packer M, et al : Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 : 1651-1658, 2001.
PubMed
P.476 掲載の参考文献
1) MacMahon S, et al : Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple risk Factor Intervention Trial. Am J Cardiol 63 : 202-210, 1989.
PubMed
2) Multiple Risk Factor Intervention Trial Research Group : Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 248 : 1465-1477, 1982.
 
3) Koren MJ, et al : Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essendal hypertension. Ann Intern Med 114 : 345-352, 1991.
PubMed
4) Pfeffer MA, et al, on behalf of the SAVE Investigators : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction : results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 327 : 669-677, 1992.
 
5) Dahlof B, et al : Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5 : 95-110, 1992.
PubMed
6) Kohno M, et al : Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy. Changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 98 : 257-265, 1995.
PubMed
7) Diez J, et al : Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circ Res 64 : 1127-1136, 1989.
 
8) Tlhurmann PA, et al : Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essendal hypertension. Circulation 98 : 2037-2041, 1998.
 
9) Tedesco MA, et al : Effects of losartan on hypertension and left ventricular mass : a long-term study. J Hum Hypertens 12 : 505-510, 1998.
 
10) Mitsunami K, et al : Three-month effects of candesartan cilexetil, an angiotensin II type I (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 12 : 469-474, 1998.
PubMed
11) Diez J, et al : Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 : 2512-2517, 2002.
PubMed
12) Verdecchia P, et al : Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97 : 48-54, 1998.
PubMed
13) Dahl6f B, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomised trial against atenolol. Lancet 359 : 995-1003, 2002.
 
14) Lindholm LH, et al : Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : arandomised trial against atenolol. Lancet 359 : 1004-1010, 2002.
PubMed
P.483 掲載の参考文献
1) Kannel WB : Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 275 : 1571-1576, 1996.
PubMed
2) National High Blood Pressure Education Program Working Group : National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med 153 : 186-208, 1993,
 
3) Dzau V, Braunwald E : Resolved and unresolved issues in the prevention and treatment of coronary artery disease : a workshop consensus statement. Am Heart J 121 : 1233-1263, 1991.
 
4) Blood Pressure Lowering Treatment Trialists' Collaboration : Effect of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs : results of prospectively designed overviews of randomised trials. Lancet 356 : 1955-1964, 2000.
 
5) Staessen JA, et al : Cardiovascular protection and blood pressure reduction : ameta-analysis. Lancet 358 : 1305-1315, 2001.
 
6) Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157 : 2413-2446, 1997.
PubMed
7) Hunt SA, et al ; American College of Cardiology/American Heart Association : ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult : executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 38 : 2101-2113, 2001.
 
8) 循環器病の診断と治療に関するガイドライン 慢性心不全治療ガイドライン. Jpn Circ J 64 (Suppl IV) : 1023-1079, 2000.
 
9) 循環器病の診断と治療に関するガイドライン 急性重症心不全治療ガイドライン. Jpn Circ J 64 (Suppl IV) : 1129-1165, 2000.
 
10) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン, 日本高血圧学会, 2000.
 
11) Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289 : 2560-2572, 2003.
 
12) Kaplan NM : Low-dose combination therapy : The rationalization for ACE inhibitor and a calcium channel blocker in higher risk patients. Am J Hypertens 14 : S8-S11, 2001.
 
P.488 掲載の参考文献
1) Arakawa K : Effect of exercise on hypertension and associated complications. Hypertens Res 19 (Suppl 1) : S87-S91, 1996.
 
2) 上原吉就, 荒川規矩男 : 非薬物療法. 日本臨牀 55 : 2034-2038, 1997.
Medical*Online
3) Stamler R, et al : Nutritional therapy for high blood pressure. JAMA 257 : 1484-1491, 1987.
PubMed
4) Langford HG, et al : Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA 253 : 657-664, 1985.
PubMed
5) Schmieder RE, et al : Antihypertensive therapy. To stop or not to stop. JAMA 265 : 1566-1571, 1991.
 
6) Whelton P, et al : Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 279 : 839-846, 1998.
 
7) Kanai H, et al : Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 16 : 484-490, 1990.
PubMed
8) Dannenberg AL, Kannel WB : Remission of hypertension. JAMA 257 : 1477-1483, 1987.
PubMed
9) Sugiyama T, et al : Remission of hypertension ; Retrospective observation over a period of 20 years. Hypertens Res 21 : 103-108, 1998.
 
10) Fujii J, Seki A : Compliance and compliance-improving strategies in hypertension : The Japanese experience. J Hypertens 3 (Suppl 1) : 19-22, 1985.
 
11) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure : The JNC 7 Report. JAMA 289 : 2560-2572, 2003.
 
P.492 掲載の参考文献
1) 片山宗一 : 睡眠時無呼吸症候群と高血圧. 日本臨牀 58 (増刊 : 高血圧 (下)) : 571-578, 2000.
 
2) Silverberg DS, et al : Sleep related breathing disorders are common contributing factors to the production of essential hypertension but are neglected, underdiagnosed, and undertreated. Am J Hypertens 10 : 1319-1325, 1997.
 
3) Nieto FJ, et al : Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 283 : 1829-1836, 2000.
 
4) Sharabi Y, et al : Diastolic blood pressure is the first to rise in association with early subclinical obstructive sleep apnea : lessons from periodic examination screening. Am J Hypertens 16 : 236-239, 2003.
PubMed
5) Becker HF, et al : Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107 : 68-73, 2003.
PubMed
6) Brooks D, et al : Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. J Clin Invest 99 : 106-109, 1997.
 
7) Roux F, et al : Sleep-related breathing disorders and cardiovascular disease. Am J Med 108 : 396-402, 2000.
PubMed
8) Guyenet PG : Neural structures that mediate sympathoexcitation during hypoxia. Respir Physiol 121 : 147-162, 2000.
PubMed
9) Moller DS, et al : Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 16 : 274-280, 2003.
PubMed
10) Greenberg HE, et al : Expression of c-fos in the rat brainstem after chronic intermittent hypoxia. Brain Res 816 : 638-645, 1999.
PubMed
11) Sica AL, et al : Chronic-intermittent hypoxia : a model of sympathetic activation in the rat. Respir Physiol 121 : 173-184, 2000.
 
12) 十川和博 : 低酸素応答におけるHIF-1の役割. 医学のあゆみ 194 : 752-756, 2000.
Medical*Online
P.496 掲載の参考文献
1) 龍野一郎, 齋藤康 : 動脈硬化症. 日本臨牀 61 (増刊号 1) : 259-265, 2003.
 
2) Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure ; National High Blood Pressure Education Program Coordinating Committee : The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 (21) : 2413-2446, 1997.
 
3) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 : 2981-2997, 2002.
PubMed
4) Chobanian AV, et al : The Seventh Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (The JNC 7 Report). JAMA 289 : 2560-2572, 2003.
PubMed
5) 日本痛風・核酸代謝学会治療ガイドライン作成委員会 : 高尿酸血症・痛風の治療ガイドライン. 痛風と核酸代謝 26 (Suppl) : 1, 2002.
 
6) Selby JV, et al : Precursors of essential hypertension : pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 131 : 1017-1027, 1990.
PubMed
7) Goldstein HS, Manowitz P : Relation between uric acid and blood pressure in adolescents. Ann Hum Biol 20 : 423-431, 1993.
PubMed
8) Jossa F, et al : Serum uric acid and hypertension : the Olivetti heart study. J Hum Hypertens 8 (9) : 677-681, 1994.
PubMed
9) Cannon PJ, et al : Hyperuricemia in primary and renal hypertension. N Engl J Med 275 (9) : 457-464, 1966.
PubMed
10) Bulpitt CJ : Serum uric acid in hypertensive patients. Br Heart J 37 (12) : 1210-1215, 1975.
PubMed
11) Gertler MM, et al : Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 34 : 1421-1431, 1951.
PubMed
12) Wannamethee SG, et al : Serum urate and the risk of major coronary heart disease events. Heart 78 (2) : 147-153, 1997.
PubMed
13) Culleton BF, et al : Serum uric acid and risk for cardiovascular disease and death : the Framingham Heart Study. Ann Intern Med 131 (1) : 7-13, 1999.
PubMed
14) Fang J, Alderman MH : Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283 (18) : 2404-2410, 2000.
PubMed
15) Nderman MH, et al : Serum uric acid and cardiovascular events in successfUlly treated hypertensive patients. Hypertension 34 (1) : 144-150, 1999.
 
16) Tomita M, et al : Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 10 (6) : 403-409, 2000.
PubMed
17) 箱田雅之ほか : 心血管疾患リスクファクターとしての尿酸値の意義-原爆被爆患者の長期追跡調査による解析. 痛風と核酸代謝 24 : 61, 2000.
 
18) Ward HJ : Uric acid as an independent risk factor in the treatment of hypertension. Lancet 352 : 670-671, 1998.
PubMed
19) Spiekermann S, et al : Electron spin resonance characterization of vascular xanthine and NAD (P) H oxidase activity in patients with coronary artery disease. Circulation 107 : 1383-1389, 2003.
PubMed
20) Ginsberg MH, et al : Release of platelet constituents by monosodium urate crystals. J Clin Invest 60 : 999-1007, 1997.
 
21) Johnson WD, et al : A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 121 : 20-24, 1991.
PubMed
P.502 掲載の参考文献
1) Safian RD, Textor SC : Renal-artery stenosis. N Engl J Med 344 : 431-442, 2001.
PubMed
2) Uzu T, et al : Prevalence and predictors of renal artery stenosis in patients with myocardial infarction. Am J Kidney Dis 29 : 733-738, 1997.
PubMed
3) Uzu T, et al : Prevalence and outcome of renal artery stenosis in atherosclerotic patients with renal dysfunction. Hypertens Res 25 (4) : 537-542, 2002.
PubMed
4) Plouin PF, et al : Atherosclerotic renal artery stenosis : surgery, percutaneous transluminal angioplasty, or medical therapy. Curr Hypertens Rep 2 (5) : 482-489, 2000.
 
5) Crowley JJ, et al : Progression of renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J 136 (5) : 913-918, 1998.
PubMed
6) Dorros G, et al : Multicenter Palmaz stent renal artery stenosis revascularization registry report : Four-year follow-up of 1,058 successful patients. Catheter Cardiovasc Interv 55 (2) : 182-188, 2002.
PubMed
P.506 掲載の参考文献
1) An overview of regular dialysis treatment in Japan as of Dec. 31, 2002. Jpn Soc Dial Ther 2003.
 
2) Cameron J : Hypertension in glomerulonephritis. Contrib Nephrol 54 : 103-112, 1987.
PubMed
3) Bell PE, et al : Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 34 (5) : 683-690, 1988.
PubMed
4) Orofino L, et al : Hypertension in primary chronic glomerulonephritis : analysis of 288 biopsied patients. Nephron 45 (1) : 22-26, 1987.
PubMed
5) Smith MC, Dunn MJ : Hypertension in renal parenchymal disease. In : Hypertension (ed by Laragh JH, Brenner BM), p 2081, Raven Press, New York, 1995.
 
6) D'Amico G, Vendemia F : Hypertension in IgA nephropathy. Contrib Nephrol 54 : 113-118, 1987.
 
7) Rydel JJ, et al : Focal segmental glomerular sclerosis in adults : presentation, course, and response to treatment. Am J Kidney Dis 25 (4) : 534-542, 1995.
PubMed
8) Donati D, et al : Natural history and treatment of uremia secondary to Fabry's disease : an European experience. Nephron 46 (4) : 353-359, 1987.
 
9) Guyton AC : Arterial Pressure and Hypertension, WB Saunders, Philadelphia, 1980.
 
10) Danielson H, et al : Arterial hypertension in chronic glomerulonephritis. An analysis of 310 cases. Clin Nephrol 19 : 284-298, 1984.
 
11) Tylicki L, et al : Multifactorial determination of hypertensive nephroangiosclerosis. Kidney Blood Press Res 25 (6) : 341-353, 2002.
PubMed
12) Maschio G, et al : Effect of the angiotensin converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334 : 939-945, 1996.
PubMed
13) Klahr S, et al : The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330 : 877-884, 1994.
PubMed
14) Ruggenenti P, et al : Chronic proteinuric nephropathies : outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35 (6) : 1155-1165, 2000.
 
15) Jafar T, et al : Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135 : 73-87, 2001.
PubMed
16) Russo D, et al : Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33 : 851-856, 1999.
PubMed
17) Agarwal R : Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 59 : 2282-2289, 2001.
PubMed
P.511 掲載の参考文献
1) 島津章 : 先端巨大症・下垂体性巨人症. 別冊・医学のあゆみ 内分泌・代謝疾患 -State of Arts (赤沼安夫ほか編), p319-321, 医歯薬出版, 1997.
 
2) Fukuda I, et al : Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University. Intern Med 40 : 987-992, 2001.
 
3) Minniti G, et al : Prevalence of hypertension in acromegalic patients : Clinical measurement versus 24-hour ambulatory blood pressure monitoring. Clin Endocrinol 48 : 149-152, 1998.
PubMed
4) Davies DL, et al : Acromegaly : the effects of growth hormone on blood vessels, sodium homeostasis and blood pressure. In : Handbook of Hypertension, Vol 15 : Clinical Hypertension (ed by Robertson JIS), p 545-567, Elsevier Science Publishers BV, Amsterdam, 1992.
 
5) Ohtsuka H, et al : Hypertension in acromegaly : hereditary hypertensive factor produces hypertension by enhancing IGF-1 production. Endocr J 42 : 781-787, 1995.
PubMed
6) Pietrobelli DJ, et al : Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J Hum Hypertens 15 : 601-605, 2001.
PubMed
7) Bondanelli M, et al : Diumal rhythm of plasma catecholamines in acromegaly. J Clin Endocrinol Metab 84 : 2458-2467, 1999.
 
8) Terzolo M, et al : Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. J Endocrinol Invest 22 : 48-54, 1999.
PubMed
9) Clayton RN : Cardiovascular function in acromegaly. Endocr Rev 24 : 272-277, 2003.
PubMed
10) Newman CB, et al : Safety and efficacy of long term octreotide therapy of acromegaly : results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 80 : 2768-2775, 1995.
PubMed
P.515 掲載の参考文献
1) Klein I, Levey GS : New perspectives on thyroid hormone catecholamine and heart. Am J Med 76 : 167-171, 1981.
 
2) Kapitola J, Vilimovska D : Inhibition of the early circulatory effects of triiodothyronine in rats by propranolol. Physiol Bohemoslov 30 : 347-351, 1981.
PubMed
3) Kim D, Smith TW : Effects of thyroid hormone on sodium pump sites, sodium content, and contractile responses to cardiac glycosides in cultured chick ventricular cells. J Clin Invest 74 : 1481-1488, 1984.
 
4) Mizuma H, et al : Thyroid hormone activation in human vascular smooth muscle cells : expression of type II iodothyronine deiodinase. Circ Res 88 : 313-318, 2001.
PubMed
5) Anthonisen P, et al : Determination of cardiac output and other hemodynamic data in patients with hyper-and hypothyroidism, using dye dilution technique. Scand J Clin Lab Invest 12 : 472-480, 1960.
PubMed
6) Morkin E, et al : Biochemical and physiologic effects of thyroid hormone on cardiac performance. Prog Cardiovasc Dis 25 : 435-464, 1983.
PubMed
7) Johansson C, et al : Cardiovascular phenotype and temperature control in mice lacking thyroid hormone receptor-β or both α1 and β. Am J Physiol 276 : H2006-H2012, 1999.
 
8) Klein I, Hong C : Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. J Clin Invest 77 : 1694-1698, 1986.
 
9) Hauger-Klevene JH, et al : Plasma renin activity in hyper-and hypothyroidism : effect of adrenergic blocking agents. J Clin Endocrinol Metab 34 : 625-629, 1972.
PubMed
10) Bing RF, Swales JD : Thyroid disease and hypertension. In : Handbook of Hypertension, Vol 2, Clinical Aspects of Secondary Hypertension (ed by Robertson JIS), p 276-290, Elsevier, Amsterdam, 1989.
 
11) Tseng YC, et al : Thyrotropin modulates receptors for atrial natriuretic peptide on intact human thyroid cells. Am J Med Sci 298 : 15-19, 1989.
PubMed
12) Derubertis FR Jr, et al : Impaired water excretion in myxedema. Am J Med 51 : 41-53, 1971.
PubMed
13) Hurxthal LM : Blood pressure before and after operation in hyperthyroidism. Arch Intern Med 47 : 167-174, 1931.
 
14) Levey GS : Catecholamine sensitivity, thyroid hormone and the heart : areevaluation. Am J Med 50 : 413-420, 1971.
 
15) Arnsdorf MF, Childers RW : Atrial electrophysiology in experimental hyperthyroidism in rabbits. Circ Res 26 : 575-581, 1970.
PubMed
16) Klein I : Thyroid hormone and blood pressure regulation. In : Endocrine Mechanism in Hypertension, Vol 2 (ed by Laragh JH, et al), p 61-80, Raven Press, New York, 1989.
 
17) Endo T, et al : Re-evaluation of a possible high incidence of hypertension in hypothyroid patients. Am Heart J 98 : 684-688, 1979.
PubMed
18) Saito I, Saruta T : Hypothyroidism as a cause of hypertension. Hypertension 5 : 112-115, 1982.
 
19) Bradley SE, et al : Changes in glomerulotubular dimensions, single nephron glomerular filtration rates and the renin-angiotensin system in hypothyroid rats. Life Sci 30 : 633-639, 1982.
PubMed
20) Fuller H Jr, et al : Myxedema : a cause of reversible hypertension. Circulation 31 : 91-92, 1965.
 
21) Shenker Y : Hypertension caused by thyroid and parathyroid abnormalities, acromegaly, and androgens. In : Hypertension Primer Third Edition (ed by Izzo JL, Black HR), p 150-152, American Heart Association, Dallas, 2003.
 
P.519 掲載の参考文献
1) Hellstrom J, et al : Hypertension in hyperparathyroidism. Br J Urol 30 : 13-24, 1958.
PubMed
2) George JM, et al : Calcareous renal disease and hyperparathyroidism. Q J Med 34 : 291-301, 1965.
PubMed
3) Browder W, et al : Primary hyperparathyroidism in the seventies : A decade of change. Am J Surg 146 : 360-365, 1983.
PubMed
4) Smith JC, et al : Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 85 : 3515-3519, 2000.
PubMed
5) Barletta G, et al : Cardiovascular effects of parathyroid hormone : a study in healthy subjects and normotensive patients with mild primary hyperparathyroidism. J Clin Endocrinol Metab 85 : 1815-1821, 2000.
PubMed
6) Nilsson IL, et al : Left ventricular systolic and diastolic function and exercise testing in a primary hyperparathyroidism-effects of parathyroidectomy. Surgery 128 : 895-902, 2000.
 
7) Diamond TW, et al : Parathyroid hypertension. A reversible disorder. Arch Intern Med 146 : 1709-1712, 1986.
PubMed
8) Bemini G, et al : Renin-angiotensin-aldosterone system in primary hyperparathyroidism before and after surgery. Metabolism 48 : 298-300, 1999.
 
9) Piovesan A, et al : Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol 50 : 321-328, 1999.
PubMed
10) Raine AE, et al : Hyperparathyroidism, platelet intracellular free calcium concentration ( [Ca2+] i) and hypertension in chronic renal failure. Kidney Int 43 : 700-705, 1993.
PubMed
11) Poch E, et al : Parathyroid hormone and platelet cytosolic calcium concentration in essential hypertension. Nephrol Dial Transplant 10 : 366-371, 1995.
PubMed
12) Ellison DH, et al : Effects of calcium infusion on blood pressure in hypertensive and normotensive humans. Hypertension 8 : 497-505, 1986.
PubMed
13) McCarron DA : Calcium metabolism and hypertension. Kidney Int 35 : 717-736, 1989.
PubMed
14) Brinton GS, et al : Hypertension in primary hyperparathyroidism : the role of the renin-angiotensin system. J Clin Endocrinol Metab 41 : 1025-1029, 1975.
PubMed
15) Bro S, Olgaard K : Effects of excess PTH on nonclassical target organ. Am J Kidney Dis 30 : 606-620, 1997.
PubMed
16) Hulther HN, et al : Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 4 : 360-370, 1986.
 
17) Pang PTK, et al : Parathyroid hypertensive factor and intracellular calcium regulation. J Hypertens 14 : 1053-1060, 1996.
 
18) Fuji Y, et al : Endothelin as an autocrine factor in the regulation of parathyroid cells. Proc Natl Acad Sci USA 88 : 4235-4239, 1991.
 
19) Eguchi S, et al : Endothelin receptors in human parathyroid glands. Biochem Biophys Res Commun 184 : 1448-1455, 1992.
PubMed
20) Daniels J, Goodman AD : Hypertension and hyperparathyroidism. Inverse relation of serum phosphate level and blood pressure. Am J Med 75 : 17-23, 1983.
PubMed
21) Potts JT : Proceedings of the NIH consensus development conference on diagnosis and management of asymptomatic primary hyperparathyroidism. J Bone Miner Res 6 (Suppl 2) : S1-S166, 1991.
 
22) Bilezikian JP, Potts JT : Asymptomatic primary hyperparathyroidism : a perspective for the 21st century. J Bone Miner Res 17 (Suppl 2) : N1-N162, 2002.
 
P.524 掲載の参考文献
1) Conn JW : Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45 : 3-16, 1955.
PubMed
2) Gordon RD, et al : High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21 : 315-318, 1994.
PubMed
3) Komiya I, et al : An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-aldosterone system. J Hypertens 15 : 65-72, 1997.
PubMed
4) Nishikawa T, Omura M : Clinical characteristics of primary aldosteronism : Its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 54 (Supp11) : 83s-85s, 2000.
PubMed
5) 大村昌夫, 関原久彦 : 原発性アルドステロン症. 循環器科 53 : 120-129, 2003.
 
6) 名和田新ほか : 副腎ホルモン産生異常症の全国疫学調査. 厚生省特定疾患内分泌系疾患調査研究班「副腎ホルモン産生異常症」調査分科会平成10年度研究報告書 (班長 : 名和田新), p11-53, 厚生省特定疾患副腎ホルモン産生異常症調査研究班, 1999.
 
7) Kaplan NM : Caution over the current epidemic of primary aldosteronism. Lancet 357 : 953-954, 2001.
 
8) Montori VM, et al : Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 76 : 877-882, 2001.
PubMed
9) Montori VM, Young WF Jr : Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of literature. Endocrinol Metab Clin North Am 31 : 619-632, 2002.
PubMed
10) Hirohara D, et al : Performance of the basal aldosterone to renin ratio and of the renin stimulation test by frosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab 86 : 4292-4298, 2001.
 
11) Naomi S, et al : Clinical evaluation of captopril screening test for primary aldosteronism. Jpn Heart J 26 : 549-556, 1985.
PubMed
12) Omura M, et al : Unique cases of unilateral hyperaldosteronism due to multiple adrenocortical micronodules, which can only be detected by selected adrenal venous sampling. Metabolism 51 : 350-355, 2002.
PubMed
13) Magill SB, et al : Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 86 : 1066-1071, 2001.
PubMed
14) 大村昌夫ほか : 原発性アルドステロン症における副腎静脈採血法の重要性についての検討. Folia Endocrinol Jpn 76 (Suppl) : 112-114, 2000.
 
15) Lifton RP, et al : A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355 : 262-265, 1992.
 
P.530 掲載の参考文献
1) 加藤堅一ほか : 昭和57年度厚生省特定疾患「ステロイドホルモン産生異常症」調査研究班 Cushing症候群および副腎性器症候群, p6-61, 1983.
 
2) Bailey RE, et al : Periodic hormonogenesis-a new phenomenon. Periodicity in function of a hormone-producing tumor in man. J Clin Endocrinol Metab 32 : 317-327, 1971.
 
3) 名和田新ほか : 平成7年度厚生省特定疾患「副腎ホルモン産生異常症」調査研究班 副腎性preclinical Cushing症候群, p 223-226, 1995.
 
4) Papanicolaou DA, et al : A single midnight serum cortisol measurement distinguishes Cushing's syndrome from pseudo-Cushing states. J Clin Endocrinol Metab 83 : 1163-1167, 1998.
 
5) Krakoff L, et al : Effect of methylprednisolone upon arterial pressure and the renin angiotensin system in the rat. Am J Med 228 : 613-617, 1975.
 
6) Saruta T, et al : Mechanism of glucocorticoid-induced hypertension. Hypertens Res 19 : 1-8, 1996.
 
7) Schomig A, et al : Changes in vascular smooth muscle sensitivity to vasoconstrictor agents induced by corticosteroids, adrenalectomy and differing salt intake. Clin Sci 51 : 61s-63s, 1976.
 
8) Rascher W, et al : Modulation of sympathetic vascular tone by prostaglandins in corticosterone induced hypertension of rats. Clin Sci 57 : 235s-237s, 1979.
PubMed
9) Connell JMC, et al : The effect of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal human. J Hypertens 5 : 425-433, 1987.
 
10) Tam SH, et al : Autonomic blockade amplhies conisol-induced hypertension in man. Clin Exp Pharmacol Physiol 24 : 31-33, 1997.
PubMed
11) Handa M, et al : Urinary prostaglandin E and kallikrein excretion in glucocorticoid hypertension in rat. Clin Sci 65 : 37-42, 1983.
PubMed
12) Kelly JJ, et al : The nitric oxide system and cortisol induced hypertension in human. Clin Exp Pharmacol Physiol 25 : 945-946, 1998.
PubMed
13) Simmons WW, et al : Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-arginine transport. J Biol Chem 271 : 23928-23937, 1996.
PubMed
14) Williamson PM, et al : Dose response relationships and mineraloconicoid activity in cortisol induced hypertension in humans. J Hypertens (Suppl) 14 : 537-541, 1996.
 
P.535 掲載の参考文献
1) 柳瀬敏彦, 名和田新 : ステロイドホルモン合成チトクロームP450の構造と機能. 最新医学 46 : 2169-2178, 1991.
Medical*Online
2) Yanase T, et al : 17α-hydroxylase/17, 20-lyase deficiency : From clinical investigation to molecular definition. Endocr Rev 12 : 91-108, 1991.
 
3) 柳瀬敏彦ほか : 副腎ステロイド合成酵素異常症の診断と治療の動向. ホルモンと臨床 44 : 821-828, 1996.
 
4) Geller DH, et al : The genetic and functional basis of isolated 17, 20-lyase deficiency. Nat Genet 17 : 201-205, 1997.
PubMed
5) Wilkins L, et al : Treatment of congenital adrenal hyperplasia with cortisone. J Clin Endocrinol Metab 11 : 1-10, 1951.
PubMed
6) 中川祐一, 五十嵐良雄 : ステロイドホルモン生合成代謝異常. ホルモンと臨床 43 : 439-444, 1995.
 
7) Southerland DJA, et al : Hypertension, increased aldosterone secretion and low plasma renin activity by dexamethasone. Can Med Assoc J 95 : 1109-1119, 1966.
 
8) Lifton RP, et al : A chimaeric 11β-hydroxylase/aldosterone synthetase gene causes glucocorticoid-remediable aldosteronism. Nature 355 : 262-265, 1992.
 
P.539 掲載の参考文献
1) Pacak K, et al : Recent advance in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134 : 315-329, 2001.
 
2) Thrasher JB, et al : Pheochromocytoma of urinary bladder : contemporary methods of diagnosis and treatment options. Urology 41 : 435-439, 1993.
PubMed
3) Lenders JWM, et al : Biochemical diagnosis of pheochromocytoma. JAMA 287 : 1427-1434, 2002.
 
4) Averbuch SD, et al : Neoplasms of the neuroendocrine system. In : Cancer Medicine, 3rd ed (ed by Holland JF, et al), p 1153-1180, Lea & Febiger, Philadelphia, 1993.
 
5) Averbuch SD, et al : Malignant pheochromocytoma : effective treatment with a combination cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109 : 267-273, 1988.
PubMed
P.543 掲載の参考文献
1) Dampney RAL, et al : Medullary and supramedullary mechanisms regulating sympathetic vasomotor tone. Acta Physiol Scand 177 : 209-218, 2003.
 
2) Matsuura T, et al : Rostral ventrolateral medulla neurons of neonatal Wistar-Kyoto and spontaneously hypertensive rats. Hypertension 40 : 560-565, 2002.
PubMed
3) Morimoto S, et al : Neurovascular compression of the rostral ventrolateral medulla related to essential hypertension. Hypertension 30 (Part 1) : 77-82, 1997.
 
4) Morimoto S, et al : Sympathetic activation and contribution of genetic factors in hypertension with neurovascular compression of the rostral ventrolateral medulla. J Hypertens 17 : 1577-1582, 1999.
PubMed
5) Schobel HP, et al : Hypertension in patients with neurovascular compression is associated with increased central sympathetic oudiow. J Am Soc Nephrol 13 : 35-41, 2002.
PubMed
6) Gajjar D, et al : Vascular compression of the rostral ventrolateral medulla in sympathetic mediated essential hypertension. Hypertension 36 : 78-82, 2000.
PubMed
7) Hohenbleicher H, et al : Neurovascular contact and blood pressure response in young, healthy, normotensive men. Am J Hypertens 15 : 119-124, 2002.
PubMed
8) Morimoto S, et al : Nitric oxide is an excitatory modulator in the rostral ventrolateral medulla in rats. Am J Hypertens 13 : 1125-1134, 2000.
PubMed
9) Levy EI, et al : Microvascular decompression in the treatment of hypertension : review and update. Surg Neurol 55 : 2-11, 2001.
PubMed
10) Morimoto S, et al : Decreases in blood pressure and sympathetic nerve activity by microvascular decompression of the rostral ventrolateral medulla in essential hypertension. Stroke 30 : 1707-1710, 1999.
PubMed
11) Frank H, et al : Long-term results after microvascular decompression in essential hypertension. Stroke 32 : 2950-2955, 2001.
PubMed
P.549 掲載の参考文献
1) Woods JW : Oral contraceptives and hypertension. Hypertension 11 : 11-15, 1988.
PubMed
2) Khaw KT, et al : Blood pressure and contraceptive use. BMJ 285 : 403-407, 1982.
PubMed
3) Steward PM, et al : Syndrome of apparent mineralocorticoid excess. A defect in cortisol-cortisone shuttle. J Clin Invest 82 : 340-349, 1988.
 
4) van Uum SHM, et al : The role of 11 beta-hydroxysteroid dehydrogenase in the pathogenesis of hypertension. Cardiovasc Res 38 : 16-24, 1998.
 
5) Louie AK, et al : Systemic hypertension associated with tricyclic anti-depressant in patients with panic disorder. Anl J Cardiol 170 : 1306-1309, 1992.
 
6) Curtis JJ, et al : Hypertension in Cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 85 : 134-139, 1988.
PubMed
7) Husberg M, et al : ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 33 : 862-869, 1999.
 
8) del Castillo D, et al : Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 68 (Suppl) : S135-S139, 1998.
PubMed
9) del Castillo D, et al : The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system. Nephrol Dial Transplant 10 : 505-508, 1995.
 
10) Tojo A, et al : Endothelin-mediated effect of erythropoietin on blood pressure and renal hemodynamics in hypertensive rats. Am J Physiol 270 : R744-R748, 1996.
PubMed
11) Miller BA, et al : Mechanisms of erythropoietin signal transduction : involvement of calcium channels. Proc Soc Exp Biol Med 206 : 263-267, 1994.
PubMed
12) Pope JE, et al : A meta-analysis of the effect of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153 : 477-484, 1993.
PubMed
13) Jonson AG, et al : Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121 : 289-300, 1994.
 

VIII 合併症・臓器障害時の降圧薬の選択

P.557 掲載の参考文献
1) VA Study Veterans Administration Cooperative Study Group on Anti-hypertensive agents. JAMA 202 : 116-122, 1967.
 
2) Dahlof B, et al : Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5 : 95-110, 1992.
PubMed
3) Yu HC, et al : Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 98 : 2621-2628, 1998.
PubMed
4) Cailar G, et al : Dietary sodium and target organ damage in essential hypertension. Am J Hypertens 15 : 222-229, 2002.
PubMed
5) Takeda Y, et al : Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens 19 : 635-639, 2001.
 
6) Kempner W : Treatment of hypertensive vascular disease with rice diet. Am J Med 4 : 545-577, 1948.
PubMed
7) Arakawa K : Antihypertensive mechanism of exercise. J Hypertens 11 : 223-229, 1993.
PubMed
8) Takezako T, et al : Adenosine activates aromatic L-amino acid decarboxylase activity in the kidney and increases dopamine. J Am Soc Nephrol 12 : 29-36, 2001.
PubMed
9) Lee IM, Paffenbarger RS Jr : Physical activity and stroke incidence : the Harvard Alumni Health Study. Stroke 29 : 2049-2054, 1998.
PubMed
10) Blair SN, et al : Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 262 : 2395-2401, 1989.
PubMed
P.563 掲載の参考文献
1) Hansson L, et al : Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 : 1755-1762, 1998.
 
2) Tumer R, et al : Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. Brit Med J 317 : 703-713, 1998.
 
3) Staessen JA, et al : Cardiovascular protection and blood pressure reduction : ameta-analysis. Lancet 358 : 1305-1315, 2001.
 
4) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288 : 2981-2997, 2002.
PubMed
5) Tuomilehto J, et al : Effect of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340 : 677-684, 1999.
 
6) Liu L, et al : Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 16 : 1823-1829, 1998.
PubMed
7) Forette F, et al : Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352 : 1347-1351, 1998.
PubMed
8) Levy D, et al : Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 : 1561-1566, 1990.
PubMed
9) Verdecchia P : Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97 : 48-54, 1998.
PubMed
10) Schmieder RE, et al : Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275 : 1507-1513, 1996.
PubMed
11) Terpstra WF, et al : Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients : the ELVERA trial. J Hypertens 19 : 303-309, 2001.
 
12) Berl T, et al : Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138 : 542-549, 2003.
PubMed
13) Pitt B, et al : Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102 : 1503-1510, 2000.
PubMed
P.568 掲載の参考文献
1) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289 : 2560-2572, 2003.
PubMed
2) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 : 2981-2997, 2002.
PubMed
3) Guidelines Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
4) Hansson L, et al : Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension : the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 : 611-616, 1999.
 
5) The CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
 
6) The SOLVD Investigators : Efifect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 : 293-302, 1991.
 
7) Cohn JN, et al : Acomparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 : 303-310, 1991.
 
8) Dahlof B, et al : Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5 : 95-110, 1992.
PubMed
9) Pfeffer MA, et al : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 : 669-677, 1992.
 
10) Hall AS, et al : Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction : AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 349 : 1493-1497, 1997.
 
11) Torp-Pedersen C, et al : Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 354 : 9-12, 1999.
 
12) Swedberg K, et al : Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction : results of the Cooperative North Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327 : 678-684, 1992.
 
13) Dickstein K, et al : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction : the OPTIMAAL randomised trial. Lancet 360 : 752-760, 2002.
PubMed
14) Lewis EJ, et al : The effects of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 : 1456-1462, 1993.
PubMed
15) Lebovitz HE, et al : Enalapril slows the progression of renal disease in non-insulin dependent diabetes mellitus. Results of a 3-yr multicenter, randomized, prospective, double-blinded study. J Am Soc Nephrol 3 : 335, 1992.
 
16) Schnack C, et al : Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia 39 : 1611-1616, 1996.
PubMed
17) Maschio G, et al : Effects of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334 : 939-945, 1996.
PubMed
18) Zuccheli P, et al : Long term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42 : 453-458, 1992.
 
19) Ruggenenti P, et al : Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354 : 359-364, 1999.
PubMed
20) Nako N, et al : Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) : a randomised controlled trial. Lancet 361 : 117-124, 2003.
 
P.572 掲載の参考文献
1) アンジオテンシンII受容体と受容体拮抗薬 (ARB) の最新研究動向 (特集). 日本臨牀 60 : 1868-2049, 2002.
 
2) Cohn JN, et al : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
PubMed
3) Maggioni AP, et al : Effects of valsartan on morbidity and mortality in patients With heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40 : 1414-1421, 2002.
 
4) Granger CB, et al : Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors : the CHARM-Alternative trial. Lancet 362 : 772-776, 2003.
PubMed
5) Dahlof B, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet 359 : 995-1003, 2002.
PubMed
6) Lithell H, et al : The study on cognition and prognosis in the elderly (SCOPE) : principal results of a randomized double-blind intervention trial. J Hypertens 21 : 875-886, 2003.
 
7) Matsuura T, et al : Rostral ventrolateral medulla neurons of neonatal Wistar-Kyoto and spontaneously hypertensive rats. Hypertension 40 : 560-565, 2002.
PubMed
8) Sakata K, et al : Potentiated sympathetic nervous and renin-angiotensin systems reduce nonlinear correlation between sympathetic activity and blood pressure in conscious spontaneously hypertensive rats. Circulation 106 : 620-625, 2002.
PubMed
9) Grassi G, et al : Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals : results of the CROSS study. J Hypertens 21 : 1761-1769, 2003.
PubMed
10) Brenner BM, et al : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861-869, 2001.
PubMed
11) Viberti G, Wheeldon NM, for the MARVAL Study Investigators : Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106 : 672-678, 2002.
 
12) 熊谷裕生ほか : 慢性腎炎における, カンデサルタンのエナラプリルより良好な尿蛋白減少とアルドステロン低下作用-2年間の前向き比較研究-. 腎と透析 54 : 157-162, 2003.
 
13) Hostetter TH, et al : Aldosterone in renal disease. Curr Opin Nephrol Hypertens 10 : 105-110, 2001.
PubMed
14) Tryggvason K, Wartiovaara J : Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 10 : 543-549, 2001.
PubMed
15) Davis BJ, et al : Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension : potential role of nephrin. J Hypertens 21 : 209-216, 2003.
PubMed
16) Chobanian AV, et al : The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 289 : 2560-2572, 2003.
PubMed
P.577 掲載の参考文献
1) Staessen JA, et al : Cardiovascular protection and blood pressure reduction : a meta-analysis. Lancet 358 (9290) : 1305-1315, 2001.
PubMed
2) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (23) : 2981-2997, 2002.
PubMed
3) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
4) Ho KK, et al : The epidemiology of heart failure : the Framingham Study. J Am Coll Cardiol 22 (4 Suppl A) : 6A-13A, 1993.
PubMed
5) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2000年度版. 日本高血圧学会, 2000.
 
6) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
7) Guidelines Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
8) Guidelines for the evaluation and management of heart failure. Report of the American College of Cadiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 26 : 1376-1398, 1995.
 
9) Pitt B, et al for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Ethcacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
 
10) The CONSENSUS Trial Group : Effects of enarapril on mortality in severe congestive heart failure. Results of Cooperative North Scandinavian Enarapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
 
11) The SOLVD Investigators : Effect of enarapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 : 293-302, 1991.
 
12) Zanchetti A, Ruilope LM : Antihypertensive treatment in patients with type-2 diabetes mellitus. What guidance from recent controlled randomized trials? J Hypertens 20 : 2099-2110, 2002.
PubMed
13) Jafar TH, et al : Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135 : 73-87, 2001.
PubMed
14) Lewis EJ, et al ; Collaborative Study Group : Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 : 851-860, 2001.
 
15) PROGRESS Collaborative Group : Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 : 1033-1041, 2001.
PubMed
P.581 掲載の参考文献
1) Chobanian AV, et al : The Seventh Report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289 : 2560-2572, 2003.
PubMed
2) Guidelines Subcommittee : 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 17 : 151-183, 1999.
PubMed
3) Guidelines Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
4) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2000年版 (JSH2000), 日本高血圧学会, 2000.
 
5) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone : the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283 : 1967-1975, 2000.
 
6) Davis BR, et al : Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone : Further analyses from the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Ann Intern Med 137 : 313-320, 2002.
PubMed
7) Grimm RH Jr, et al : Baseline characteristics of participants in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 37 : 19-27, 2001.
 
8) Kario K, et al : Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. A prospective study. Circulation 107 : 1401-1406, 2003.
PubMed
9) Panza JA, et al : Circadian variation in vascular tone and its relation to α-sympathetic vasoconstrictor activity. N Engl J Med 325 : 986-990, 1991.
 
10) Dodt C, et al : Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. Hypertension 30 : 71-76, 1997.
PubMed
11) Kario K, et al : Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of α-adrenergic blocker, doxazosin. Results from the HALT Study. Hypertension 35 : 787-794, 2000.
 
12) Kawano Y, et al : Doxazosin suppresses the morning increase in blood pressure and sympathetic nervous activity in patients with essential hypertension. Hypertens Res 20 : 149-156, 1997.
PubMed
13) Ebata H, et al : Dififerential effects of an alpha 1-blocker (doxazosin) on diumal blood pressure variation in dipper and non-dipper type hypertension. Hypertens Res 18 : 125-130, 1995.
 
14) Pickering TG, et al : Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT study. Hypertension and lipid trial study group. Am J Hypertens 7 : 844-847, 1994.
 
15) Verdecchia P, et al : Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 24 : 793-801, 1994.
PubMed
16) Staessen JA, et al : Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 282 : 539-546, 1999.
PubMed
17) Pool JL : Effects of doxazosin on serum lipids : A review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J 121 : 251-260, 1991.
PubMed
18) Grimm RH, et al : Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 275 : 1549-1556, 1996.
PubMed
19) Levy D, et al : Principal results of the hypertension and lipid trial (HALT) : amulticenter study of doxazosin in patients with hypertension. Am Heart J 131 : 966-973, 1996.
 
P.586 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編) : 臓器障害を合併する高血圧の治療. 高血圧治療ガイドライン 2000年版, p45, 日本高血圧学会, 2000.
 
2) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
3) Guidelines Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
4) Yusuf S, et al : Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin and risk factor reduction. JAMA 260 : 2259-2263, 1988.
 
5) First Intemational Study of Infarct Survival Collaborative Group : Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction : ISIS-1. Lancet 335 : 57-66, 1986.
 
6) The CAPRICORN Investigators : Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomized trial. Lancet 357 : 1385-1390, 2001.
 
7) A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results. JAMA 247 : 1707-1714, 1982.
PubMed
8) Freemantle N, et al : β Blockade after myocardial infarction : systematic review and meta regression analysis. BMJ 318 : 1730-1737, 1999.
 
9) Schmieder RE, et al : Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 13 : 564-569, 1998.
PubMed
10) Lindholm LH, et al : Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomized trial against atenolol. Lancet 359 : 1004-1010, 2002.
PubMed
11) Fassbinder W, et al : Treatment with carvedilol is associated with a significant reduction in microalbuminuria : a multicentre randomised study. Int J Clin Pract 53 : 519-522, 1999.
PubMed
P.590 掲載の参考文献
1) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289 : 2560-2572, 2003.
PubMed
2) Guidelines Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
3) Guidelines Subcommittee : 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17 : 151-183, 1999.
PubMed
4) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2000年版, 日本高血圧学会, 2000.
 
5) Packer M, et al : The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 : 1349-1355, 1996.
PubMed
6) Bristow MR, et al : Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 : 2807-2816, 1996.
PubMed
7) The CAPRICORN Investigators : Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomized trial. Lancet 357 : 1385-1390, 2001.
 
8) Packer M, et al : Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 : 1651-1658, 2001.
PubMed
9) Poole-Wilson PA, et al : Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET) : randomised controlled trial. Lancet 362 : 7-13, 2003.
 
P.595 掲載の参考文献
1) 瀧下修一 : 高血圧の成因-20世紀を総括して-, 3) 中枢神経系と高血圧. 日内会誌 89 : 1786-1791, 2000.
 
2) Van Zwieten PA : The renaissance of centrally acting antihypertensive drugs. J Hypertens 17 (Suppl 3) : S15-S21, 1999.
 
3) Takishita S, et al : Neural effects on renal blood flow during acute hypotension vary with antihypertensive drugs. Hypertension 23 (Suppl I) : I-97-I-101, 1994.
 
4) Kaplan NM : Treatment of hypertension : drug therapy. In : Kaplan's Clinical Hypertension, p 237-338, Lippincott Williams & Wilkins, Philadelphia, 2002.
 
5) 三浦幸雄, 野城孝夫 : 各種降圧薬の特徴と治療効果 : 中枢性交感神経抑制薬. 循環器科 46 (Suppl 1) : 494-503, 1999.
 
6) Cockburn J, et al : Final report of study on hypertension during Pregnancy : the effects of specific treatment of the growth and development of the children. Lancet i : 674-679, 1982.
 
7) 高橋伯夫ほか : 本態性高血圧症患者の早朝高血圧治療の試み-guanabenz眠前投与の血圧日内変動に及ぼす影響-. Ther Res 10 : 4611-4619, 1989.
Medical*Online
8) Hashimoto J, et al : Therapeutic effects of evening administration of guanabenz and clonidine on morning hypertension : evaluation using home-based blood pressure measurements. J Hypertens 21 : 805-811, 2003.
PubMed
9) Hayashi J, et al : Guanabenz, an antihypertensive centrally acting alpha2-agonist, suppresses morning elevations in aggregation of human platelets. J Cardiovasc Pharmacol 37 : 89-93, 2001.
PubMed
10) Suzuki H, et al : Blood pressure reduction in the morning yields beneficial effects on progression of chronic renal insufficiency with regression of left ventricular hypertrophy. Clin Exp Hypertens 24 : 51-63, 2002.
PubMed
P.601 掲載の参考文献
1) Staessen JA, et al : Cardiovascular protection and blood pressure reduction : a meta-analysis. Lancet 358 : 1305-1315, 2001.
PubMed
2) Gradman AH, Acevedo C : Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 4 : 343-349, 2002.
PubMed
3) Ruzicka M, Leenen FH : Combination therapy as first-line treatment of arterial hypertension. Can J Cardiol 18 : 1317-1327, 2002.
PubMed
4) Elliott WJ : Is fixed combination therapy appropriate for initial hypertension treatment? Curr Hypertens Rep 4 : 278-285, 2002.
PubMed
5) Materson BJ : Combination therapy as the initial drug treatment for hypertension : when is it appropriate? Am J Hypertens 14 : 293-295, 2001.
PubMed
6) Neutel JM, et al : Low-dose combination therapy : an important first-line treatment in the management of hypertension. Am J Hypertens 14 : 286-292, 2001.
PubMed
7) Bakris GL, et al : Preserving renal function in adults with hypertension and diabetes : a consensus approach. Am J Kidney Dis 36 : 646-661, 2000.
PubMed
8) Chobanian AV, et al : The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289 : 2560-2572, 2003.
PubMed
9) Flack JM, et al : The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension. The Quinapril Titration Interval Management Evaluation (ATIME) Study. Arch Intern Med 160 : 1842-1847, 2000.
PubMed
10) Guidelines Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
11) Psaty BM, et al : Health outcomes associated with various antihypertensive therapies used as first-line agents. A network meta-analysis. JAMA 289 : 2534-2544, 2003.
PubMed
12) Staessen JA, et al : Cardiovascular prevention and blood pressure reduction : aquantitative overview updated until 1 March 2003. J Hypertens 21 : 1055-1076, 2003.
 
13) Dickerson JEC, et al : Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353 : 2008-2013, 1999.
 
14) Brown MJ, et al : Better blood pressure control : how to combine drugs. J Hum Hypertens 17 : 81-86, 2003.
PubMed
15) Holzgreve H, et al : Antihypertensive therapy with verapamil plus trandolapril versus atenolol plus chlorthalidone. Am J Hypertens 16 : 381-386, 2003.
PubMed
16) Dunder K, et al : Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction. BMJ 326 : 681-686, 2003.
PubMed
17) Prisant LM : Fixed low-dose combination in first-line treatment of hypertension. J Hypertens 20 (Suppl 1) : S11-S19, 2002.
 
18) Weir MR : Combination therapy of calcium channel antagonists and diuretics. In : Combination Drug Therapy f6r Hypertension (ed by Opie LH, Messerli FH), p 53-63, Authors'Publishing House, Lippincott-Raven Publishers, New York, 1997.
 
19) PROGRESS Collaborative Group : Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 358 : 1033-1041, 2001.
PubMed
20) PROGRESS Collaborative Group : Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 24 : 475-484, 2003.
 
21) Zanchetti A, et al : Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles : does a J-shaped curve exist in smokers? J Hypertens 21 : 797-804, 2003.
 

IX 大規模介入試験と臓器障害進展予防

P.609 掲載の参考文献
1) Warlow C : Secondary prevention of stroke. Lancet 339 : 724-727, 1992.
PubMed
2) Hypertension, Detection, and Follow-up Program Cooperative Group : I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242 : 2562-2571, 1979.
 
3) Meissner I, et al : Hypertension management and stroke recurrence in a community (Rochester, Minnesota, 1950-79). Stroke 19 : 459-463, 1988.
 
4) Yamamoto H, Bogousslavsky J : Mechanisms of second and further strokes. J Neurol Neurosurg Psychiatry 64 : 771-776, 1998.
PubMed
5) 入江克美, 井林雪郎 : 降圧薬治療は脳卒中の再発予防にも有効か? EBMジャーナル 2 : 296-302, 2001.
 
6) Irie K, et al : The J-curve phenomenon in stroke recurrence. Stroke 24 : 1844-1849, 1993,
 
7) The INDANA project collaborators : Effect of antihypertensive treatment in patients having already suffered from stroke : Gathering the evidence. Stroke 28 : 2557-2562, 1997.
PubMed
8) PROGRESS Collaborative Group : Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358 : 1033-1041, 2001.
PubMed
9) Gueyffier F, et al : New meta-analysis of treatment trials of hypertension : improving the estimate of therapeutic benefit. J Hum Hypertens 10 : 1-8, 1996.
PubMed
10) PATS Collaborating Group : Post-stroke Antihypertensive Treatment Study. A preliminary result. Chin Med J 108 : 710-717, 1995.
 
11) 松岡博昭ほか : 「PROGRESS」発表の意義. 血圧 8 : 1311-1322, 2001.
 
12) Tzourio C, et al : Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163 : 1069-1075, 2003.
 
13) Frasen M, et al : Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease : arandomized controlled trial. Stroke 34 : 2333-2338, 2003.
 
14) Chapman N, et al : Effects of a perindopri1-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history. The PROGRESS trial. Stroke 35 : 116-121, 2004.
PubMed
15) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2000年版 (JSH2000), 日本. 高血圧学会, 2000.
 
16) 厚生労働省長寿科学総合研究班 (荻原俊男ほか) : 老年者高血圧治療ガイドライン-2002年改訂版-. 日老医誌 39 : 322-351, 2002.
 
17) Chobanian AV, et al : Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 : 1206-1252, 2003.
PubMed
18) 尾前照雄 : 日本における大規模臨床試験のあり方-国際共同研究PROGRESSの経験から- (尾前照雄編), 日本医事新報社, 2003.
 
P.615 掲載の参考文献
1) Verdecchia P, et al : Left ventricular mass and cardiovascular morbidity in essential hypertension : the MAVI study. J Am Coll Cardiol 38 : 1829-1835, 2001.
PubMed
2) Van Zvieten PA : The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy. Cardiovasc Res 45 : 82-91, 2000.
 
3) Wachtell K, et al : Change in diastolic left ventricular filling after one year of antihypertensive treatment : The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 105 : 1071-1076, 2002.
PubMed
4) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
5) Guidelines Committees : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
 
6) Devereux RB, et al : Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension : the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 104 : 1248-1254, 2001.
PubMed
7) Dahlof B, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomised trial against atenolol. Lancet 359 : 995-1003, 2002.
PubMed
8) Mathew J, et al ; Heart Outcomes Prevention Evaluation (HOPE) Investigators : Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104 : 1615-1621, 2001.
PubMed
9) Angeja BG, Grossman W : Evaluation and management of diastolic heart failure. Circulation 107 : 659-663, 2003.
PubMed
10) Hansson L, et al : Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 : 1755-1762, 1998.
 
11) Pitt B, et al : Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 102 : 1503-1510, 2000.
PubMed
12) Klein WW, et al : Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris : a meta-analysis. Coron Artery Dis 13 : 427-436, 2002.
PubMed
13) Yusuf S, et al : Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 : 145-153, 2000.
 
14) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 : 2981-2997, 2002.
PubMed
15) del Sol AI, et al : Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Stroke 32 : 1532-1538, 2001.
PubMed
P.621 掲載の参考文献
1) Agodoa LY, et al : Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis : a randomized controlled trial. JAMA 285 : 2719-2728, 2001.
PubMed
2) Jackson TW Jr, et al : Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288 : 2412-2431, 2002.
 
3) Maschio G, et al : Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334 : 939-945, 1996.
PubMed
4) The GISEN Group (Gnlppo Italiano di Studi Epidemiologici in Nefrologia) : Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 : 1857-1863, 1997.
PubMed
5) Baba S, et al : Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetes. Diabetes Res Clin Pract 54 : 191-201, 2001.
PubMed
6) Marin R, et al : A randomized comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 19 : 1871-1876, 2001.
 
7) Brenner BM, et al : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861-869, 2001.
PubMed
8) Lewis EJ, et al : Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type II diabetes. N Engl J Med 345 : 851-860, 2001.
PubMed
9) Parving HH, et al : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 : 870-878, 2001.
PubMed
10) Giancarlo V, et al : Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106 : 672-678, 2002.
 
P.627 掲載の参考文献
1) UK Prospective Diabetes Study Group : Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 39. BMJ 317 : 703-720, 1998.
Medical*Online
2) Hansson L, et al : Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351 : 1755-1762, 1998.
PubMed
3) Hansson L, et al, for the Captopril Prevention Project study group : Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension : the Captopril Prevention Project (CAPPP) randomized trial. Lancet 353 : 611-616, 1999.
 
4) Estacio RO, et al : The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338 (10) : 645-652, 1998.
PubMed
5) Tatti P, et al : Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21 (4) : 597-603, 1998.
PubMed
6) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (23) : 2981-2997, 2002.
PubMed
7) Fuchs FD : Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study. Lancet 359 : 2203-2204, 2002.
 
8) Tuomilehto J, et al : Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340 : 677-684, 1999.
PubMed
9) Kostis JB, et al : Prevention of heart failure by antihypertensive dnlg treatment in older persons with isolated systolic hypertension. JAMA 278 : 212-216, 1997.
 
10) Hansson L, et al : Randomized trial of old and new antihypertensive drugs in elderly patients : cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354 : 1751-1756, 1999.
PubMed
11) Brenner BM, et al : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861-869, 2001.
PubMed
12) Lewis EJ, et al ; Collaborative Study Group : Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (12) : 851-860, 2001.
 
13) Viberti G, Wheeldon NM ; MicroAlbuminuria Reduction with VALsartan (MARVAL) Study lnvestigators : Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus : a blood pressure-independent effect. Circulation 106 (6) : 672-678, 2002.
PubMed
14) Parving HH, et al ; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (12) : 870-878, 2001.
 
P.636 掲載の参考文献
1) Stamler J, et al : Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor lntervention Trial (MRFIT). JAMA 256 (20) : 2823-2828, 1986.
 
2) Shepherd J, et al : Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (20) : 1301-1307, 1995.
 
3) Downs JR, et al : Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels : results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (20) : 1615-1622, 1998.
PubMed
4) Scandinavian Simvastatin Survival Study Group : Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease : Scandinavian Simvastatin Survival Study (4S). Lancet 344 : 1383-1389, 1994.
 
5) Sacks FM, et al : The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (14) : 1001-1009, 1996.
 
6) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (19) : 1349-1357, 1998.
 
7) Forrester JS, et al : The aggressive low density lipoprotein lowering controversy. J Am Coll Cardiol 36 (4) : 1419-1425, 2000.
PubMed
8) Bucher HC, et al : Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 128 (2) : 89-95, 1998.
PubMed
9) Crouse JR 3rd, et al : Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 157 (12) : 1305-1310, 1997.
PubMed
10) Blauw GJ, et al : Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 28 (5) : 946-950, 1997.
PubMed
11) Pedersen TR, et al : Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 81 (3) : 333-335, 1998.
PubMed
12) Plehn JF, et al : Reduction of stroke incidence after myocardial infarction with pravastatin : the Cholesterol and Recurrent Events (CARE) study. Circulation 99 (2) : 216-223, 1999.
PubMed
13) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals : a randomised placebo-controlled trial. Lancet 360 : 7-22, 2002.
PubMed
14) Matsuzawa Y, et al : Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 67 (4) : 287-294, 2003.
PubMed
15) Matsuzaki M, et al : Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 66 (12) : 1087-1095, 2002.
PubMed
16) Mabuchi H, et al : Japan Lipid lntervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease : secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 66 (12) : 1096-1100, 2002.
 
17) 日本動脈硬化学会診療・疫学委員会 : 動脈硬化性疾患診療ガイドライン 2002版.
 

X 特論

P.643 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 日本高血圧学会高血圧治療ガイドライン 2000年版, 日本高血圧学会, 2000.
 
2) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). JAMA 289 : 2560-2572, 2003.
PubMed
3) Guideline Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial pressure. J Hypertens 21 : 1015-1053, 2003.
 
4) National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157 : 2413-2446, 1997.
 
5) Guidelines Sub-Committee : 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 17 : 151-183, 1999.
 
6) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study lnvestigators. N Engl J Med 341 : 709-717, 1999.
PubMed
7) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288 : 2981-2997, 2002.
PubMed
P.647 掲載の参考文献
1) Yusuf S, et al : Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 : 145-153, 2000.
 
2) PROGRESS Collaborative Group : Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 : 1033-1041, 2001.
PubMed
3) Dahlof B, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomised trial against atenolol. Lancet 359 : 995-1003, 2002.
PubMed
4) Lithell H, et al : The Study on Cognition and Prognosis in the Elderly (SCOPE) : principal results of a randomized double-blind intervention trial. J Hypertens 21 : 875-886, 2003.
 
P.653 掲載の参考文献
1) The ALLHAT officers and coordinators for the ALLHAT collaborative research group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic ; the antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA 288 : 2981-2997, 2002.
PubMed
2) The ALLHAT officers and coordinators for the ALLHAT collaborative research group : Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care ; the antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA 288 : 2998-3007, 2002.
 
P.661 掲載の参考文献
1) Kimura K, et al : Diversity and variability of smooth muscle phenotypes of renal arterioles as revealed by myosin isoform expression. Kidney Int 48 : 372-382, 1995.
PubMed
2) Hayashi K, et al : Calcium antagonists and the kidney. In : Calcium Antagonists in Clinical Medicine, 2nd ed (ed by Epstein M), Hanley & Belfus, Philadelphia, 1998.
 
3) Loutzenhiser R, et al : Divergent effects of KCl-induced depolarization on afferent and efferent arterioles. Am J Physiol 257 : F561-F564, 1989.
PubMed
4) Carmines PK, et al : Effects of calcium antagonists on renal hemodynamics and glomerular function. Kidney Int 41 (Suppl 36) : S43-S48, 1992.
 
5) Hayashi K, et al : Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 19 : 31-36, 1996.
 
6) Furukawa T, et al : Selectivities of dihydropyridine derivatives in blocking Ca2+ channel subtypes expressed in xenopus oocytes. J Pharmacol Exp Ther 291 : 464-473, 1999.
 
7) Shudo C, et al : Beneficial effect of efonidipine hydrochloride (NZ-105) on proteinuria in aged spontaneously hypertensive rats (SHR). Pharm Sci 1 : 333-335, 1995.
 
8) Fujiwara K, et al : Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. Clin Exp Hypertens 20 : 295-312, 1998.
PubMed
P.665 掲載の参考文献
1) Moser M, et al : JAMA 237 : 255-262, 1977.
 
2) Report of a WHO Expert Committee/Technical Report Series 628, WHO, Geneva, 1978.
 
3) VA Study Veterans Administration Cooperative Study Group on Anti-hypertensive agents. JAMA 202 : 116-122, 1967.
 
4) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
5) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288 : 2981-2997, 2002.
PubMed
6) MacKay JH, et al : Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 156 : 278-285, 1996.
PubMed

書評

最近チェックした商品履歴

Loading...